Molecules for disease detection and treatment

ABSTRACT

The present invention provides purified disease detection and treatment molecule polynucleotides (mddt). Also encompassed are the polypeptides (MDDT) encoded by mddt. The invention also provides for the use of mddt, or complements, oligonucleotides, or fragments thereof in diagnostic assays. The invention further provides for vectors and host cells containing mddt for the expression of MDDT. The invention additionally provides for the use of isolated and purified MDDT to induce antibodies and to screen libraries of compounds and the use of anti-MDDT antibodies in diagnostic assays. Also provided are microarrays containing mddt and methods of use.

TECHNICAL FIELD

[0001] The present invention relates to molecules for disease detection and treatment and to the use of these sequences in the diagnosis, study, prevention, and treatment of diseases associated with, as well as effects of exogenous compounds on, the expression of molecules for disease detection and treatment.

BACKGROUND OF THE INVENTION

[0002] The human genome is comprised of thousands of genes, many encoding gene products that function in the maintenance and growth of the various cells and tissues in the body. Aberrant expression or mutations in these genes and their products is the cause of, or is associated with, a variety of human diseases such as cancer and other cell proliferative disorders. The identification of these genes and their products is the basis of an ever-expanding effort to find markers for early detection of diseases, and targets for their prevention and treatment.

[0003] For example, cancer represents a type of cell proliferative disorder that affects nearly every tissue in the body. A wide variety of molecules, either aberrantly expressed or mutated, can be the cause of, or involved with, various cancers because tissue growth involves complex and ordered patterns of cell proliferation, cell differentiation, and apoptosis. Cell proliferation must be regulated to maintain both the number of cells and their spatial organization. This regulation depends upon the appropriate expression of proteins which control cell cycle progression in response to extracellular signals such as growth factors and other mitogens, and intracellular cues such as DNA damage or nutrient starvation. Molecules which directly or indirectly modulate cell cycle progression fall into several categories, including growth factors and their receptors, second messenger and signal transduction proteins, oncogene products, tumor-suppressor proteins, and mitosis-promoting factors. Aberrant expression or mutations in any of these gene products can result in cell proliferative disorders such as cancer. Oncogenes are genes generally derived from normal genes that, through abnormal expression or mutation, can effect the transformation of a normal cell to a malignant one (oncogenesis). Oncoproteins, encoded by oncogenes, can affect cell proliferation in a variety of ways and include growth factors, growth factor receptors, intracellular signal transducers, nuclear transcription factors, and cell-cycle control proteins. In contrast, tumor-suppressor genes are involved in inhibiting cell proliferation. Mutations which cause reduced or loss of function in tumor-suppressor genes result in aberrant cell proliferation and cancer. Thus a wide variety of genes and their products have been found that are associated with cell proliferative disorders such as cancer, but many more may exist that are yet to be discovered.

[0004] DNA-based arrays can provide a simple way to explore the expression of a single polymorphic gene or a large number of genes. When the expression of a single gene is explored, DNA-based arrays are employed to detect the expression of specific gene variants. For example, a p53 tumor suppressor gene array is used to determine whether individuals are carrying mutations that predispose them to cancer. A cytochrome p450 gene array is useful to determine whether individuals have one of a number of specific mutations that could result in increased drug metabolism, drug resistance or drug toxicity.

[0005] DNA-based array technology is especially relevant for the rapid screening of expression of a large number of genes. There is a growing awareness that gene expression is affected in a global fashion. A genetic predisposition, disease or therapeutic treatment may affect, directly or indirectly, the expression of a large number of genes. In some cases the interactions may be expected, such as when the genes are part of the same signaling pathway. In other cases, such as when the genes participate in separate signaling pathways, the interactions may be totally unexpected. Therefore, DNA-based arrays can be used to investigate how genetic predisposition, disease, or therapeutic treatment affects the expression of a large number of genes.

[0006] The discovery of new molecules for disease detection and treatment satisfies a need in the art by providing new compositions which are useful in the diagnosis, study, prevention, and treatment of diseases associated with, as well as effects of exogenous compounds on, the expression of molecules for disease detection and treatment.

SUMMARY OF THE INVENTION

[0007] The present invention relates to human disease detection and treatment molecule polynucleotides (mddt) as presented in the Sequence Listing. The mddt uniquely identify genes encoding structural, functional, and regulatory disease detection and treatment molecules.

[0008] The invention provides an isolated polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36; b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36; c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide complementary to the polynucleotide of b); and e) an RNA equivalent of a) through d). In one alternative, the polynucleotide comprises a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36. In another alternative, the polynucleotide comprises at least 30 contiguous nucleotides of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36; b) a polynucleotide comprising a naturally occurring polynucleotide comprising a polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36; c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide complementary to the polynucleotide of b); and e) an RNA equivalent of a) through d). In another alternative, the polynucleotide comprises at least 60 contiguous nucleotides of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36; b) a polynucleotide comprising a naturally occurring polynucleotide comprising a polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36; c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide complementary to the polynucleotide of b); and e) an RNA equivalent of a) through d). The invention further provides a composition for the detection of expression of disease detection and treatment molecule polynucleotides comprising at least one isolated polynucleotide comprising a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36; b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36; c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide complementary to the polynucleotide of b); and e) an RNA equivalent of a) through d); and a detectable label.

[0009] The invention also provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a polynucleotide sequence of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence of a polynucleotide selected from the group consisting of SEQ ID NO: 1-36; b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36; c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide complementary to the polynucleotide of b); and e) an RNA equivalent of a) through d). The method comprises a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

[0010] The invention also provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36; b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36; c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide complementary to the polynucleotide of b); and e) an RNA equivalent of a) through d). The method comprises a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide, and b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof. In one alternative, the invention provides a composition comprising a target polynucleotide of the method, wherein said probe comprises at least 30 contiguous nucleotides. In one alternative, the invention provides a composition comprising a target polynucleotide of the method, wherein said probe comprises at least 60 contiguous nucleotides.

[0011] The invention further provides a recombinant polynucleotide comprising a promoter sequence operably linked to an isolated polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36; b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36; c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide complementary to the polynucleotide of b); and e) an RNA equivalent of a) through d). In one alternative, the invention provides a cell transformed with the recombinant polynucleotide. In another alternative, the invention provides a transgenic organism comprising the recombinant polynucleotide.

[0012] The invention also provides a method for producing a disease detection and treatment molecule polypeptide, the method comprising a) culturing a cell under conditions suitable for expression of the disease detection and treatment molecule polypeptide, wherein said cell is transformed with a recombinant polynucleotide, said recombinant polynucleotide comprising an isolated polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36; ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36; iii) a polynucleotide complementary to the polynucleotide of i); iv) a polynucleotide complementary to the polynucleotide of ii); and v) an RNA equivalent of i) through iv), and b) recovering the disease detection and treatment molecule polypeptide so expressed. The invention additionally provides a method wherein the polypeptide has an amino acid sequence selected from the group consisting of SEQ ID NO:37-72.

[0013] The invention also provides an isolated disease detection and treatment molecule polypeptide (MDDT) encoded by at least one polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36. The invention further provides a method of screening for a test compound that specifically binds to the polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72. The method comprises a) combining the polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72 with at least one test compound under suitable conditions, and b) detecting binding of the polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72 to the test compound, thereby identifying a compound that specifically binds to the polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72.

[0014] The invention further provides a microarray wherein at least one element of the microarray is an isolated polynucleotide comprising at least 30 contiguous nucleotides of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36; b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36; c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide complementary to the polynucleotide of b); and e) an RNA equivalent of a) through d). The invention also provides a method for generating a transcript image of a sample which contains polynucleotides. The method comprises a) labeling the polynucleotides of the sample, b) contacting the elements of the microarray with the labeled polynucleotides of the sample under conditions suitable for the formation of a hybridization complex, and c) quantifying the expression of the polynucleotides in the sample.

[0015] Additionally, the invention provides a method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36; b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36; c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide complementary to the polynucleotide of b); and e) an RNA equivalent of a) through d). The method comprises a) exposing a sample comprising the target polynucleotide to a compound, b) detecting altered expression of the target polynucleotide, and c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.

[0016] The invention further provides a method for assessing toxicity of a test compound, said method comprising a) treating a biological sample containing nucleic acids with the test compound; b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36; ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36; iii) a polynucleotide complementary to the polynucleotide of i); iv) a polynucleotide complementary to the polynucleotide of ii); and v) an RNA equivalent of i) through iv). Hybridization occurs under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36; ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36; iii) a polynucleotide complementary to the polynucleotide of i); iv) a polynucleotide complementary to the polynucleotide of ii); and v) an RNA equivalent of i) through iv), and alternatively, the target polynucleotide comprises a polynucleotide sequence of a fragment of a polynucleotide selected from the group consisting of i-v above; c) quantifying the amount of hybridization complex; and d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

[0017] The invention further provides an isolated polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72. In one alternative, the invention provides an isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72.

[0018] The invention further provides an isolated polynucleotide encoding a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72. In one alternative, the polynucleotide encodes a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72. In another alternative, the polynucleotide comprises a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36.

[0019] Additionally, the invention provides an isolated antibody which specifically binds to a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72.

[0020] The invention further provides a composition comprising a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72, and a pharmaceutically acceptable excipient. In one embodiment, the composition comprises a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72. The invention additionally provides a method of treating a disease or condition associated with decreased expression of functional MDDT, comprising administering to a patient in need of such treatment the composition.

[0021] The invention also provides a method for screening a compound for effectiveness as an agonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting agonist activity in the sample. In one alternative, the invention provides a composition comprising an agonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with decreased expression of functional MDDT, comprising administering to a patient in need of such treatment the composition.

[0022] Additionally, the invention provides a method for screening a compound for effectiveness as an antagonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting antagonist activity in the sample. In one alternative, the invention provides a composition comprising an antagonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with overexpression of functional MDDT, comprising administering to a patient in need of such treatment the composition.

[0023] The invention further provides a method of screening for a compound that modulates the activity of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72. The method comprises a) combining the polypeptide with at least one test compound under conditions permissive for the activity of the polypeptide, b) assessing the activity of the polypeptide in the presence of the test compound, and c) comparing the activity of the polypeptide in the presence of the test compound with the activity of the polypeptide in the absence of the test compound, wherein a change in the activity of the polypeptide in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide.

DESCRIPTION OF THE TABLES

[0024] Table 1 shows the sequence identification numbers (SEQ ID NO:s) and template identification numbers (template IDs) corresponding to the polynucleotides of the present invention, along with the sequence identification numbers (SEQ ID NO:s) and open reading frame identification numbers (ORF IDs) corresponding to polypeptides encoded by the template ID.

[0025] Table 2 shows the sequence identification numbers (SEQ ID NO:s) and template identification numbers (template IDs) corresponding to the polynucleotides of the present invention, along with their GenBank hits (GI Numbers), probability scores, and functional annotations corresponding to the GenBank hits.

[0026] Table 3 shows the sequence identification numbers (SEQ ID NO:s) and template identification numbers (template IDs) corresponding to the polynucleotides of the present invention, along with polynucleotide segments of each template sequence as defined by the indicated “start” and “stop” nucleotide positions. The reading frames of the polynucleotide segments and the Pfam hits, Pfam descriptions, and E-values corresponding to the polypeptide domains encoded by the polynucleotide segments are indicated.

[0027] Table 4 shows the sequence identification numbers (SEQ ID NO:s) and template identification numbers (template IDs) corresponding to the polynucleotides of the present invention, along with polynucleotide segments of each template sequence as defined by the indicated “start” and “stop” nucleotide positions. The reading frames of the polynucleotide segments are shown, and the polypeptides encoded by the polynucleotide segments constitute either signal peptide (SP) or transmembrane (TM) domains, as indicated. For TM domains, the membrane topology of the encoded polypeptide sequence is indicated as being transmembrane or on the cytosolic or non-cytosolic side of the cell membrane or organelle.

[0028] Table 5 shows the sequence identification numbers (SEQ ID NO:s) and template identification numbers (template IDs) corresponding to the polynucleotides of the present invention, along with component sequence identification numbers (component IDs) corresponding to each template. The component sequences, which were used to assemble the template sequences, are defined by the indicated “start” and “stop” nucleotide positions along each template.

[0029] Table 6 shows the tissue distribution profiles for the templates of the invention.

[0030] Table 7 shows the sequence identification numbers (SEQ ID NO:s) corresponding to the polypeptides of the present invention, along with the reading frames used to obtain the polypeptide segments, the lengths of the polypeptide segments, the “start” and “stop” nucleotide positions of the polynucleotide sequences used to define the encoded polypeptide segments, the GenBank hits (GI Numbers), probability scores, and functional annotations corresponding to the GenBank hits.

[0031] Table 8 summarizes the bioinformatics tools which are useful for analysis of the polynucleotides of the present invention. The first column of Table 8 lists analytical tools, programs, and algorithms, the second column provides brief descriptions thereof, the third column presents appropriate references, all of which are incorporated by reference herein in their entirety, and the fourth column presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the score, the greater the homology between two sequences).

DETAILED DESCRIPTION OF THE INVENTION

[0032] Before the nucleic acid sequences and methods are presented, it is to be understood that this invention is not limited to the particular machines, methods, and materials described. Although particular embodiments are described, machines, methods, and materials similar or equivalent to these embodiments may be used to practice the invention. The preferred machines, methods, and materials set forth are not intended to limit the scope of the invention which is limited only by the appended claims.

[0033] The singular forms “a”, “an”, and “the” include plural reference unless the context clearly dictates otherwise. All technical and scientific terms have the meanings commonly understood by one of ordinary skill in the art. All publications are incorporated by reference for the purpose of describing and disclosing the cell lines, vectors, and methodologies which are presented and which might be used in connection with the invention. Nothing in the specification is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

[0034] Definitions

[0035] As used herein, the lower case “mddt” refers to a nucleic acid sequence, while the upper case “MDDT” refers to an amino acid sequence encoded by mddt. A “full-length” mddt refers to a nucleic acid sequence containing the entire coding region of a gene endogenously expressed in human tissue.

[0036] “Adjuvants” are materials such as Freund's adjuvant, mineral gels (aluminum hydroxide), and surface active substances (lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol) which may be administered to increase a host's immunological response.

[0037] “Allele” refers to an alternative form of a nucleic acid sequence. Alleles result from a “mutation,” a change or an alternative reading of the genetic code. Any given gene may have none, one, or many allelic forms. Mutations which give rise to alleles include deletions, additions, or substitutions of nucleotides. Each of these changes may occur alone, or in combination with the others, one or more times in a given nucleic acid sequence. The present invention encompasses allelic mddt.

[0038] An “allelic variant” is an alternative form of the gene encoding MDDT. Allelic variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. A gene may have none, one, or many allelic variants of its naturally occurring form Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

[0039] “Altered” nucleic acid sequences encoding MDDT include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polypeptide the same as MDDT or a polypeptide with at least one functional characteristic of MDDT. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding MDDT, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding MDDT. The encoded protein may also be “altered,” and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent MDDT. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of MDDT is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, and positively charged amino acids may include lysine and arginine. Amino acids with uncharged polar side chains having similar hydrophilicity values may include: asparagine and glutamine; and serine and threonine. Amino acids with uncharged side chains having similar hydrophilicity values may include: leucine, isoleucine, and valine; glycine and alanine; and phenylalanine and tyrosine.

[0040] “Amino acid sequence” refers to a peptide, a polypeptide, or a protein of either natural or synthetic origin. The amino acid sequence is not limited to the complete, endogenous amino acid sequence and may be a fragment, epitope, variant, or derivative of a protein expressed by a nucleic acid sequence.

[0041] “Amplification” refers to the production of additional copies of a sequence and is carried out using polymerase chain reaction (PCR) technologies well known in the art.

[0042] “Antibody” refers to intact molecules as well as to fragments thereof, such as Fab, F(ab′)₂, and Fv fragments, which are capable of binding the epitopic determinant. Antibodies that bind MDDT polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or peptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.

[0043] The term “aptamer” refers to a nucleic acid or oligonucleotide molecule that binds to a specific molecular target. Aptamers are derived from an in vitro evolutionary process (e.g., SELEX (Systematic Evolution of Ligands by EXponential Enrichment), described in U.S. Pat. No. 5,270,163), which selects for target-specific aptamer sequences from large combinatorial libraries. Aptamer compositions may be double-stranded or single-stranded, and may include deoxyribonucleotides, ribonucleotides, nucleotide derivatives, or other nucleotide-like molecules. The nucleotide components of an aptamer may have modified sugar groups (e.g., the 2′-OH group of a ribonucleotide may be replaced by 2′-F or 2′-NH₂), which may improve a desired property, e.g., resistance to nucleases or longer lifetime in blood. Aptamers may be conjugated to other molecules, e.g., a high molecular weight carrier to slow clearance of the aptamer from the circulatory system Aptamers may be specifically cross-linked to their cognate ligands, e.g., by photo-activation of a cross-linker. (See, e.g., Brody, E. N. and L. Gold (2000) J. Biotechnol. 74:5-13.)

[0044] The term “intramer” refers to an aptamer which is expressed in vivo. For example, a vaccinia virus-based RNA expression system has been used to express specific RNA aptamers at high levels in the cytoplasm of leukocytes (Blind, M. et al. (1999) Proc. Natl Acad. Sci. USA 96:3606-3610).

[0045] The term “spiegelmer” refers to an aptamer which includes L-DNA, L-RNA, or other left-handed nucleotide derivatives or nucleotide-like molecules. Aptamers containing left-handed nucleotides are resistant to degradation by naturally occurring enzymes, which normally act on substrates containing right-handed nucleotides.

[0046] “Antisense sequence” refers to a sequence capable of specifically hybridizing to a target sequence. The antisense sequence may include DNA, RNA, or any nucleic acid mimic or analog such as peptide nucleic acid (PNA); oligonucleotides having modified backbone linkages such as phosphorothioates, methylphosphonates, or benzylphosphonates; oligonucleotides having modified sugar groups such as 2′-methoxyethyl sugars or 2′-methoxyethoxy sugars; or oligonucleotides having modified bases such as 5-methyl cytosine, 2′-deoxyuracil, or 7-deaza-2′-deoxyguanosine.

[0047] “Antisense technology” refers to any technology which relies on the specific hybridization of an antisense sequence to a target sequence.

[0048] A “bin” is a portion of computer memory space used by a computer program for storage of data, and bounded in such a manner that data stored in a bin may be retrieved by the program.

[0049] “Biologically active” refers to an amino acid sequence having a structural, regulatory, or biochemical function of a naturally occurring amino acid sequence.

[0050] “Clone joining” is a process for combining gene bins based upon the bins' containing sequence information from the same clone. The sequences may assemble into a primary gene transcript as well as one or more splice variants.

[0051] “Complementary” describes the relationship between two single-stranded nucleic acid sequences that anneal by base-pairing (5′-A-G-T-3′ pairs with its complement 3′-T-C-A-5′).

[0052] A “component sequence” is a nucleic acid sequence selected by a computer program such as PHRED and used to assemble a consensus or template sequence from one or more component sequences.

[0053] A “consensus sequence” or “template sequence” is a nucleic acid sequence which has been assembled from overlapping sequences, using a computer program for fragment assembly such as the GEL VIEW fragment assembly system (Genetics Computer Group (GCG), Madison Wis.) or using a relational database management system (RDMS).

[0054] “Conservative amino acid substitutions” are those substitutions that, when made, least interfere with the properties of the original protein, i.e., the structure and especially the function of the protein is conserved and not significantly changed by such substitutions. The table below shows amino acids which may be substituted for an original amino acid in a protein and which are regarded as conservative substitutions. Original Residue Conservative Substitution Ala Gly, Ser Arg His, Lys Asn Asp, Gln, His Asp Asn, Glu Cys Ala, Ser Gln Asn, Glu, His Glu Asp, Gln, His Gly Ala His Asn, Arg, Gln, Glu Ile Leu, Val Leu Ile, Val Lys Arg, Gln, Glu Met Leu, Ile Phe His, Met, Leu, Trp, Tyr Ser Cys, Thr Thr Ser, Val Trp Phe, Tyr Tyr His, Phe, Trp Val Ile, Leu, Thr

[0055] Conservative substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a beta sheet or alpha helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain.

[0056] “Deletion” refers to a change in either a nucleic or amino acid sequence in which at least one nucleotide or amino acid residue, respectively, is absent.

[0057] “Derivative” refers to the chemical modification of a nucleic acid sequence, such as by replacement of hydrogen by an alkyl, acyl, amino, hydroxyl, or other group.

[0058] “Differential expression” refers to increased or upregulated; or decreased, downregulated, or absent gene or protein expression, determined by comparing at least two different samples. Such comparisons may be carried out between, for example, a treated and an untreated sample, or a diseased and a normal sample.

[0059] The terms “element” and “array element” refer to a polynucleotide, polypeptide, or other chemical compound having a unique and defined position on a microarray.

[0060] The term “modulate” refers to a change in the activity of MDDT. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of MDDT.

[0061] “E-value” refers to the statistical probability that a match between two sequences occurred by chance.

[0062] “Exon shuffling” refers to the recombination of different coding regions (exons). Since an exon may represent a structural or functional domain of the encoded protein, new proteins may be assembled through the novel reassortment of stable substructures, thus allowing acceleration of the evolution of new protein functions.

[0063] A “fragment” is a unique portion of mddt or MDDT which is identical in sequence to but shorter in length than the parent sequence. A fragment may comprise up to the entire length of the defined sequence, minus one nucleotide/amino acid residue. For example, a fragment may comprise from 10 to 1000 contiguous amino acid residues or nucleotides. A fragment used as a probe, primer, antigen, therapeutic molecule, or for other purposes, may be at least 5, 10, 15, 16, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or at least 500 contiguous amino acid residues or nucleotides in length. Fragments may be preferentially selected from certain regions of a molecule. For example, a polypeptide fragment may comprise a certain length of contiguous amino acids selected from the first 250 or 500 amino acids (or first 25% or 50%) of a polypeptide as shown in a certain defined sequence. Clearly these lengths are exemplary, and any length that is supported by the specification, including the Sequence Listing and the figures, may be encompassed by the present embodiments.

[0064] A fragment of mddt comprises a region of unique polynucleotide sequence that specifically identifies mddt, for example, as distinct from any other sequence in the same genome. A fragment of mddt is useful, for example, in hybridization and amplification technologies and in analogous methods that distinguish mddt from related polynucleotide sequences. The precise length of a fragment of mddt and the region of mddt to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

[0065] A fragment of MDDT is encoded by a fragment of mddt. A fragment of MDDT comprises a region of unique amino acid sequence that specifically identifies MDDT. For example, a fragment of MDDT is useful as an immunogenic peptide for the development of antibodies that specifically recognize MDDT. The precise length of a fragment of MDDT and the region of MDDT to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

[0066] A “full length” nucleotide sequence is one containing at least a start site for translation to a protein sequence, followed by an open reading frame and a stop site, and encoding a “full length” polypeptide.

[0067] “Hit” refers to a sequence whose annotation will be used to describe a given template. Criteria for selecting the top hit are as follows: if the template has one or more exact nucleic acid matches, the top hit is the exact match with highest percent identity. If the template has no exact matches but has significant protein hits, the top hit is the protein hit with the lowest E-value. If the template has no significant protein hits, but does have significant non-exact nucleotide hits, the top hit is the nucleotide hit with the lowest E-value.

[0068] “Homology” refers to sequence similarity either between a reference nucleic acid sequence and at least a fragment of an mddt or between a reference amino acid sequence and a fragment of an MDDT.

[0069] “Hybridization” refers to the process by which a strand of nucleotides anneals with a complementary strand through base pairing. Specific hybridization is an indication that two nucleic acid sequences share a high degree of identity. Specific hybridization complexes form under defined annealing conditions, and remain hybridized after the “washing” step. The defined hybridization conditions include the annealing conditions and the washing step(s), the latter of which is particularly important in determining the stringency of the hybridization process, with more stringent conditions allowing less non-specific binding, i.e., binding between pairs of nucleic acid probes that are not perfectly matched. Permissive conditions for annealing of nucleic acid sequences are routinely determinable and may be consistent among hybridization experiments, whereas wash conditions may be varied among experiments to achieve the desired stringency.

[0070] Generally, stringency of hybridization is expressed with reference to the temperature under which the wash step is carried out. Generally, such wash temperatures are selected to be about 5° C. to 20° C. lower than the thermal melting point (T_(m)) for the specific sequence at a defined ionic strength and pH. The T_(m) is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. An equation for calculating T_(m) and conditions for nucleic acid hybridization is well known and can be found in Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, 2^(nd) ed., vol. 1-3, Cold Spring Harbor Press, Plainview N.Y.; specifically see volume 2, chapter 9.

[0071] High stringency conditions for hybridization between polynucleotides of the present invention include wash conditions of 68° C. in the presence of about 0.2×SSC and about 0.1% SDS, for 1 hour. Alternatively, temperatures of about 65° C., 60° C., or 55° C. may be used. SSC concentration may be varied from about 0.2 to 2×SSC, with SDS being present at about 0.1%. Typically, blocking reagents are used to block non-specific hybridization. Such blocking reagents include, for instance, denatured salmon sperm DNA at about 100-200 μg/ml. Useful variations on these conditions will be readily apparent to those skilled in the art. Hybridization, particularly under high stringency conditions, may be suggestive of evolutionary similarity between the nucleotides. Such similarity is strongly indicative of a similar role for the nucleotides and their resultant proteins.

[0072] Other parameters, such as temperature, salt concentration, and detergent concentration may be varied to achieve the desired stringency. Denaturants, such as formamide at a concentration of about 35-50% v/v, may also be used under particular circumstances, such as RNA:DNA hybridizations. Appropriate hybridization conditions are routinely determinable by one of ordinary skill in the art.

[0073] “Immunologically active” or “immunogenic” describes the potential for a natural, recombinant, or synthetic peptide, epitope, polypeptide, or protein to induce antibody production in appropriate animals, cells, or cell lines.

[0074] “Immune response” can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.

[0075] An “immunogenic fragment” is a polypeptide or oligopeptide fragment of MDDT which is capable of eliciting an immune response when introduced into a living organism, for example, a mammal. The term “immunogenic fragment” also includes any polypeptide or oligopeptide fragment of MDDT which is useful in any of the antibody production methods disclosed herein or known in the art.

[0076] “Insertion” or “addition” refers to a change in either a nucleic or amino acid sequence in which at least one nucleotide or residue, respectively, is added to the sequence.

[0077] “Labeling” refers to the covalent or noncovalent joining of a polynucleotide, polypeptide, or antibody with a reporter molecule capable of producing a detectable or measurable signal.

[0078] “Microarray” is any arrangement of nucleic acids, amino acids, antibodies, etc., on a substrate. The substrate may be a solid support such as beads, glass, paper, nitrocellulose, nylon, or an appropriate membrane.

[0079] “Linkers” are short stretches of nucleotide sequence which may be added to a vector or an mddt to create restriction endonuclease sites to facilitate cloning. “Polylinkers” are engineered to incorporate multiple restriction enzyme sites and to provide for the use of enzymes which leave 5′ or 3′ overhangs (e.g., BamHI, EcoRI and HindIII) and those which provide blunt ends (e.g., EcoRV, SnaBI, and StuI).

[0080] “naturally occurring” refers to an endogenous polynucleotide or polypeptide that may be isolated from viruses or prokaryotic or eukaryotic cells.

[0081] “Nucleic acid sequence” refers to the specific order of nucleotides joined by phosphodiester bonds in a linear, polymeric arrangement. Depending on the number of nucleotides, the nucleic acid sequence can be considered an oligomer, oligonucleotide, or polynucleotide. The nucleic acid can be DNA, RNA, or any nucleic acid analog, such as PNA, may be of genomic or synthetic origin, may be either double-stranded or single-stranded, and can represent either the sense or antisense (complementary) strand.

[0082] “Oligomer” refers to a nucleic acid sequence of at least about 6 nucleotides and as many as about 60 nucleotides, preferably about 15 to 40 nucleotides, and most preferably between about 20 and 30 nucleotides, that may be used in hybridization or amplification technologies. Oligomers may be used as, e.g., primers for PCR, and are usually chemically synthesized.

[0083] “Operably linked” refers to the situation in which a first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Generally, operably linked DNA sequences may be in close proximity or contiguous and, where necessary to join two protein coding regions, in the same reading frame.

[0084] “Peptide nucleic acid” (PNA) refers to a DNA mimic in which nucleotide bases are attached to a pseudopeptide backbone to increase stability. PNAs, also designated antigene agents, can prevent gene expression by targeting complementary messenger RNA.

[0085] The phrases “percent identity” and “% identity”, as applied to polynucleotide sequences, refer to the percentage of residue matches between at least two polynucleotide sequences aligned using a standardized algorithm. Such an algorithm may insert, in a standardized and reproducible way, gaps in the sequences being compared in order to optimize alignment between two sequences, and therefore achieve a more meaningful comparison of the two sequences.

[0086] Percent identity between polynucleotide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program. This program is part of the LASERGENE software package, a suite of molecular biological analysis programs (DNASTAR, Madison Wis.). CLUSTAL V is described in Higgins, D. G. and Sharp, P. M. (1989) CABIOS 5:151-153 and in Higgins, D. G. et al. (1992) CABIOS 8:189-191. For pairwise alignments of polynucleotide sequences, the default parameters are set as follows: Ktuple=2, gap penalty=5, window=4, and “diagonals saved”=4. The “weighted” residue weight table is selected as the default. Percent identity is reported by CLUSTAL V as the “percent similarity” between aligned polynucleotide sequence pairs.

[0087] Alternatively, a suite of commonly used and freely available sequence comparison algorithms is provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) (Altschul, S. F. et al. (1990) J. Mol. Biol. 215:403-410), which is available from several sources, including the NCBI, Bethesda, Md., and on the Internet at http://www.ncbi.nlm.nih.gov/BLAST/. The BLAST software suite includes various sequence analysis programs including “BLASTN,” that is used to determine alignment between a known polynucleotide sequence and other sequences on a variety of databases. Also available is a tool called “BLAST 2 Sequences” that is used for direct pairwise comparison of two nucleotide sequences. “BLAST 2 Sequences” can be accessed and used interactively at http://www.ncbi.nlm.nih.gov/gorf/bl2/. The “BLAST 2 Sequences” tool can be used for both BLASTN and BLASTP (discussed below). BLAST programs are commonly used with gap and other parameters set to default settings. For example, to compare two nucleotide sequences, one may use BLASTN with the “BLAST 2 Sequences” tool Version 2.0.9 (May 7, 1999) set at default parameters. Such default parameters may be, for example:

[0088] Matrix: BLOSUM62

[0089] Reward for match: 1

[0090] Penalty for mismatch: −2

[0091] Open Gap: 5 and Extension Gap: 2 penalties

[0092] Gap×drop-off: 50

[0093] Expect: 10

[0094] Word Size: 11

[0095] Filter: on

[0096] Percent identity may be measured over the length of an entire defined sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined sequence, for instance, a fragment of at least 20, at least 30, at least 40, at least 50, at least 70, at least 100, or at least 200 contiguous nucleotides. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in figures or Sequence Listings, may be used to describe a length over which percentage identity may be measured.

[0097] Nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences due to the degeneracy of the genetic code. It is understood that changes in nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid sequences that all encode substantially the same protein.

[0098] The phrases “percent identity” and “% identity”, as applied to polypeptide sequences, refer to the percentage of residue matches between at least two polypeptide sequences aligned using a standardized algorithm. Methods of polypeptide sequence alignment are well-known. Some alignment methods take into account conservative amino acid substitutions. Such conservative substitutions, explained in more detail above, generally preserve the hydrophobicity and acidity of the substituted residue, thus preserving the structure (and therefore function) of the folded polypeptide.

[0099] Percent identity between polypeptide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program (described and referenced above). For pairwise alignments of polypeptide sequences using CLUSTAL V, the default parameters are set as follows: Ktuple=1, gap penalty=3, window=5, and “diagonals saved”=5. The PAM250 matrix is selected as the default residue weight table. As with polynucleotide alignments, the percent identity is reported by CLUSTAL V as the “percent similarity” between aligned polypeptide sequence pairs.

[0100] Alternatively the NCBI BLAST software suite may be used. For example, for a pairwise comparison of two polypeptide sequences, one may use the “BLAST 2 Sequences” tool Version 2.0.9 (May 7, 1999) with BLASTP set at default parameters. Such default parameters may be, for 15 example:

[0101] Matrix: BLOSUM62

[0102] Open Gap: 11 and Extension Gap: 1 penalty

[0103] Gap×drop-off: 50

[0104] Expect: 10

[0105] Word Size: 3

[0106] Filter: on

[0107] Percent identity may be measured over the length of an entire defined polypeptide sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in figures or Sequence Listings, may be used to describe a length over which percentage identity may be measured.

[0108] “Post-translational modification” of an MDDT may involve lipidation, glycosylation, phosphorylation, acetylation, racemization, proteolytic cleavage, and other modifications known in the art. These processes may occur synthetically or biochemically. Biochemical modifications will vary by cell type depending on the enzymatic milieu and the MDDT.

[0109] “Probe” refers to mddt or fragments thereof, which are used to detect identical, allelic or related nucleic acid sequences. Probes are isolated oligonucleotides or polynucleotides attached to a detectable label or reporter molecule. Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes. “Primers” are short nucleic acids, usually DNA oligonucleotides, which may be annealed to a target polynucleotide by complementary base-pairing. The primer may then be extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification (and identification) of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR).

[0110] Probes and primers as used in the present invention typically comprise at least 15 contiguous nucleotides of a known sequence. In order to enhance specificity, longer probes and primers may also be employed, such as probes and primers that comprise at least 20, 30, 40, 50, 60, 70, 80, 90, 100, or at least 150 consecutive nucleotides of the disclosed nucleic acid sequences. Probes and primers may be considerably longer than these examples, and it is understood that any length supported by the specification, including the figures and Sequence Listing, may be used.

[0111] Methods for preparing and using probes and primers are described in the references, for example Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, 2^(nd) ed., vol. 1-3, Cold Spring Harbor Press, Plainview N.Y.; Ausubel et al.,1987, Current Protocols in Molecular Biology, Greene Publ. Assoc. & Wiley-Intersciences, New York N.Y.; Innis et al., 1990, PCR Protocols, A Guide to Methods and Applications, Academic Press, San Diego Calif. PCR primer pairs can be derived from a known sequence, for example, by using computer programs intended for that purpose such as Primer (Version 0.5, 1991, Whitehead Institute for Biomedical Research, Cambridge Mass.).

[0112] Oligonucleotides for use as primers are selected using software known in the art for such purpose. For example, OLIGO 4.06 software is useful for the selection of PCR primer pairs of up to 100 nucleotides each, and for the analysis of oligonucleotides and larger polynucleotides of up to 5,000 nucleotides from an input polynucleotide sequence of up to 32 kilobases. Similar primer selection programs have incorporated additional features for expanded capabilities. For example, the PrimOU primer selection program (available to the public from the Genome Center at University of Texas South West Medical Center, Dallas Tex.) is capable of choosing specific primers from megabase sequences and is thus useful for designing primers on a genome-wide-scope. The Primer3 primer selection program (available to the public from the Whitehead Institute/MIT Center for Genome Research, Cambridge Mass.) allows the user to input a “mispriming library,” in which sequences to avoid as primer binding sites are user-specified. Primer3 is useful, in particular, for the selection of oligonucleotides for microarrays. (The source code for the latter two primer selection programs may also be obtained from their respective sources and modified to meet the user's specific needs.) The PrimeGen program (available to the public from the UK Human Genome Mapping Project Resource Centre, Cambridge UK) designs primers based on multiple sequence alignments, thereby allowing selection of primers that hybridize to either the most conserved or least conserved regions of aligned nucleic acid sequences. Hence, this program is useful for identification of both unique and conserved oligonucleotides and polynucleotide fragments. The oligonucleotides and polynucleotide fragments identified by any of the above selection methods are useful in hybridization technologies, for example, as PCR or sequencing primers, microarray elements, or specific probes to identify fully or partially complementary polynucleotides in a sample of nucleic acids. Methods of oligonucleotide selection are not limited to those described above.

[0113] “Purified” refers to molecules, either polynucleotides or polypeptides that are isolated or separated from their natural environment and are at least 60% free, preferably at least 75% free, and most preferably at least 90% free from other compounds with which they are naturally associated.

[0114] A “recombinant nucleic acid” is a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two or more otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques such as those described in Sambrook, supra. The term recombinant includes nucleic acids that have been altered solely by addition, substitution, or deletion of a portion of the nucleic acid. Frequently, a recombinant nucleic acid may include a nucleic acid sequence operably linked to a promoter sequence. Such a recombinant nucleic acid may be part of a vector that is used, for example, to transform a cell.

[0115] Alternatively, such recombinant nucleic acids may be part of a viral vector, e.g., based on a vaccinia virus, that could be use to vaccinate a mammal wherein the recombinant nucleic acid is expressed, inducing a protective immunological response in the mammal.

[0116] “Regulatory element” refers to a nucleic acid sequence from nontranslated regions of a gene, and includes enhancers, promoters, introns, and 3′ untranslated regions, which interact with host proteins to carry out or regulate transcription or translation.

[0117] “Reporter” molecules are chemical or biochemical moieties used for labeling a nucleic acid, an amino acid, or an antibody. They include radionuclides; enzymes; fluorescent, chemiluminescent, or chromogenic agents; substrates; cofactors; inhibitors; magnetic particles; and other moieties known in the art.

[0118] An “RNA equivalent,” in reference to a DNA sequence, is composed of the same linear sequence of nucleotides as the reference DNA sequence with the exception that all occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

[0119] “Sample” is used in its broadest sense. Samples may contain nucleic or amino acids, antibodies, or other materials, and may be derived from any source (e.g., bodily fluids including, but not limited to, saliva, blood, and urine; chromosome(s), organelles, or membranes isolated from a cell; genomic DNA, RNA, or cDNA in solution or bound to a substrate; and cleared cells or tissues or blots or imprints from such cells or tissues).

[0120] “Specific binding” or “specifically binding” refers to the interaction between a protein or peptide and its agonist, antibody, antagonist, or other binding partner. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope “A,” the presence of a polypeptide containing epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

[0121] “Substitution” refers to the replacement of at least one nucleotide or amino acid by a different nucleotide or amino acid.

[0122] “Substrate” refers to any suitable rigid or semi-rigid support including, e.g., membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles or capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.

[0123] A “transcript image” refers to the collective pattern of gene expression by a particular tissue or cell type under given conditions at a given time.

[0124] “Transformation” refers to a process by which exogenous DNA enters a recipient cell. Transformation may occur under natural or artificial conditions using various methods well known in the art. Transformation may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method is selected based on the host cell being transformed.

[0125] “Transformants” include stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as cells which transiently express inserted DNA or RNA.

[0126] A “transgenic organism,” as used herein, is any organism, including but not limited to animals and plants, in which one or more of the cells of the organism contains heterologous nucleic acid introduced by way of human intervention, such as by transgenic techniques well known in the art. The nucleic acid is introduced into the cell, directly or indirectly by introduction into a precursor of the cell, by way of deliberate genetic manipulation, such as by microinjection or by infection with a recombinant virus. The term genetic manipulation does not include classical cross-breeding, or in vitro fertilization, but rather is directed to the introduction of a recombinant DNA molecule. The transgenic organisms contemplated in accordance with the present invention include bacteria, cyanobacteria, fungi, and plants and animals. The isolated DNA of the present invention can be introduced into the host by methods known in the art, for example infection, transfection, transformation or transconjugation. Techniques for transferring the DNA of the present invention into such organisms are widely known and provided in references such as Sambrook et al. (1989), supra.

[0127] A “variant” of a particular nucleic acid sequence is defined as a nucleic acid sequence having at least 25% sequence identity to the particular nucleic acid sequence over a certain length of one of the nucleic acid sequences using BLASTN with the “BLAST 2 Sequences” tool Version 2.0.9 (May 7, 1999) set at default parameters. Such a pair of nucleic acids may show, for example, at least 30%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or greater sequence identity over a certain defined length. The variant may result in “conservative” amino acid changes which do not affect structural and/or chemical properties. A variant may be described as, for example, an “allelic” (as defined above), “splice,” “species,” or “polymorphic” variant. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or lack domains that are present in the reference molecule. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides generally will have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass “single nucleotide polymorphisms” (SNPs) in which the polynucleotide sequence varies by one base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

[0128] In an alternative, variants of the polynucleotides of the present invention may be generated through recombinant methods. One possible method is a DNA shuffling technique such as MOLECULARBREEDING (Maxygen Inc., Santa Clara Calif.; described in U.S. Pat. No. 5,837,458; Chang, C. -C. et al. (1999) Nat. Biotechnol. 17:793-797; Christians, F. C. et al. (1999) Nat. Biotechnol. 17:259-264; and Crameri, A. et al. (1996) Nat. Biotechnol. 14:315-319) to alter or improve the biological properties of MDDT, such as its biological or enzymatic activity or its ability to bind to other molecules or compounds. DNA shuffling is a process by which a library of gene variants is produced using PCR-mediated recombination of gene fragments. The library is then subjected to selection or screening procedures that identify those gene variants with the desired properties. These preferred variants may then be pooled and further subjected to recursive rounds of DNA shuffling and selection/screening. Thus, genetic diversity is created through “artificial” breeding and rapid molecular evolution. For example, fragments of a single gene containing random point mutations may be recombined, screened, and then reshuffled until the desired properties are optimized. Alternatively, fragments of a given gene may be recombined with fragments of homologous genes in the same gene family, either from the same or different species, thereby maximizing the genetic diversity of multiple naturally occurring genes in a directed and controllable manner.

[0129] A “variant” of a particular polypeptide sequence is defined as a polypeptide sequence having at least 40% sequence identity to the particular polypeptide sequence over a certain length of one of the polypeptide sequences using BLASTP with the “BLAST 2 Sequences” tool Version 2.0.9 (May 7, 1999) set at default parameters. Such a pair of polypeptides may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or greater sequence identity over a certain defined length of one of the polypeptides.

THE INVENTION

[0130] In a particular embodiment, cDNA sequences derived from human tissues and cell lines were aligned based on nucleotide sequence identity and assembled into “consensus” or “template” sequences which are designated by the template identification numbers (template IDs) in column 2 of Table 2. The sequence identification numbers (SEQ ID NO:s) corresponding to the template IDs are shown in column 1. The template sequences have similarity to GenBank sequences, or “hits,” as designated by the GI Numbers in column 3. The statistical probability of each GeniBank hit is indicated by a probability score in column 4, and the functional annotation corresponding to each GenBank hit is listed in column 5.

[0131] The invention incorporates the nucleic acid sequences of these templates as disclosed in the Sequence Listing and the use of these sequences in the diagnosis and treatment of disease states characterized by defects in disease detection and treatment molecules. The invention further utilizes these sequences in hybridization and amplification technologies, and in particular, in technologies which assess gene expression patterns correlated with specific cells or tissues and their responses in vivo or in vitro to pharmaceutical agents, toxins, and other treatments. In this manner, the sequences of the present invention are used to develop a transcript image for a particular cell or tissue.

[0132] Derivation of Nucleic Acid Sequences

[0133] cDNA was isolated from libraries constructed using RNA derived from normal and diseased human tissues and cell lines. The human tissues and cell lines used for cDNA library construction were selected from a broad range of sources to provide a diverse population of cDNAs representative of gene transcription throughout the human body. Descriptions of the human tissues and cell lines used for cDNA library construction are provided in the LIESEQ database (Incyte Genomics, Inc. (Incyte), Palo Alto Calif.). Human tissues were broadly selected from, for example,cardiovascular, dermatologic, endocrine, gastrointestinal, hematopoietic/immune system, musculoskeletal, neural, reproductive, and urologic sources.

[0134] Cell lines used for cDNA library construction were derived from, for example, leukemic cells, teratocarcinomas, neuroepitheliomas, cervical carcinoma, lung fibroblasts, and endothelial cells. Such cell lines include, for example, THP-1, Jurkat, HUVEC, hNT2, WI38, HeLa, and other cell lines commonly used and available from public depositories (American Type Culture Collection, Manassas Va.). Prior to mRNA isolation, cell lines were untreated, treated with a pharmaceutical agent such as 5′-aza-2′-deoxycytidine, treated with an activating agent such as lipopolysaccharide in the case of leukocytic cell lines, or, in the case of endothelial cell lines, subjected to shear stress.

[0135] Sequencing of the cDNAs

[0136] Methods for DNA sequencing are well known in the art. Conventional enzymatic methods employ the Klenow fragment of DNA polymerase I, SEQUENASE DNA polymerase (U.S. Biochemical Corporation, Cleveland Ohio), Taq polymerase (Applied Biosystems, Foster City Calif.), thermostable T7 polymerase (Amersham Pharmacia Biotech, Inc. (Amersham Pharmacia Biotech), Piscataway N.J.), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE amplification system (Life Technologies Inc. (Life Technologies), Gaithersburg Md.), to extend the nucleic acid sequence from an oligonucleotide primer annealed to the DNA template of interest. Methods have been developed for the use of both single-stranded and double-stranded templates. Chain termination reaction products may be electrophoresed on urea-polyacrylamide gels and detected either by autoradiography (for radioisotope-labeled nucleotides) or by fluorescence (for fluorophore-labeled nucleotides). Automated methods for mechanized reaction preparation, sequencing, and analysis using fluorescence detection methods have been developed. Machines used to prepare cDNAs for sequencing can include the MICROLAB 2200 liquid transfer system (Hamilton Company (Hamilton), Reno Nev.), Peltier thermal cycler (PTC200; MJ Research, Inc. (MJ Research), Watertown Mass.), and ABI CATALYST 800 thermal cycler (Applied Biosystems). Sequencing can be carried out using, for example, the ABI 373 or 377 (Applied Biosystems) or MEGABACE 1000 (Molecular Dynamics, Inc. (Molecular Dynamics), Sunnyvale Calif.) DNA sequencing systems, or other automated and manual sequencing systems well known in the art.

[0137] The nucleotide sequences of the Sequence Listing have been prepared by current, state-of-the-art, automated methods and, as such, may contain occasional sequencing errors or unidentified nucleotides. Such unidentified nucleotides are designated by an N. These infrequent unidentified bases do not represent a hindrance to practicing the invention for those skilled in the art. Several methods employing standard recombinant techniques may be used to correct errors and complete the missing sequence information. (See, e.g., those described in Ausubel, F. M. et al. (1997) Short Protocols in Molecular Biology, John Wiley & Sons, New York N.Y.; and Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview N.Y.)

[0138] Assembly of cDNA Sequences

[0139] Human polynucleotide sequences may be assembled using programs or algorithms well known in the art. Sequences to be assembled are related, wholly or in part, and may be derived from a single or many different transcripts. Assembly of the sequences can be performed using such programs as PHRAP (Phils Revised Assembly Program) and the GELVIEW fragment assembly system (GCG), or other methods known in the art.

[0140] Alternatively, cDNA sequences are used as “component” sequences that are assembled into “template” or “consensus” sequences as follows. Sequence chromatograms are processed, verified, and quality scores are obtained using PHRED. Raw sequences are edited using an editing pathway known as Block 1 (See, e.g., the LIFESEQ Assembled User Guide, Incyte Genomics, Palo Alto, Calif.). A series of BLAST comparisons is performed and low-information segments and repetitive elements (e.g., dinucleotide repeats, Alu repeats, etc.) are replaced by “n's”, or masked, to prevent spurious matches. Mitochondrial and ribosomal RNA sequences are also removed. The processed sequences are then loaded into a relational database management system (RDMS) which assigns edited sequences to existing templates, if available. When additional sequences are added into the RDMS, a process is initiated which modifies existing templates or creates new templates from works in progress (i.e., nonfinal assembled sequences) containing queued sequences or the sequences themselves. After the new sequences have been assigned to templates, the templates can be merged into bins. If multiple templates exist in one bin, the bin can be split and the templates reannotated.

[0141] Once gene bins have been generated based upon sequence alignments, bins are “clone joined” based upon clone information. Clone joining occurs when the 5′ sequence of one clone is present in one bin and the 3′ sequence from the same clone is present in a different bin, indicating that the two bins should be merged into a: single bin. Only bins which share at least two different clones are merged.

[0142] A resultant template sequence may contain either a partial or a full length open reading frame, or all or part of a genetic regulatory element. This variation is due in part to the fact that the full length cDNAs of many genes are several hundred, and sometimes several thousand, bases in length. With current technology, cDNAs comprising the coding regions of large genes cannot be cloned because of vector limitations, incomplete reverse transcription of the mRNA, or incomplete “second strand” synthesis. Template sequences may be extended to include additional contiguous sequences derived from the parent RNA transcript using a variety of methods known to those of skill in the art. Extension may thus be used to achieve the full length coding sequence of a gene.

[0143] Analysis of the cDNA Sequences

[0144] The cDNA sequences are analyzed using a variety of programs and algorithms which are well known in the art. (See, e.g., Ausubel, 1997, supra, Chapter 7.7; Meyers, R. A. (Ed.) (1995) Molecular Biology and Biotechnology, Wiley VCH, New York N.Y., pp. 856-853; and Table 8.) These analyses comprise both reading frame determinations, e.g., based on triplet codon periodicity for particular organisms (Fickett, J. W. (1982) Nucleic Acids Res. 10:5303-5318); analyses of potential start and stop codons; and homology searches.

[0145] Computer programs known to those of skill in the art for performing computer-assisted searches for amino acid and nucleic acid sequence similarity, include, for example, Basic Local Alignment Search Tool (BLAST; Altschul, S. F. (1993) J. Mol. Evol. 36:290-300; Altschul, S. F. et al. (1990) J. Mol. Biol. 215:403-410). BLAST is especially useful in determining exact matches and comparing two sequence fragments of arbitrary but equal lengths, whose alignment is locally maximal and for which the alignment score meets or exceeds a threshold or cutoff score set by the user (Karlin, S. et al. (1988) Proc. Natl. Acad. Sci. USA 85:841-845). Using an appropriate search tool (e.g., BLAST or HMM), GenBank, SwissProt, BLOCKS, PFAM and other databases may be searched for sequences containing regions of homology to a query mddt or MDDT of the present invention.

[0146] Other approaches to the identification, assembly, storage, and display of nucleotide and polypeptide sequences are provided in “Relational Database for Storing Biomolecule Information,” U.S. Ser. No. 08/947,845, filed Oct. 9, 1997; “Project-Based Full-Length Biomolecular Sequence Database,” U.S. Pat. No. 5,953,727, and “Relational Database and System for Storing Information Relating to Biomolecular Sequences,“U.S. Ser. No. 09/034,807, filed Mar. 4, 1998, all of which are incorporated by reference herein in their entirety.

[0147] Protein hierarchies can be assigned to the putative encoded polypeptide based on, e.g., motif, BLAST, or biological analysis. Methods for assigning these hierarchies are described, for example, in “Database System Employing Protein Function Hierarchies for Viewing Biomolecular Sequence Data,” U.S. Pat. No. 6,023,659, incorporated herein by reference.

[0148] Human Disease Detection and Treatment Molecule Sequences

[0149] The mddt of the present invention may be used for a variety of diagnostic and therapeutic purposes. For example, an mddt may be used to diagnose a particular condition, disease, or disorder associated with disease detection and treatment molecules. Such conditions, diseases, and disorders include, but are not limited to, a cell proliferative disorder, such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, a cancer of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; and an autoimmune/inflammatory disorder, such as actinic keratosis, acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, arteriosclerosis, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, bronchitis, bursitis, cholecystitis, cirrhosis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, paroxysmal nocturnal hemoglobinuria, hepatitis, hypereosinophilia, irritable bowel syndrome, episodic lymphopenia with lymphocytotoxins, mixed connective tissue disease (MCTD), multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, myelofibrosis, osteoarthritis, osteoporosis, pancreatitis, polycythemia vera, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, primary thrombocythemia, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, trauma, and hematopoietic cancer including lymphoma, leukemia, and myeloma. The mddt can be used to detect the presence of, or to quantify the amount of, an mddt-related polynucleotide in a sample. This information is then compared to information obtained from appropriate reference samples, and a diagnosis is established. Alternatively, a polynucleotide complementary to a given mddt can inhibit or inactivate a therapeutically relevant gene related to the mddt.

[0150] Analysis of mddt Expression Patterns

[0151] The expression of mddt may be routinely assessed by hybridization-based methods to determine, for example, the tissue-specificity, disease-specificity, or developmental stage-specificity of mddt expression. For example, the level of expression of mddt may be compared among different cell types or tissues, among diseased and normal cell types or tissues, among cell types or tissues at different developmental stages, or among cell types or tissues undergoing various treatments. This type of analysis is useful, for example, to assess the relative levels of mddt expression in fully or partially differentiated cells or tissues, to determine if changes in mddt expression levels are correlated with the development or progression of specific disease states, and to assess the response of a cell or tissue to a specific therapy, for example, in pharmacological or toxicological studies. Methods for the analysis of mddt expression are based on hybridization and amplification technologies and include membrane-based procedures such as northern blot analysis, high-throughput procedures that utilize, for example, microarrays, and PCR-based procedures.

[0152] Hybridization and Genetic Analysis

[0153] The mddt, their fragments, or complementary sequences, may be used to identify the presence of and/or to determine the degree of similarity between two (or more) nucleic acid sequences. The mddt may be hybridized to naturally occurring or recombinant nucleic acid sequences under appropriately selected temperatures and salt concentrations. Hybridization with a probe based on the nucleic acid sequence of at least one of the mddt allows for the detection of nucleic acid sequences, including genomic sequences, which are identical or related to the mddt of the Sequence Listing. Probes may be selected from non-conserved or unique regions of at least one of the polynucleotides of SEQ ID NO: 1-36 and tested for their ability to identify or amplify the target nucleic acid sequence using standard protocols.

[0154] Polynucleotide sequences that are capable of hybridizing, in particular, to those shown in SEQ ID NO: 1-36 and fragments thereof, can be identified using various conditions of stringency. (See, e.g., Wahl, G. M. and S. L. Berger (1987) Methods Enzymol. 152:399-407; Kimmel, A. R. (1987) Methods Enzymol. 152:507-511.) Hybridization conditions are discussed in “Definitions.”

[0155] A probe for use in Southern or northern hybridization may be derived from a fragment of an mddt sequence, or its complement, that is up to several hundred nucleotides in length and is either single-stranded or double-stranded. Such probes may be hybridized in solution to biological materials such as plasmids, bacterial, yeast, or human artificial chromosomes, cleared or sectioned tissues, or to artificial substrates containing mddt. Microarrays are particularly suitable for identifying the presence of and detecting the level of expression for multiple genes of interest by examining gene expression correlated with, e.g., various stages of development, treatment with a drug or compound, or disease progression. An array analogous to a dot or slot blot may be used to arrange and link polynucleotides to the surface of a substrate using one or more of the following: mechanical (vacuum), chemical, thermal, or UV bonding procedures. Such an array may contain any number of mddt and may be produced by hand or by using available devices, materials, and machines.

[0156] Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T. M. et al. (1995) U.S. Pat. No. 5,474,796; Schena, M. et al. (1996) Proc. Natl. Acad. Sci. USA 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R. A. et al. (1997) Proc. Natl. Acad. Sci. USA 94:2150-2155; and Heller, M. J. et al. (1997) U.S. Pat. No. 5,605,662.)

[0157] Probes may be labeled by either PCR or enzymatic techniques using a variety of commercially available reporter molecules. For example, commercial kits are available for radioactive and chemiluminescent labeling (Amersham Pharmacia Biotech) and for alkaline phosphatase labeling (Life Technologies). Alternatively, mddt may be cloned into commercially available vectors for the production of RNA probes. Such probes may be transcribed in the presence of at least one labeled nucleotide (e.g., ³²P-ATP, Amersham Pharmacia Biotech).

[0158] Additionally the polynucleotides of SEQ ID NO: 1-36 or suitable fragments thereof can be used to isolate full length cDNA sequences utilizing hybridization and/or amplification procedures well known in the art, e.g., cDNA library screening, PCR amplification, etc. The molecular cloning of such full length cDNA sequences may employ the method of cDNA library screening with probes using the hybridization, stringency, washing, and probing strategies described above and in Ausubel, supra, Chapters 3, 5, and 6. These procedures may also be employed with genomic libraries to isolate genomic sequences of mddt in order to analyze, e.g., regulatory elements.

[0159] Genetic Mapping

[0160] Gene identification and mapping are important in the investigation and treatment of almost all conditions, diseases, and disorders. Cancer, cardiovascular disease, Alzheimer's disease, arthritis, diabetes, and mental illnesses are of particular interest. Each of these conditions is more complex than the single gene defects of sickle cell anemia or cystic fibrosis, with select groups of genes being predictive of predisposition for a particular condition, disease, or disorder. For example, cardiovascular disease may result from malfunctioning receptor molecules that fail to clear cholesterol from the bloodstream, and diabetes may result when a particular individual's immune system is activated by an infection and attacks the insulin-producing cells of the pancreas. In some studies, Alzheimer's disease has been linked to a gene on chromosome 21; other studies predict a different gene and location. Mapping of disease genes is a complex and reiterative process and generally proceeds from genetic linkage analysis to physical mapping.

[0161] As a condition is noted among members of a family, a genetic linkage map traces parts of chromosomes that are inherited in the same pattern as the condition. Statistics link the inheritance of particular conditions to particular regions of chromosomes, as defined by RFLP or other markers. (See, for example, Lander, E. S. and Botstein, D. (1986) Proc. Natl. Acad. Sci. USA 83:7353-7357.) Occasionally, genetic markers and their locations are known from previous studies. More often, however, the markers are simply stretches of DNA that differ among individuals. Examples of genetic linkage maps can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) World Wide Web site.

[0162] In another embodiment of the invention, mddt sequences may be used to generate hybridization probes useful in chromosomal mapping of naturally occurring genomic sequences. Either coding or noncoding sequences of mddt may be used, and in some instances, noncoding sequences may be preferable over coding sequences. For example, conservation of an mddt coding sequence among members of a multi-gene family may potentially cause undesired cross hybridization during chromosomal mapping. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Harrington, J. J. et al. (1997) Nat. Genet. 15:345-355; Price, C. M. (1993) Blood Rev. 7:127-134; and Trask, B. J. (1991) Trends Genet. 7:149-154.)

[0163] Fluorescent in situ hybridization (FISH) may be correlated with other physical chromosome mapping techniques and genetic map data. (See, e.g., Meyers, supra, pp. 965-968.) Correlation between the location of mddt on a physical chromosomal map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder. The mddt sequences may also be used to detect polymorphisms that are genetically linked to the inheritance of a particular condition, disease, or disorder.

[0164] In situ hybridization of chromosomal preparations and genetic mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending existing genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the number or arm of the corresponding human chromosome is not known. These new marker sequences can be mapped to human chromosomes and may provide valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once a disease or syndrome has been crudely correlated by genetic linkage with a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti, R. A. et al. (1988) Nature 336:577-580.) The nucleotide sequences of the subject invention may also be used to detect differences in chromosomal architecture due to translocation, inversion, etc., among normal, carrier, or affected individuals.

[0165] Once a disease-associated gene is mapped to a chromosomal region, the gene must be cloned in order to identify mutations or other alterations (e.g., translocations or inversions) that may be correlated with disease. This process requires a physical map of the chromosomal region containing the disease-gene of interest along with associated markers. A physical map is necessary for determining the nucleotide sequence of and order of marker genes on a particular chromosomal region. Physical mapping techniques are well known in the art and require the generation of overlapping sets of cloned DNA fragments from a particular organelle, chromosome, or genome. These clones are analyzed to reconstruct and catalog their order. Once the position of a marker is determined, the DNA from that region is obtained by consulting the catalog and selecting clones from that region. The gene of interest is located through positional cloning techniques using hybridization or similar methods.

[0166] Diagnostic Uses

[0167] The mddt of the present invention may be used to design probes useful in diagnostic assays. Such assays, well known to those skilled in the art, may be used to detect or confirm conditions, disorders, or diseases associated with abnormal levels of mddt expression. Labeled probes developed from mddt sequences are added to a sample under hybridizing conditions of desired stringency. In some instances, mddt, or fragments or oligonucleotides derived from mddt, may be used as primers in amplification steps prior to hybridization. The amount of hybridization complex formed is quantified and compared with standards for that cell or tissue. If mddt expression varies significantly from the standard, the assay indicates the presence of the condition, disorder, or disease. Qualitative or quantitative diagnostic methods may include northern, dot blot, or other membrane or dip-stick based technologies or multiple-sample format technologies such as PCR, enzyme-linked immunosorbent assay (ELISA)-like, pin, or chip-based assays.

[0168] The probes described above may also be used to monitor the progress of conditions, disorders, or diseases associated with abnormal levels of mddt expression, or to evaluate the efficacy of a particular therapeutic treatment. The candidate probe may be identified from the mddt that are specific to a given human tissue and have not been observed in GenBank or other genome databases. Such a probe may be used in animal studies, preclinical tests, clinical trials, or in monitoring the treatment of an individual patient. In a typical process, standard expression is established by methods well known in the art for use as a basis of comparison, samples from patients affected by the disorder or disease are combined with the probe to evaluate any deviation from the standard profile, and a therapeutic agent is administered and effects are monitored to generate a treatment profile. Efficacy is evaluated by determining whether the expression progresses toward or returns to the standard normal pattern. Treatment profiles may be generated over a period of several days or several months. Statistical methods well known to those skilled in the art may be use to determine the significance of such therapeutic agents.

[0169] The polynucleotides are also useful for identifying individuals from minute biological samples, for example, by matching the RFLP pattern of a sample's DNA to that of an individual's DNA. The polynucleotides of the present invention can also be used to determine the actual base-by-base DNA sequence of selected portions of an individual's genome. These sequences can be used to prepare PCR primers for amplifying and isolating such selected DNA, which can then be sequenced. Using this technique, an individual can be identified through a unique set of DNA sequences. Once a unique ID database is established for an individual, positive identification of that individual can be made from extremely small tissue samples.

[0170] In a particular aspect, oligonucleotide primers derived from the mddt of the invention may be used to detect single nucleotide polymorphisms (SNPs). SNPs are substitutions, insertions and deletions that are a frequent cause of inherited or acquired genetic disease in humans. Methods of SNP detection include, but are not limited to, single-stranded conformation polymorphism (SSCP) and fluorescent SSCP (fSSCP) methods. In SSCP, oligonucleotide primers derived from mddt are used to amplify DNA using the polymerase chain reaction (PCR). The DNA may be derived, for example, from diseased or normal tissue, biopsy samples, bodily fluids, and the like. SNPs in the DNA cause differences in the secondary and tertiary structures of PCR products in single-stranded form, and these differences are detectable using gel electrophoresis in non-denaturing gels. In fSCCP, the oligonucleotide primers are fluorescently labeled, which allows detection of the amplimers in high-throughput equipment such as DNA sequencing machines. Additionally, sequence database analysis methods, termed in silico SNP (isSNP), are capable of identifying polymorphisms by comparing the sequences of individual overlapping DNA fragments which assemble into a common consensus sequence. These computer-based methods filter out sequence variations due to laboratory preparation of DNA and sequencing errors using statistical models and automated analyses of DNA sequence chromatograms. In the alternative, SNPs may be detected and characterized by mass spectrometry using, for example, the high throughput MASSARRAY system (Sequenom, Inc., San Diego Calif.).

[0171] DNA-based identification techniques are critical in forensic technology. DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, semen, etc., can be amplified using, e.g., PCR, to identify individuals. (See, e.g., Erlich, H. (1992) PCR Technology, Freeman and Co., New York, N.Y.). Similarly, polynucleotides of the present invention can be used as polymorphic markers.

[0172] There is also a need for reagents capable of identifying the source of a particular tissue. Appropriate reagents can comprise, for example, DNA probes or primers prepared from the sequences of the present invention that are specific for particular tissues. Panels of such reagents can identify tissue by species and/or by organ type. In a similar fashion, these reagents can be used to screen tissue cultures for contamination.

[0173] The polynucleotides of the present invention can also be used as molecular weight markers on nucleic acid gels or Southern blots, as diagnostic probes for the presence of a specific mRNA in a particular cell type, in the creation of subtracted cDNA libraries which aid in the discovery of novel polynucleotides, in selection and synthesis of oligomers for attachment to an array or other support, and as an antigen to elicit an immune response.

[0174] Disease Model Systems Using mddt

[0175] The mddt of the invention or their mammalian homologs may be “knocked out” in an animal model system using homologous recombination in embryonic stem (ES) cells. Such techniques are well known in the art and are useful for the generation of animal models of human disease. (See, e.g., U.S. Pat. No. 5,175,383 and U.S. Pat. No. 5,767,337.) For example, mouse ES cells, such as the mouse 129/SvJ cell line, are derived from the early mouse embryo and grown in culture. The ES cells are transformed with a vector containing the gene of interest disrupted by a marker gene, e.g., the neomycin phosphotransferase gene (neo; Capecchi, M. R. (1989) Science 244:1288-1292). The vector integrates into the corresponding region of the host genome by homologous recombination. Alternatively, homologous recombination takes place using the Cre-loxP system to knockout a gene of interest in a tissue- or developmental stage-specific manner (Marth, J. D. (1996) Clin. Invest. 97:1999-2002; Wagner, K. U. et al. (1997) Nucleic Acids Res. 25:4323-4330). Transformed ES cells are identified and microinjected into mouse cell blastocysts such as those from the C57BL/6 mouse strain. The blastocysts are surgically transferred to pseudopregnant dams, and the resulting chimeric progeny are genotyped and bred to produce heterozygous or homozygous strains. Transgenic animals thus generated may be tested with potential therapeutic or toxic agents.

[0176] The mddt of the invention may also be manipulated in vitro in ES cells derived from human blastocysts. Human ES cells have the potential to differentiate into at least eight separate cell lineages including endoderm, mesoderm, and ectodermal cell types. These cell lineages differentiate into, for example, neural cells, hematopoietic lineages, and cardiomyocytes (Thomson, J. A. et al. (1998) Science 282:1145-1147).

[0177] The mddt of the invention can also be used to create “knockin” humanized animals (pigs) or transgenic animals (mice or rats) to model human disease. With knockin technology, a region of mddt is injected into animal ES cells, and the injected sequence integrates into the animal cell genome. Transformed cells are injected into blastulae, and the blastulae are implanted as described above. Transgenic progeny or inbred lines are studied and treated with potential pharmaceutical agents to obtain information on treatment of a human disease. Alternatively, a mammal inbred to overexpress mddt, resulting, e.g., in the secretion of MDDT in its milk, may also serve as a convenient source of that protein (Janne, J. et al. (1998) Biotechnol. Annu. Rev. 4:55-74).

[0178] Screening Assays

[0179] MDDT encoded by polynucleotides of the present invention may be used to screen for molecules that bind to or are bound by the encoded polypeptides. The binding of the polypeptide and the molecule may activate (agonist), increase, inhibit (antagonist), or decrease activity of the polypeptide or the bound molecule. Examples of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

[0180] Preferably, the molecule is closely related to the natural ligand of the polypeptide, e.g., a ligand or fragment thereof, a natural substrate, or a structural or functional mimetic. (See, Coligan et al., (1991) Current Protocols in Immunology 1(2): Chapter 5.) Similarly, the molecule can be closely related to the natural receptor to which the polypeptide binds, or to at least a fragment of the receptor, e.g., the active site. In either case, the molecule can be rationally designed using known techniques. Preferably, the screening for these molecules involves producing appropriate cells which express the polypeptide, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, Drosophila, or E coli. Cells expressing the polypeptide or cell membrane fractions which contain the expressed polypeptide are then contacted with a test compound and binding, stimulation, or inhibition of activity of either the polypeptide or the molecule is analyzed.

[0181] An assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a fluorophore, radioisotope, enzyme conjugate, or other detectable label. Alternatively, the assay may assess binding in the presence of a labeled competitor.

[0182] Additionally, the assay can be carried out using cell-free preparations, polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures. The assay may also simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a standard.

[0183] Preferably, an ELISA assay using, e.g., a monoclonal or polyclonal antibody, can measure polypeptide level in a sample. The antibody can measure polypeptide level by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate.

[0184] All of the above assays can be used in a diagnostic or prognostic context. The molecules discovered using these assays can be used to treat disease or to bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the polypeptide/molecule. Moreover, the assays can discover agents which may inhibit or enhance the production of the polypeptide from suitably manipulated cells or tissues.

[0185] Transcript Imaging and Toxicological Testing

[0186] Another embodiment relates to the use of mddt to develop a transcript image of a tissue or cell type. A transcript image represents the global pattern of gene expression by a particular tissue or cell type. Global gene expression patterns are analyzed by quantifying the number of expressed genes and their relative abundance under given conditions and at a given time. (See Seilhamer et al., “Comparative Gene Transcript Analysis,” U.S. Pat. No. 5,840,484, expressly incorporated by reference herein.) Thus a transcript image may be generated by hybridizing the polynucleotides of the present invention or their complements to the totality of transcripts or reverse transcripts of a particular tissue or cell type. In one embodiment, the hybridization takes place in high-throughput format, wherein the polynucleotides of the present invention or their complements comprise a subset of a plurality of elements on a microarray. The resultant transcript image would provide a profile of gene activity pertaining to disease detection and treatment molecules.

[0187] Transcript images which profile mddt expression may be generated using transcripts isolated from tissues, cell lines, biopsies, or other biological samples. The transcript image may thus reflect mddt expression in vivo, as in the case of a tissue or biopsy sample, or in vitro, as in the case of a cell line.

[0188] Transcript images which profile mddt expression may also be used in conjunction with in vitro model systems and preclinical evaluation of pharmaceuticals, as well as toxicological testing of industrial and naturally-occurring environmental compounds. All compounds induce characteristic gene expression patterns, frequently termed molecular fingerprints or toxicant signatures, which are indicative of mechanisms of action and toxicity (Nuwaysir, E. F. et al. (1999) Mol. Carcinog. 24:153-159; Steiner, S. and Anderson, N. L. (2000) Toxicol. Lett. 112-113:467-71, expressly incorporated by reference herein). If a test compound has a signature similar to that of a compound with known toxicity, it is likely to share those toxic properties. These fingerprints or signatures are most useful and refined when they contain expression information from a large number of genes and gene families. Ideally, a genome-wide measurement of expression provides the highest quality signature. Even genes whose expression is not altered by any tested compounds are important as well, as the levels of expression of these genes are used to normalize the rest of the expression data. The normalization procedure is useful for comparison of expression data after treatment with different compounds. While the assignment of gene function to elements of a toxicant signature aids in interpretation of toxicity mechanisms, knowledge of gene function is not necessary for the statistical matching of signatures which leads to prediction of toxicity. (See, for example, Press Release 00-02 from the National Institute of Environmental Health Sciences, released Feb. 29, 2000, available at http://www.niehs.nih.gov/oc/news/toxchip.htm) Therefore, it is important and desirable in toxicological screening using toxicant signatures to include all expressed gene sequences.

[0189] In one embodiment, the toxicity of a test compound is assessed by treating a biological sample containing nucleic acids with the test compound. Nucleic acids that are expressed in the treated biological sample are hybridized with one or more probes specific to the polynucleotides of the present invention, so that transcript levels corresponding to the polynucleotides of the present invention may be quantified. The transcript levels in the treated biological sample are compared with levels in an untreated biological sample. Differences in the transcript levels between the two samples are indicative of a toxic response caused by the test compound in the treated sample.

[0190] Another particular embodiment relates to the use of MDDT encoded by polynucleotides of the present invention to analyze the proteome of a tissue or cell type. The term proteome refers to the global pattern of protein expression in a particular tissue or cell type. Each protein component of a proteome can be subjected individually to further analysis. Proteome expression patterns, or profiles, are analyzed by quantifying the number of expressed proteins and their relative abundance under given conditions and at a given time. A profile of a cell's proteome may thus be generated by separating and analyzing the polypeptides of a particular tissue or cell type. In one embodiment, the separation is achieved using two dimensional gel electrophoresis, in which proteins from a sample are separated by isoelectric focusing in the first dimension, and then according to molecular weight by sodium dodecyl sulfate slab gel electrophoresis in the second dimension (Steiner and Anderson, supra. The proteins are visualized in the gel as discrete and uniquely positioned spots, typically by staining the gel with an agent such as Coomassie Blue or silver or fluorescent stains. The optical density of each protein spot is generally proportional to the level of the protein in the sample. The optical densities of equivalently positioned protein spots from different samples, for example, from biological samples either treated or untreated with a test compound or therapeutic agent, are compared to identify any changes in protein spot density related to the treatment. The proteins in the spots are partially sequenced using, for example, standard methods employing chemical or enzymatic cleavage followed by mass spectrometry. The identity of the protein in a spot may be determined by comparing its partial sequence, preferably of at least 5 contiguous amino acid residues, to the polypeptide sequences of the present invention. In some cases, further sequence data may be obtained for definitive protein identification.

[0191] A proteomic profile may also be generated using antibodies specific for MDDT to quantify the levels of MDDT expression. In one embodiment, the antibodies are used as elements on a microarray, and protein expression levels are quantified by exposing the microarray to the sample and detecting the levels of protein bound to each array element (Lueking, A. et al. (1999) Anal. Biochem. 270:103-11; Mendoze, L. G. et al. (1999) Biotechniques 27:778-88). Detection may be performed by a variety of methods known in the art, for example, by reacting the proteins in the sample with a thiol- or amino-reactive fluorescent compound and detecting the amount of fluorescence bound at each array element.

[0192] Toxicant signatures at the proteome level are also useful for toxicological screening, and should be analyzed in parallel with toxicant signatures at the transcript level. There is a poor correlation between transcript and protein abundances for some proteins in some tissues (Anderson, N. L. and Seilhamer, J. (1997) Electrophoresis 18:533-537), so proteome toxicant signatures may be useful in the analysis of compounds which do not significantly affect the transcript image, but which alter the proteomic profile. In addition, the analysis of transcripts in body fluids is difficult, due to rapid degradation of mRNA, so proteomic profiling may be more reliable and informative in such cases.

[0193] In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins that are expressed in the treated biological sample are separated so that the amount of each protein can be quantified. The amount of each protein is compared to the amount of the corresponding protein in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample. Individual proteins are identified by sequencing the amino acid residues of the individual proteins and comparing these partial sequences to the MDDT encoded by polynucleotides of the present invention.

[0194] In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins from the biological sample are incubated with antibodies specific to the MDDT encoded by polynucleotides of the present invention. The amount of protein recognized by the antibodies is quantified. The amount of protein in the treated biological sample is compared with the amount in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample.

[0195] Transcript images may be used to profile mddt expression in distinct tissue types. This process can be used to determine disease detection and treatment molecule activity in a particular tissue type relative to this activity in a different tissue type. Transcript images may be used to generate a profile of mddt expression characteristic of diseased tissue. Transcript images of tissues before and after treatment may be used for diagnostic purposes, to monitor the progression of disease, and to monitor the efficacy of drug treatments for diseases which affect the activity of disease detection and treatment molecules.

[0196] Transcript images of cell lines can be used to assess disease detection and treatment molecule activity and/or to identify cell lines that lack or misregulate this activity. Such cell lines may then be treated with pharmaceutical agents, and a transcript image following treatment may indicate the efficacy of these agents in restoring desired levels of this activity. A similar approach may be used to assess the toxicity of pharmaceutical agents as reflected by undesirable changes in disease detection and treatment molecule activity. Candidate pharmaceutical agents may be evaluated by comparing their associated transcript images with those of pharmaceutical agents of known effectiveness.

[0197] Antisense Molecules

[0198] The polynucleotides of the present invention are useful in antisense technology. Antisense technology or therapy relies on the modulation of expression of a target protein through the specific binding of an antisense sequence to a target sequence encoding the target protein or directing its expression. (See, e.g., Agrawal, S., ed. (1996) Antisense Therapeutics, Humana Press Inc., Totawa N.J.; Alama, A. et al. (1997) Pharmacol. Res. 36(3):171-178; Crooke, S. T. (1997) Adv. Pharmacol. 40:149; Sharma, H. W. and R. Narayanan (1995) Bioessays 17(12):1055-1063; and Lavrosky, Y. et al. (1997) Biochem. Mol. Med. 62(1):11-22.) An antisense sequence is a polynucleotide sequence capable of specifically hybridizing to at least a portion of the target sequence. Antisense sequences bind to cellular mRNA and/or genomic DNA, affecting translation and/or transcription. Antisense sequences can be DNA, RNA, or nucleic acid mimics and analogs. (See, e.g., Rossi, J. J. et al. (1991) Antisense Res. Dev. 1(3):285-288; Lee, R. et al. (1998) Biochemistry 37(3):900-1010; Pardridge, W. M. et al. (1995) Proc. Natl. Acad. Sci. USA 92(12):5592-5596; and Nielsen, P. E. and Haaima, G. (1997) Chem. Soc. Rev. 96:73-78.) Typically, the binding which results in modulation of expression occurs through hybridization or binding of complementary base pairs. Antisense sequences can also bind to DNA duplexes through specific interactions in the major groove of the double helix.

[0199] The polynucleotides of the present invention and fragments thereof can be used as antisense sequences to modify the expression of the polypeptide encoded by mddt. The antisense sequences can be produced ex vivo, such as by using any of the ABI nucleic acid synthesizer series (Applied Biosystems) or other automated systems known in the art. Antisense sequences can also be produced biologically, such as by transforming an appropriate host cell with an expression vector containing the sequence of interest. (See, e.g., Agrawal, supra.)

[0200] In therapeutic use, any gene delivery system suitable for introduction of the antisense sequences into appropriate target cells can be used. Antisense sequences can be delivered intracellularly in the form of an expression plasmid which, upon transcription, produces a sequence complementary to at least a portion of the cellular sequence encoding the target protein. (See, e.g., Slater, J. E., et al. (1998) J. Allergy Clin. Immunol. 102(3):469-475; and Scanlon, K. J., et al. (1995) 9(13):1288-1296.). Antisense sequences can also be introduced intracellularly through the use of viral vectors, such as retrovirus and adeno-associated virus vectors. (See, e.g., Miller, A. D. (1990) Blood 76:271; Ausubel, F. M. et al. (1995) Current Protocols in Molecular Biology, John Wiley & Sons, New York N.Y.; Uckert, W. and W. Walther (1994) Pharmacol. Ther. 63(3):323-347.) Other gene delivery mechanisms include liposome-derived systems, artificial viral envelopes, and other systems known in the art. (See, e.g., Rossi, J. J. (1995) Br. Med. Bull. 51(1):217-225; Boado, R. J. et al. (1998) J. Pharm Sci. 87(11):1308-1315; and Morris, M. C. et al. (1997) Nucleic Acids Res. 25(14):2730-2736.)

[0201] Expression

[0202] In order to express a biologically active MDDT, the nucleotide sequences encoding MDDT or fragments thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding MDDT and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, supra, Chapters 4, 8, 16, and 17; and Ausubel, supra, Chapters 9, 10, 13, and 16.)

[0203] A variety of expression vector/host systems may be utilized to contain and express sequences encoding MDDT. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal (mammalian) cell systems. (See, e.g., Sambrook, supra; Ausubel, 1995, supra, Van Heeke, G. and S. M. Schuster (1989) J. Biol. Chem. 264:5503-5509; Bitter, G. A. et al. (1987) Methods Enzymol. 153:516-544; Scorer, C. A. et al. (1994) Bio/Technology 12:181-184; Engelhard, E. K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945; Takamatsu, N. (1987) EMBO J. 6:307-311; Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105; The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York N.Y., pp. 191-196; Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659; and Harrington, J. J. et al. (1997) Nat. Genet. 15:345-355.) Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. (See, e.g., Di Nicola, M. et al. (1998) Cancer Gen. Ther. 5(6):350-356; Yu, M. et al., (1993) Proc. Natl. Acad. Sci. USA 90(13):6340-6344; Buller, R. M. et al. (1985) Nature 317(6040):813-815; McGregor, D. P. et al. (1994) Mol. Immunol. 31(3):219-226; and Verma, I. M. and N. Somia (1997) Nature 389:239-242.) The invention is not limited by the host cell employed.

[0204] For long term production of recombinant proteins in mammalian systems, stable expression of MDDT in cell lines is preferred. For example, sequences encoding MDDT can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Any number of selection systems may be used to recover transformed cell lines. (See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.; Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. USA 77:3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol. Biol. 150:1-14; Hartman, S. C. and R. C. Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:8047-8051; Rhodes, C. A. (1995) Methods Mol. Biol. 55:121-131.)

[0205] Therapeutic Uses of mddt

[0206] The mddt of the invention may be used for somatic or germline gene therapy. Gene therapy may be performed to (i) correct a genetic deficiency (e.g., in the cases of severe combined immunodeficiency (SCID)-X1 disease characterized by X-linked inheritance (Cavazzana-Calvo, M. et al. (2000) Science 288:669-672), severe combined immunodeficiency syndrome associated with an inherited adenosine deaminase (ADA) deficiency (Blaese, R. M. et al. (1995) Science 270:475-480; Bordignon, C. et al. (1995) Science 270:470-475), cystic fibrosis (Zabner, J. et al. (1993) Cell 75:207-216; Crystal, R. G. et al. (1995) Hum. Gene Therapy 6:643-666; Crystal, R. G. et al. (1995) Hum. Gene Therapy 6:667-703), thalassemias, familial hypercholesterolemia, and hemophilia resulting from Factor VIII or Factor IX deficiencies (Crystal, R. G. (1995) Science 270:404-410; Verma, I. M. and Somia, N. (1997) Nature 389:239-242)), (ii) express a conditionally lethal gene product (e.g., in the case of cancers which result from unregulated cell proliferation), or (iii) express a protein which affords protection against intracellular parasites (e.g., against human retroviruses, such as human immunodeficiency virus (HIV) (Baltimore, D. (1988) Nature 335:395-396; Poeschla, E. et al. (1996) Proc. Natl. Acad. Sci. USA. 93:11395-11399), hepatitis B or C virus (HBV, HCV); fungal parasites, such as Candida albicans and Paracoccidioides brasiliensis; and protozoan parasites such as Plasmodium falciparum and Trypanosoma cruzi). In the case where a genetic deficiency in mddt expression or regulation causes disease, the expression of mddt from an appropriate population of transduced cells may alleviate the clinical manifestations caused by the genetic deficiency.

[0207] In a further embodiment of the invention, diseases or disorders caused by deficiencies in mddt are treated by constructing mammalian expression vectors comprising mddt and introducing these vectors by mechanical means into mddt-deficient cells. Mechanical transfer technologies for use with cells in vivo or ex vitro include (i) direct DNA microinjection into individual cells, (ii) ballistic gold particle delivery, (iii) liposome-mediated transfection, (iv) receptor-mediated gene transfer, and (v) the use of DNA transposons (Morgan, R. A. and Anderson, W. F. (1993) Annu. Rev. Biochem. 62:191-217; Ivics, Z. (1997) Cell 91:501-510; Boulay, J -L. and Récipon, H. (1998) Curr. Opin. Biotechnol. 9:445-450).

[0208] Expression vectors that may be effective for the expression of mddt include, but are not limited to, the PCDNA 3.1, EPITAG, PRCCMV2, PREP, PVAX vectors (Invitrogen, Carlsbad Calif.), PCMV-SCRIPT, PCMV-TAG, PEGSH/PERV (Stratagene, La Jolla Calif.), and PTET-OFF, PTET-ON, PTRE2, PTRE2-LUC, PTK-HYG (Clontech, Palo Alto Calif.). The mddt of the invention may be expressed using (i) a constitutively active promoter, (e.g., from cytomegalovirus (CMV), Rous sarcoma virus (RSV), SV40 virus, thymidine kinase (TK), or β-actin genes), (ii) an inducible promoter (e.g., the tetracycline-regulated promoter (Gossen, M. and Bujard, H. (1992) Proc. Natl. Acad. Sci. U.S.A. 89:5547-5551; Gossen, M. et al., (1995) Science 268:1766-1769; Rossi, F. M. V. and Blau, H. M. (1998) Curr. Opin. Biotechnol. 9:451-456), commercially available in the T-REX plasmid (Invitrogen); the ecdysone-inducible promoter (available in the plasmids PVGRXR and PIND; Invitrogen); the FK506/rapamycin inducible promoter; or the RU486/mifepristone inducible promoter (Rossi, F. M. V. and Blau, H. M. supra), or (iii) a tissue-specific promoter or the native promoter of the endogenous gene encoding MDDT from a normal individual.

[0209] Commercially available liposome transformation kits (e.g., the PERFECT LIPID TRANSFECTION KIT, available from Invitrogen) allow one with ordinary skill in the art to deliver polynucleotides to target cells in culture and require minimal effort to optimize experimental parameters. In the alternative, transformation is performed using the calcium phosphate method (Graham, F. L. and Eb, A. J. (1973) Virology 52:456-467), or by electroporation (Neumann, E. et al. (1982) EMBO J. 1:841-845). The introduction of DNA to primary cells requires modification of these standardized mammalian transfection protocols.

[0210] In another embodiment of the invention, diseases or disorders caused by genetic defects with respect to mddt expression are treated by constructing a retrovirus vector consisting of (i) mddt under the control of an independent promoter or the retrovirus long terminal repeat (LTR) promoter, (ii) appropriate RNA packaging signals, and (iii) a Rev-responsive element (RRE) along with additional retrovirus cis-acting RNA sequences and coding sequences required for efficient vector propagation. Retrovirus vectors (e.g., PFB and PFBNEO) are commercially available (Stratagene) and are based on published data (Riviere, I. et al. (1995) Proc. Natl. Acad. Sci. U.S.A. 92:6733-6737), incorporated by reference herein. The vector is propagated in an appropriate vector producing cell line (VPCL) that expresses an envelope gene with a tropism for receptors on the target cells or a promiscuous envelope protein such as VSVg (Armentano, D. et al. (1987) J. Virol. 61:1647-1650; Bender, M. A. et al. (1987) J. Virol. 61:1639-1646; Adam, M. A. and Miller, A. D. (1988) J. Virol. 62:3802-3806; Dull, T. et al. (1998) J. Virol. 72:8463-8471; Zufferey, R. et al. (1998) J. Virol. 72:9873-9880). U.S. Pat. No. 5,910,434 to Rigg (“Method for obtaining retrovirus packaging cell lines producing high transducing efficiency retroviral supernatant”) discloses a method for obtaining retrovirus packaging cell lines and is hereby incorporated by reference. Propagation of retrovirus vectors, transduction of a population of cells (e.g., CD4⁺ T-cells), and the return of transduced cells to a patient are procedures well known to persons skilled in the art of gene therapy and have been well documented (Ranga, U. et al. (1997) J. Virol. 71:7020-7029; Bauer, G. et al. (1997) Blood 89:2259-2267; Bonyhadi, M. L. (1997) J. Virol. 71:4707-4716; Ranga, U. et al. (1998) Proc. Natl. Acad. Sci. U.S.A. 95:1201-1206; Su, L. (1997) Blood 89:2283-2290).

[0211] In the alternative, an adenovirus-based gene therapy delivery system is used to deliver mddt to cells which have one or more genetic abnormalities with respect to the expression of mddt. The construction and packaging of adenovirus-based vectors are well known to those with ordinary skill in the art. Replication defective adenovirus vectors have proven to be versatile for importing genes encoding immunoregulatory proteins into intact islets in the pancreas (Csete, M. E. et al. (1995) Transplantation 27:263-268). Potentially useful adenoviral vectors are described in U.S. Pat. No. 5,707,618 to Armentano (“Adenovirus vectors for gene therapy”), hereby incorporated by reference. For adenoviral vectors, see also Antinozzi, P. A. et al. (1999) Annu. Rev. Nutr. 19:511-544 and Verma, I. M. and Somia, N. (1997) Nature 18:389:239-242, both incorporated by reference herein.

[0212] In another alternative, a herpes-based, gene therapy delivery system is used to deliver mddt to target cells which have one or more genetic abnormalities with respect to the expression of mddt. The use of herpes simplex virus (HSV)-based vectors may be especially valuable for introducing mddt to cells of the central nervous system, for which HSV has a tropism. The construction and packaging of herpes-based vectors are well known to those with ordinary skill in the art. A replication-competent herpes simplex virus (HSV) type 1-based vector has been used to deliver a reporter gene to the eyes of primates (Liu, X. et al. (1999) Exp. Eye Res.169:385-395). The construction of a HSV-1 virus vector has also been disclosed in detail in U.S. Pat. No. 5,804,413 to DeLuca (“Herpes simplex virus strains for gene transfer”), which is hereby incorporated by reference. U.S. Pat. No. 5,804,413 teaches the use of recombinant HSV d92 which consists of a genome containing at least one exogenous gene to be transferred to a cell under the control of the appropriate promoter for purposes including human gene therapy. Also taught by this patent are the construction and use of recombinant HSV strains deleted for ICP4, ICP27 and ICP22. For HSV vectors, see also Goins, W. F. et al. 1999 J. Virol. 73:519-532 and Xu, H. et al., (1994) Dev. Biol. 163:152-161, hereby incorporated by reference. The manipulation of cloned herpesvirus sequences, the generation of recombinant virus following the transfection of multiple plasmids containing different segments of the large herpesvirus genomes, the growth and propagation of herpesvirus, and the infection of cells with herpesvirus are techniques well known to those of ordinary skill in the art.

[0213] In another alternative, an alphavirus (positive, single-stranded RNA virus) vector is used to deliver mddt to target cells. The biology of the prototypic alphavirus, Semliki Forest Virus (SFV), has been studied extensively and gene transfer vectors have been based on the SFV genome (Garoff, H. and Li, K -J. (1998) Curr. Opin. Biotech. 9:464-469). During alphavirus RNA replication, a subgenomic RNA is generated that normally encodes the viral capsid proteins. This subgenomic RNA replicates to higher levels than the full-length genomic RNA, resulting in the overproduction of capsid proteins relative to the viral proteins with enzymatic activity (e.g., protease and polymerase). Similarly, inserting mddt into the alphavirus genome in place of the capsid-coding region results in the production of a large number of mddt RNAs and the synthesis of high levels of MDDT in vector transduced cells. While alphavirus infection is typically associated with cell lysis within a few days, the ability to establish a persistent infection in hamster normal kidney cells (BHK-21) with a variant of Sindbis virus (SIN) indicates that the lytic replication of alphaviruses can be altered to suit the needs of the gene therapy application (Dryga, S. A. et al. (1997) Virology 228:74-83). The wide host range of alphaviruses will allow the introduction of mddt into a variety of cell types. The specific transduction of a subset of cells in a population may require the sorting of cells prior to transduction. The methods of manipulating infectious cDNA clones of alphaviruses, performing alphavirus cDNA and RNA transfections, and performing alphavirus infections, are well known to those with ordinary skill in the art.

[0214] Antibodies

[0215] Anti-MDDT antibodies may be used to analyze protein expression levels. Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, and Fab fragments. For descriptions of and protocols of antibody technologies, see, e.g., Pound J. D. (1998) Immunochemical Protocols, Humana Press, Totowa, N.J.

[0216] The amino acid sequence encoded by the mddt of the Sequence Listing may be analyzed by appropriate software (e.g., LASERGENE NAVIGATOR software, DNASTAR) to determine regions of high immunogenicity. The optimal sequences for immunization are selected from the C-terminus, the N-terminus, and those intervening, hydrophilic regions of the polypeptide which are likely to be exposed to the external environment when the polypeptide is in its natural conformation. Analysis used to select appropriate epitopes is also described by Ausubel (1997, supra, Chapter 11.7). Peptides used for antibody induction do not need to have biological activity; however, they must be antigenic. Peptides used to induce specific antibodies may have an amino acid sequence consisting of at least five amino acids, preferably at least 10 amino acids, and most preferably at least 15 amino acids. A peptide which mimics an antigenic fragment of the natural polypeptide may be fused with another protein such as keyhole hemolimpet cyanin (KLH; Sigma, St. Louis Mo.) for antibody production. A peptide encompassing an antigenic region may be expressed from an mddt, synthesized as described above, or purified from human cells.

[0217] Procedures well known in the art may be used for the production of antibodies. Various hosts including mice, goats, and rabbits, may be immunized by injection with a peptide. Depending on the host species, various adjuvants may be used to increase immunological response.

[0218] In one procedure, peptides about 15 residues in length may be synthesized using an ABI 431A peptide synthesizer (Applied Biosystems) using fmoc-chemistry and coupled to KLH (Sigma) by reaction with M-maleimidobenzoyl-N-hydroxysuccinimide ester (Ausubel, 1995, supra). Rabbits are immunized with the peptide-KLH complex in complete Freund's adjuvant. The resulting antisera are tested for antipeptide activity by binding the peptide to plastic, blocking with 1% bovine serum albumin (BSA), reacting with rabbit antisera, washing, and reacting with radioiodinated goat anti-rabbit IgG. Antisera with antipeptide activity are tested for anti-MDDT activity using protocols well known in the art, including ELISA, radioimmunoassay (RIA), and immunoblotting.

[0219] In another procedure, isolated and purified peptide may be used to immunize mice (about 100 μg of peptide) or rabbits (about 1 mg of peptide). Subsequently, the peptide is radioiodinated and used to screen the immunized animals' B-lymphocytes for production of antipeptide antibodies. Positive cells are then used to produce hybridomas using standard techniques. About 20 mg of peptide is sufficient for labeling and screening several thousand clones. Hybridomas of interest are detected by screening with radioiodinated peptide to identify those fusions producing peptide-specific monoclonal antibody. In a typical protocol, wells of a multi-well plate (FAST, Becton-Dickinson, Palo Alto, Calif.) are coated with affinity-purified, specific rabbit-anti-mouse (or suitable anti-species IgG) antibodies at 10 mg/ml. The coated wells are blocked with 1% BSA and washed and exposed to supernatants from hybridomas. After incubation, the wells are exposed to radiolabeled peptide at 1 mg/ml.

[0220] Clones producing antibodies bind a quantity of labeled peptide that is detectable above background. Such clones are expanded and subjected to 2 cycles of cloning. Cloned hybridomas are injected into pristane-treated mice to produce ascites, and monoclonal antibody is purified from the ascitic fluid by affinity chromatography on protein A (Amersham Pharmacia Biotech). Several procedures for the production of monoclonal antibodies, including in vitro production, are described in Pound (supra). Monoclonal antibodies with antipeptide activity are tested for anti-MDDT activity using protocols well known in the art, including ELISA, RIA, and immunoblotting.

[0221] Antibody fragments containing specific binding sites for an epitope may also be generated. For example, such fragments include, but are not limited to, the F(ab′)2 fragments produced by pepsin digestion of the antibody molecule, and the Fab fragments generated by reducing the disulfide bridges of the F(ab′)2 fragments. Alternatively, construction of Fab expression libraries in filamentous bacteriophage allows rapid and easy identification of monoclonal fragments with desired specificity (Pound, supra, Chaps. 45-47). Antibodies generated against polypeptide encoded by mddt can be used to purify and characterize full-length MDDT protein and its activity, binding partners, etc.

[0222] Assays Using Antibodies

[0223] Anti-MDDT antibodies may be used in assays to quantify the amount of MDDT found in a particular human cell. Such assays include methods utilizing the antibody and a label to detect expression level under normal or disease conditions. The peptides and antibodies of the invention may be used with or without modification or labeled by joining them, either covalently or noncovalently, with a reporter molecule.

[0224] Protocols for detecting and measuring protein expression using either polyclonal or monoclonal antibodies are well known in the art. Examples include ELISA, RIA, and fluorescent activated cell sorting (FACS). Such immunoassays typically involve the formation of complexes between the MDDT and its specific antibody and the measurement of such complexes. These and other assays are described in Pound (supra).

[0225] Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

[0226] The disclosures of all patents, applications, and publications mentioned above and below, including U.S. Ser. No.60/261,865, U.S. Ser. No.60/263,065, U.S. Ser. No.60/263,329, U.S. Ser. No. 60/262,209, U.S. Ser. No. 60/262,208, U.S. Ser. No. 60/262,326, U.S. Ser. No. 60/263,063, and U.S. Ser. No. 60/261,622 are hereby expressly incorporated by reference.

EXAMPLES

[0227] I. Construction of cDNA Libraries

[0228] RNA was purchased from CLONTECH Laboratories, Inc. (Palo Alto Calif.) or isolated from various tissues. Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged over CsCl cushions or extracted with chloroform. RNA was precipitated with either isopropanol or sodium acetate and ethanol, or by other routine methods.

[0229] Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA purity. In most cases, RNA was treated with DNase. For most libraries, poly(A+) RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega Corporation (Promega), Madison Wis.), OLIGOTEX latex particles (QIAGEN, Inc. (QIAGEN), Valencia Calif.), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA purification kit (Ambion, Inc., Austin Tex.).

[0230] In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene Cloning Systems, Inc. (Stratagene), La Jolla Calif.) or SUPERSCRIPT plasmid system (Life Technologies), using the recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, supra, Chapters 5.1 through 6.6.) Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., PBLUESCRIPT plasmid (Stratagene), PSPORT1 plasmid (Life Technologies), PCDNA2.1 plasmid (Invitrogen, Carlsbad Calif.), PBK-CMV plasmid (Stratagene), PCR2-TOPOTA plasmid (Invitrogen), PCMV-ICIS plasmid (Stratagene), pIGEN (Incyte Genomics, Palo Alto Calif.), pRARE (Incyte Genomics), or pINCY (Incyte Genomics), or derivatives thereof. Recombinant plasmids were transformed into competent E. coli cells including XL1-Blue, XL1-BlueMRF, or SOLR from Stratagene or DH5α, DH10B, or ElectroMAX DH10B from Life Technologies.

[0231] H. Isolation f cDNA Clones

[0232] Plasmids were recovered from host cells by in vivo excision using the UNIZAP vector system (Stratagene) or by cell lysis. Plasmids were purified using at least one of the following: the Magic or WIZARD Minipreps DNA purification system (Promega); the AGTC Miniprep purification kit (Edge BioSystems, Gaithersburg Md.); and the QIAWELL 8, QIAWELL 8 Plus, and QIAWELL 8 Ultra plasmid purification systems or the R.E.A.L; PREP 96 plasmid purification kit (QIAGEN). Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4° C.

[0233] Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format. (Rao, V. B. (1994) Anal. Biochem. 216:1-14.) Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes, Inc. (Molecular Probes), Eugene Oreg.) and a FLUOROSKAN II fluorescence scanner (Labsystems Oy, Helsinki, Finland).

[0234] III. Sequencing and Analysis

[0235] cDNA sequencing reactions were processed using standard methods or high-throughput instrumentation such as the ABI CATALYST 800 thermal cycler (Applied Biosystems) or the PTC-200 thermal cycler (MJ Research) in conjunction with the HYDRA microdispenser (Robbins Scientific Corp., Sunnyvale Calif.) or the MICROLAB 2200 liquid transfer system (Hamilton). cDNA sequencing reactions were prepared using reagents provided by Amersham Pharmacia Biotech or supplied in ABI sequencing kits such as the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems). Electrophoretic separation of cDNA sequencing reactions and detection of labeled polynucleotides were carried out using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics); the ABI PRISM 373 or 377 sequencing system (Applied Biosystems) in conjunction with standard ABI protocols and base calling software; or other sequence analysis systems known in the art. Reading frames within the cDNA sequences were identified using standard methods (reviewed in Ausubel, 1997, supra, Chapter 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example VIII

[0236] IV. Assembly and Analysis of Sequences

[0237] Component sequences from chromatograms were subject to PHRED analysis and assigned a quality score. The sequences having at least a required quality score were subject to various pre-processing editing pathways to eliminate, e.g., low quality 3′ ends, vector and linker sequences, polyA tails, Alu repeats, mitochondrial and ribosomal sequences, bacterial contamination sequences, and sequences smaller than 50 base pairs. In particular, low-information sequences and repetitive elements (e.g., dinucleotide repeats, Alu repeats, etc.) were replaced by “n's”, or masked, to prevent spurious matches.

[0238] Processed sequences were then subject to assembly procedures in which the sequences were assigned to gene bins (bins). Each sequence could only belong to one bin. Sequences in each gene bin were assembled to produce consensus sequences (templates). Subsequent new sequences were added to existing bins using BLASTN (v.1.4 WashU) and CROSSMATCH. Candidate pairs were identified as all BLAST hits having a quality score greater than or equal to 150. Alignments of at least 82% local identity were accepted into the bin. The component sequences from each bin were assembled using a version of PHRAP. Bins with several overlapping component sequences were assembled using DEEP PHRAP. The orientation (sense or antisense) of each assembled template was determined based on the number and orientation of its component sequences. Template sequences as disclosed in the sequence listing correspond to sense strand sequences (the “forward” reading frames), to the best determination. The complementary (antisense) strands are inherently disclosed herein. The component sequences which were used to assemble each template consensus sequence are listed in Table 5, along with their positions along the template nucleotide sequences.

[0239] Bins were compared against each other and those having local similarity of at least 82% were combined and reassembled. Reassembled bins having templates of insufficient overlap (less than 95% local identity) were re-split. Assembled templates were also subject to analysis by STITCHER/EXON MAPPER algorithms which analyze the probabilities of the presence of splice variants, alternatively spliced exons, splice junctions, differential expression of alternative spliced genes across tissue types or disease states, etc. These resulting bins were subject to several rounds of the above assembly procedures.

[0240] Once gene bins were generated based upon sequence alignments, bins were clone joined based upon clone information. If the 5′ sequence of one clone was present in one bin and the 3′ sequence from the same clone was present in a different bin, it was likely that the two bins actually belonged together in a single bin. The resulting combined bins underwent assembly procedures to regenerate the consensus sequences.

[0241] The final assembled templates were subsequently annotated using the following procedure. Template sequences were analyzed using BLASTN (v2.0, NCBI) versus gbpri (GenBank version 126). “Hits” were defined as an exact match having from 95% local identity over 200 base pairs through 100% local identity over 100 base pairs, or a homolog match having an E-value, i.e. a probability score, of ≦1×10⁻⁸. The hits were subject to frameshift FASTx versus GENPEPT (GenBank version 126). (See Table 8). In this analysis, a homolog match was defined as having an E-value of ≦1×10⁻⁸. The assembly method used above was described in “System and Methods for Analyzing Biomolecular Sequences,” U.S. Ser. No. 09/276,534, filed Mar. 25, 1999, and the LIFESEQ Gold user manual (Incyte) both incorporated by reference herein.

[0242] Following assembly, template sequences were subjected to motif, BLAST, and functional analyses, and categorized in protein hierarchies using methods described in, e.g., “Database System Employing Protein Function Hierarchies for Viewing Biomolecular Sequence Data,” U.S. Pat. No. 6,023,659; “Relational Database for Storing Biomolecule Information,” U.S. Ser. No. 08/947,845, filed Oct. 9, 1997; “Project-Based Full-Length Biomolecular Sequence Database,” U.S. Pat. No. 5,953,727; and “Relational Database and System for Storing Information Relating to Biomolecular Sequences,” U.S. Ser. No. 09/034,807, filed Mar. 4, 1998, all of which are incorporated by reference herein.

[0243] The template sequences were further analyzed by translating each template in all three forward reading frames and searching each translation against the Pfam database of hidden Markov model-based protein families and domains using the HMMER software package (available to the public from Washington University School of Medicine, St. Louis Mo.). Regions of templates which, when translated, contain similarity to Pfam consensus sequences are reported in Table 3, along with descriptions of Pfam protein domains and families. Only those Pfam hits with an E-value of ≦1×10³¹ ³ are reported. (See also World Wide Web site http://pfam.wustl.edu/for detailed descriptions of Pfam protein domains and families.)

[0244] Additionally, the template sequences were translated in all three forward reading frames, and each translation was searched against hidden Markov models for signal peptides using the HMMER software package. Construction of hidden Markov models and their usage in sequence analysis has been described. (See, for example, Eddy, S. R. (1996) Curr. Opin. Str. Biol. 6:361-365.) Only those signal peptide hits with a cutoff score of 11 bits or greater are reported. A cutoff score of 11 bits or greater corresponds to at least about 91-94% true-positives in signal peptide prediction. Template sequences were also translated in all three forward reading frames, and each translation was searched against TMHMMER, a program that uses a hidden Markov model (HMM) to delineate transmembrane segments on protein sequences and determine orientation (Sonnhammer, E. L. et al. (1998) Proc. Sixth Intl. Conf. On Intelligent Systems for Mol. Biol., Glasgow et al., eds., The Am. Assoc. for Artificial Intelligence (AAAI) Press, Menlo Park, Calif., and MIT Press, Cambridge, Mass., pp. 175-182.) Regions of templates which, when translated, contain similarity to signal peptide or transmembrane consensus sequences are reported in Table 4.

[0245] The results of HMMER analysis as reported in Tables 3 and 4 may support the results of BLAST analysis as reported in Table 2 or may suggest alternative or additional properties of template-encoded polypeptides not previously uncovered by BLAST or other analyses.

[0246] Template sequences are further analyzed using the bioinformatics tools listed in Table 8, or using sequence analysis software known in the art such as MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco Calif.) and LASERGENE software (DNASTAR). Template sequences may be further queried against public databases such as the GenBank rodent, mammalian, vertebrate, prokaryote, and eukaryote databases.

[0247] The template sequences were translated to derive the corresponding longest open reading frame as presented by the polypeptide sequences as reported in Table 7. Alternatively, a polypeptide of the invention may begin at any of the methionine residues within the full length translated polypeptide. Polypeptide sequences were subsequently analyzed by querying against the GenBank protein database (GENPEPT, (GenBank version 126)). Full length polynucleotide sequences are also analyzed using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco Calif.) and LASERGENE software (DNASTAR). Polynucleotide and polypeptide sequence alignments are generated using default parameters specified by the CLUSTAL algorithm as incorporated into the MEGALIGN multisequence alignment program (DNASTAR), which also calculates the percent identity between aligned sequences.

[0248] Table 7 shows sequences with homology to the polypeptides of the invention as identified by BLAST analysis against the GenBank protein (GENPEPT) database. Column 1 shows the polypeptide sequence identification number (SEQ ID NO:) for the polypeptide segments of the invention. Column 2 shows the reading frame used in the translation of the polynucleotide sequences encoding the polypeptide segments. Column 3 shows the length of the translated polypeptide segments. Columns 4 and 5 show the start and stop nucleotide positions of the polynucleotide sequences encoding the polypeptide segments. Column 6 shows the GenBank identification number (GI Number) of the nearest GenBank homolog. Column 7 shows the probability score for the match between each polypeptide and its GenBank homolog. Column 8 shows the annotation of the GenBank homolog.

[0249] V. Analysis of Polynucleotide Expression

[0250] Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, supra, ch. 7; Ausubel, 1995, supra, ch. 4 and 16.)

[0251] Analogous computer techniques applying BLAST were used to search for identical or related molecules in cDNA databases such as GenBank or LIFESEQ (Incyte Genomics). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar. The basis of the search is the product score, which is defined as: $\frac{\text{BLAST Score} \times \text{Percent~~Identity}}{5 \times \text{minimum}\left\{ \text{length(Seq.~~1),~~length(Seq.~~2)} \right\}}$

[0252] The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. The product score is a normalized value between 0 and 100, and is calculated as follows: the BLAST score is multiplied by the percent nucleotide identity and the product is divided by (5 times the length of the shorter of the two sequences). The BLAST score is calculated by assigning a score of +5 for every base that matches in a high-scoring segment pair (HSP), and −4 for every mismatch. Two sequences may share more than one HSP (separated by gaps). If there is more than one HSP, then the pair with the highest BLAST score is used to calculate the product score. The product score represents a balance between fractional overlap and quality in a BLAST alignment. For example, a product score of 100 is produced only for 100% identity over the entire length of the shorter of the two sequences being compared. A product score of 70 is produced either by 100% identity and 70% overlap at one end, or by 88% identity and 100% overlap at the other. A product score of 50 is produced either by 100% identity and 50% overlap at one end, or 79% identity and 100% overlap.

[0253] VI. Tissue Distribution Profiling

[0254] A tissue distribution profile is determined for each template by compiling the cDNA library tissue classifications of its component cDNA sequences. Each component sequence, is derived from a cDNA library constructed from a human tissue. Each human tissue is classified into one of the following categories: cardiovascular system; connective tissue; digestive system; embryonic structures; endocrine system; exocrine glands; genitalia, female; genitalia, male; germ cells; hemic and immune system; liver; musculoskeletal system; nervous system; pancreas; respiratory system; sense organs; skin; stomatognathic system; unclassified/mixed; or urinary tract. Template sequences, component sequences, and cDNA library/tissue information are found in the LIFESEQ GOLD database (Incyte Genomics, Palo Alto Calif.).

[0255] Table 6 shows the tissue distribution profile for the templates of the invention. For each template, the three most frequently observed tissue categories are shown in column 3, along with the percentage of component sequences belonging to each category. Only tissue categories with percentage values of ≧10% are shown. A tissue distribution of “widely distributed” in column 3 indicates percentage values of <10% in all tissue categories.

[0256] VII. Transcript Image Analysis

[0257] Transcript images are generated as described in Seilhamer et al., “Comparative Gene Transcript Analysis,” U.S. Pat. No. 5,840,484, incorporated herein by reference.

[0258] VIII. Extension of Polynucleotide Sequences and Is Lation f a Full-Length cDNA

[0259] Oligonucleotide primers designed using an mddt of the Sequence Listing are used to extend the nucleic acid sequence. One primer is synthesized to initiate 5′ extension of the template, and the other primer, to initiate 3′ extension of the template. The initial primers may be designed using OLIGO 4.06 software (National Biosciences, Inc. (National Biosciences), Plymouth Minn.), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68° C. to about 72° C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations are avoided. Selected human cDNA libraries are used to extend the sequence. If more than one extension is necessary or desired, additional or nested sets of primers are designed.

[0260] High fidelity amplification is obtained by PCR using methods well known in the art. PCR is performed in 96-well plates using the PTC-200 thermal cycler (MJ Research). The reaction mix contains DNA template, 200 nmol of each primer, reaction buffer containing Mg²⁺, (NH₄)₂SO₄, and β-mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94° C., 3 min; Step 2: 94° C., 15 sec; Step 3: 60° C., 1 min; Step 4: 68° C. 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68° C., 5 min; Step 7: storage at 4° C. In the alternative, the parameters for primer pair T7 and SK+ are as follows: Step 1: 94° C., 3 min; Step 2: 94° C., 15 sec; Step 3: 57° C., 1 min; Step 4: 68° C., 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68° C., 5 min; Step 7: storage at 4° C.

[0261] The concentration of DNA in each well is determined by dispensing 100 μl PICOGREEN quantitation reagent (0.25% (v/v); Molecular Probes) dissolved in 1X Tris-EDTA (TE) and 0.5 μl of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Incorporated (Corning), Corning N.Y.), allowing the DNA to bind to the reagent. The plate is scanned in a FLUOROSKAN II (Labsystems Oy) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5 μl to 10 μl aliquot of the reaction mixture is analyzed by electrophoresis on a 1% agarose mini-gel to determine which reactions are successful in extending the sequence.

[0262] The extended nucleotides are desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison Wis.), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested nucleotides are separated on low concentration (0.6 to 0.8%) agarose gels, fragments are excised, and agar digested with AGAR ACE (Promega). Extended clones are religated using T4 ligase (New England Biolabs, Inc., Beverly Mass.) into pUC 18 vector (Amersham Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent E. coli cells. Transformed cells are selected on antibiotic-containing media, individual colonies are picked and cultured overnight at 37° C. in 384-well plates in LB/2× carbenicillin liquid media.

[0263] The cells are lysed, and DNA is amplified by PCR using Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94° C., 3 min; Step 2: 94° C., 15 sec; Step 3: 60° C., 1 min; Step 4: 72° C., 2 min; Step 5: Step 2, 3, and 4 repeated 29 times; Step 6: 72° C., 5 min; Step 7: storage at 4° C. DNA is quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries are reamplified using the same conditions as described above. Samples are diluted with 20% dimethysulfoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems).

[0264] In like manner, the mddt is used to obtain regulatory sequences (promoters, introns, and enhancers) using the procedure above, oligonucleotides designed for such extension, and an appropriate genomic library.

[0265] IX. Labeling of Probes and Southern Hybridization Analyses

[0266] Hybridization probes derived from the mddt of the Sequence Listing are employed for screening cDNAs, mRNAs, or genomic DNA. The labeling of probe nucleotides between 100 and 1000 nucleotides in length is specifically described, but essentially the same procedure may be used with larger cDNA fragments. Probe sequences are labeled at room temperature for 30 minutes using a T4 polynucleotide kinase, γ³²P-ATP, and 0.5× One-Phor-All Plus (Amersham Pharmacia Biotech) buffer and purified using a ProbeQuant G-50 Microcolumn (Amersham Pharmacia Biotech). The probe mixture is diluted to 10⁷ dpm/μg/ml hybridization buffer and used in a typical membrane-based hybridization analysis.

[0267] The DNA is digested with a restriction endonuclease such as Eco RV and is electrophoresed through a 0.7% agarose gel. The DNA fragments are transferred from the agarose to nylon membrane (NYTRAN Plus, Schleicher & Schuell, Inc., Keene N.H.) using procedures specified by the manufacturer of the membrane. Prehybridization is carried out for three or more hours at 68° C., and hybridization is carried out overnight at 68° C. To remove non-specific signals, blots are sequentially washed at room temperature under increasingly stringent conditions, up to 0.1× saline sodium citrate (SSC) and 0.5% sodium dodecyl sulfate. After the blots are placed in a PHOSPHORIMAGER cassette (Molecular Dynamics) or are exposed to autoradiography film, hybridization patterns of standard and experimental lanes are compared. Essentially the same procedure is employed when screening RNA.

[0268] X. Chromosome Mapping of mddt

[0269] The cDNA sequences which were used to assemble SEQ ID NO: 1-36 are compared with sequences from the Incyte LIEESEQ database and public domain databases using BLAST and other implementations of the Smith-Waterman algorithm. Sequences from these databases that match SEQ ID NO: 1-36 are assembled into clusters of contiguous and overlapping sequences using assembly algorithms such as PHRAP (Table 8). Radiation hybrid and genetic mapping data available from public resources such as the Stanford Human Genome Center (SHGC), Whitehead Institute for Genome Research (WIGR), and Généthon are used to determine if any of the clustered sequences have been previously mapped. Inclusion of a mapped sequence in a cluster will result in the assignment of all sequences of that cluster, including its particular SEQ ID NO:, to that map location. The genetic map locations of SEQ ID NO: 1-36 are described as ranges, or intervals, of human chromosomes. The map position of an interval, in centiMorgans, is measured relative to the terminus of the chromosome's p-arm. (The centiMorgan (cM) is a unit of measurement based on recombination frequencies between chromosomal markers. On average, 1 cM is roughly equivalent to 1 megabase (Mb) of DNA in humans, although this can vary widely due to hot and cold spots of recombination.) The cM distances are based on genetic markers mapped by Généthon which provide boundaries for radiation hybrid markers whose sequences were included in each of the clusters.

[0270] XI. Microarray Analysis

[0271] Probe Preparation from Tissue or Cell Samples

[0272] Total RNA is isolated from tissue samples using the guanidinium thiocyanate method and polyA⁺ RNA is purified using the oligo (dT) cellulose method. Each polyA⁺ RNA sample is reverse transcribed using MMLV reverse-transcriptase, 0.05 pg/μl oligo-dT primer (21mer), 1× first strand buffer, 0.03 units/μI RNase inhibitor, 500 μM dATP, 500 μM dGTP, 500 μM dTTP, 40 μM dCTP, 40 μM dCTP-Cy3 (BDS) or dCTP-Cy5 (Amersham Pharmacia Biotech). The reverse transcription reaction is performed in a 25 ml volume containing 200 ng polyA⁺ RNA with GEMBRIGHT kits (Incyte). Specific control polyA⁺ RNAs are synthesized by in vitro transcription from non-coding yeast genomic DNA (W. Lei, unpublished). As quantitative controls, the control mRNAs at 0.002 ng, 0.02 ng, 0.2 ng, and 2 ng are diluted into reverse transcription reaction at ratios of 1:100,000, 1:10,000, 1:1000, 1:100 (w/w) to sample mRNA respectively. The control mRNAs are diluted into reverse transcription reaction at ratios of 1:3, 3:1, 1:10, 10:1, 1:25, 25:1 (w/w) to sample mRNA differential expression patterns. After incubation at 37° C. for 2 hr, each reaction sample (one with Cy3 and another with Cy5 labeling) is treated with 2.5 ml of 0.5M sodium hydroxide and incubated for 20 minutes at 85° C. to the stop the reaction and degrade the RNA. Probes are purified using two successive CHROMA SPIN 30 gel filtration spin columns (CLONTECH Laboratories, Inc. (CLONTECH), Palo Alto Calif.) and after combining, both reaction samples are ethanol precipitated using 1 ml of glycogen (1 mg/ml), 60 ml sodium acetate, and 300 ml of 100% ethanol. The probe is then dried to completion using a SpeedVAC (Savant Instruments Inc., Holbrook N.Y.) and resuspended in 14 μl 5×SSC/0.2% SDS.

[0273] Microarray Preparation

[0274] Sequences of the present invention are used to generate array elements. Each array element is amplified from bacterial cells containing vectors with cloned cDNA inserts. PCR amplification uses primers complementary to the vector sequences flanking the cDNA insert. Array elements are amplified in thirty cycles of PCR from an initial quantity of 1-2 ng to a final quantity greater than 5 μg. Amplified array elements are then purified using SEPHACRYL-400 (Amersham Pharmacia Biotech).

[0275] Purified array elements are immobilized on polymer-coated glass slides. Glass microscope slides (Corning) are cleaned by ultrasound in 0.1% SDS and acetone, with extensive distilled water washes between and after treatments. Glass slides are etched in 4% hydrofluoric acid (VWR Scientific Products Corporation (VWR), West Chester, Pa.), washed extensively in distilled water, and coated with 0.05% aminopropyl silane (Sigma) in 95% ethanol. Coated slides are cured in a 110° C. oven.

[0276] Array elements are applied to the coated glass substrate using a procedure described in US Pat. No. 5,807,522, incorporated herein by reference. 1 μl of the array element DNA, at an average concentration of 100 ng/μl, is loaded into the open capillary printing element by a high-speed robotic apparatus. The apparatus then deposits about 5 nl of array element sample per slide.

[0277] Microarrays are UV-crosslinked using a STRATALINKER UV-crosslinker (Stratagene). Microarrays are washed at room temperature once in 0.2% SDS and three times in distilled water. Non-specific binding sites are blocked by incubation of microarrays in 0.2% casein in phosphate buffered saline (PBS) (Tropix, Inc., Bedford, Mass.) for 30 minutes at 60° C. followed by washes in 0.2% SDS and distilled water as before.

[0278] Hybridization

[0279] Hybridization reactions contain 9 μl of probe mixture consisting of 0.2 μg each of Cy3 and Cy5 labeled cDNA synthesis products in 5×SSC, 0.2% SDS hybridization buffer. The probe mixture is heated to 65° C. for 5 minutes and is aliquoted onto the microarray surface and covered with an 1.8 cm² coverslip. The arrays are transferred to a waterproof chamber having a cavity just slightly larger than a microscope slide. The chamber is kept at 100% humidity internally by the addition of 140 μl of 5×SSC in a corner of the chamber. The chamber containing the arrays is incubated for about 6.5 hours at 60° C. The arrays are washed for 10 min at 45° C. in a first wash buffer (1×SSC, 0.1% SDS), three times for 10 minutes each at 45° C. in a second wash buffer (0.1×SSC), and dried.

[0280] Detection

[0281] Reporter-labeled hybridization complexes are detected with a microscope equipped with an Innova 70 mixed gas 10 W laser (Coherent, Inc., Santa Clara Calif.) capable of generating spectral lines at 488 nm for excitation of Cy3 and at 632 nm for excitation of Cy5. The excitation laser light is focused on the array using a 20× microscope objective (Nikon, Inc., Melville N.Y.). The slide containing the array is placed on a computer-controlled X-Y stage on the microscope and raster-scanned past the objective. The 1.8 cm×1.8 cm array used in the present example is scanned with a resolution of 20 micrometers.

[0282] In two separate scans, a mixed gas multiline laser excites the two fluorophores sequentially. Emitted light is split, based on wavelength, into two photomultiplier tube detectors (PMT R1477, Hamamatsu Photonics Systems, Bridgewater N.J.) corresponding to the two fluorophores. Appropriate filters positioned between the array and the photomultiplier tubes are used to filter the signals. The emission maxima of the fluorophores used are 565 nm for Cy3 and 650 nm for Cy5. Each array is typically scanned twice, one scan per fluorophore using the appropriate filters at the laser source, although the apparatus is capable of recording the spectra from both fluorophores simultaneously.

[0283] The sensitivity of the scans is typically calibrated using the signal intensity generated by a cDNA control species added to the probe mix at a known concentration. A specific location on the array contains a complementary DNA sequence, allowing the intensity of the signal at that location to be correlated with a weight ratio of hybridizing species of 1:100,000. When two probes from different sources (e.g., representing test and control cells), each labeled with a different fluorophore, are hybridized to a single array for the purpose of identifying genes that are differentially expressed, the calibration is done by labeling samples of the calibrating cDNA with the two fluorophores and adding identical amounts of each to the hybridization mixture.

[0284] The output of the photomultiplier tube is digitized using a 12-bit RTI-835H analog-to-digital (A/D) conversion board (Analog Devices, Inc., Norwood, Mass.) installed in an IBM-compatible PC computer. The digitized data are displayed as an image where the signal intensity is mapped using a linear 20-color transformation to a pseudocolor scale ranging from blue (low signal) to red (high signal). The data is also analyzed quantitatively. Where two different fluorophores are excited and measured simultaneously, the data are first corrected for optical crosstalk (due to overlapping emission spectra) between the fluorophores using each fluorophore's emission spectrum

[0285] A grid is superimposed over the fluorescence signal image such that the signal from each spot is centered in each element of the grid. The fluorescence signal within each element is then integrated to obtain a numerical value corresponding to the average intensity of the signal. The software used for signal analysis is the GEMTOOLS gene expression analysis program (Incyte).

[0286] XII. Complementary Nucleic Acids

[0287] Sequences complementary to the mddt are used to detect, decrease, or inhibit expression of the naturally occurring nucleotide. The use of oligonucleotides comprising from about 15 to 30 base pairs is typical in the art. However, smaller or larger sequence fragments can also be used. Appropriate oligonucleotides are designed from the mddt using OLIGO 4.06 software (National Biosciences) or other appropriate programs and are synthesized using methods standard in the art or ordered from a commercial supplier. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5′ sequence and used to prevent transcription factor binding to the promoter sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding and processing of the transcript.

[0288] XIII. Expression of MDDT

[0289] Expression and purification of MDDT is accomplished using bacterial or virus-based expression systems. For expression of MDDT in bacteria, cDNA encoding MDDT is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the typ-lac (tac) hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the lac operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3). Antibiotic resistant bacteria express MDDT upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression of MDDT in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Autographica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding MDDT by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect Spodoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases. Infection of the latter requires additional genetic modifications to baculovirus. (See e.g., Engelhard, supra; and Sandig, supra.)

[0290] In most expression systems, MDDT is synthesized as a fusion protein with, e.g., glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma japonicum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from MDDT at specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak Company, Rochester N.Y.). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, supra, Chapters 10 and 16). Purified MDDT obtained by these methods can be used directly in the following activity assay.

[0291] XIV. Demonstration of MDDT Activity

[0292] MDDT, or biologically active fragments thereof, are labeled with ¹²⁵I Bolton-Hunter reagent. (See, e.g., Bolton, A. E. and W. M. Hunter (1973) Biochem J. 133:529-539.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled MDDT, washed, and any wells with labeled MDDT complex are assayed. Data obtained using different concentrations of MDDT are used to calculate values for the number, affinity, and association of MDDT with the candidate molecules.

[0293] Alternatively, molecules interacting with MDDT are analyzed using the yeast two-hybrid system as described in Fields, S. and O. Song (1989) Nature 340:245-246, or using commercially available kits based on the two-hybrid system, such as the MATCHMAKER system (CLONTECH).

[0294] MDDT may also be used in the PATHCALLING process (CuraGen Corp., New Haven Conn.) which employs the yeast two-hybrid system in a high-throughput manner to determine all interactions between the proteins encoded by two large libraries of genes (Nandabalan, K. et al. (2000) U.S. Pat. No. 6,057,101).

[0295] XV. Functional Assays

[0296] MDDT function is assessed by expressing mddt at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include pCMV SPORT (Life Technologies) and pCR3.1 (Invitrogen Corporation, Carlsbad Calif.), both of which contain the cytomegalovirus promoter. 5-10 μg of recombinant vector are transiently transfected into a human cell line, preferably of endothelial or hematopoietic origin, using either liposome formulations or electroporation. 1-2 μg of an additional plasmid containing sequences encoding a marker protein are co-transfected.

[0297] Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; CLONTECH), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP and to evaluate the apoptotic state of the cells and other cellular properties.

[0298] FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M. G. (1994) Flow Cytometry, Oxford, New York N.Y.

[0299] The influence of MDDT on gene expression can be assessed using highly purified populations of cells transfected with sequences encoding MDDT and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Inc., Lake Success N.Y.). mRNA can be purified from the cells using methods well known by those of skill in the art. Expression of mRNA encoding MDDT and other genes of interest can be analyzed by northern analysis or microarray techniques.

[0300] XVI. Production of Antibodies

[0301] MDDT substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e.g., Harrington, M. G. (1990) Methods Enzymol. 182:488-495), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols.

[0302] Alternatively, the MDDT amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding peptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art. (See, e.g., Ausubel, 1995, supra, Chapter 11.)

[0303] Typically, peptides 15 residues in length are synthesized using an ABI 431A peptide synthesizer (Applied Biosystems) using fmoc-chemistry and coupled to KLH (Sigma) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity. (See, e.g., Ausubel, supra.) Rabbits are immunized with the peptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide activity by, for example, binding the peptide to plastic, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG. Antisera with antipeptide activity are tested for anti-MDDT activity using protocols well known in the art, including ELISA, RIA, and immunoblotting.

[0304] XVII. Purification of Naturally Occurring MDDT Using Specific Antibodies

[0305] Naturally occurring or recombinant MDDT is substantially purified by immunoaffinity chromatography using antibodies specific for MDDT. An immunoaffinity column is constructed by covalently coupling anti-MDDT antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

[0306] Media containing MDDT are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of MDDT (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/MDDT binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and MDDT is collected.

[0307] All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the above-described modes for carrying out the invention which are obvious to those skilled in the field of molecular biology or related fields are intended to be within the scope of the following claims. TABLE 1 SEQ ID NO: Template ID SEQ ID NO: ORF ID 1 LI:180252.16:2001JAN12 37 LI:180252.16.orf2:2001JAN12 2 LI:1072919.1:2001JAN12 38 LI:1072919.1.orf1:2001JAN12 3 LI:477130.1:2001JAN12 39 LI:477130.1.orf2:2001JAN12 4 LI:351355.1:2001JAN12 40 LI:351355.1.orf1:2001JAN12 5 LI:038285.2:2001JAN12 41 LI:038285.2.orf1:2001JAN12 6 LI:1079031.1:2001JAN12 42 LI:1079031.1.orf1:2001JAN12 7 LI:306216.1:2001JAN12 43 LI:306216.1.orf1:2001JAN12 8 LI:011799.1:2001JAN12 44 LI:011799.1.orf2:2001JAN12 9 LI:109467.1:2001JAN12 45 LI:109467.1.orf1:2001JAN12 10 LI:1175250.1:2001JAN12 46 LI:1175250.1.orf2:2001JAN12 11 LI:2121744.1:2001JAN12 47 LI:2121744.1.orf2:2001JAN12 12 LI:1170908.1:2001JAN12 48 LI:1170908.1.orf3:2001JAN12 13 LI:1173119.1:2001JAN12 49 LI:1173119.1.orf3:2001JAN12 14 LI:1175131.1:2001JAN12 50 LI:1175131.1.orf2:2001JAN12 15 LI:1174107.2:2001JAN12 51 LI:1174107.2.orf3:2001JAN12 16 LI:901832.1:2001JAN12 52 LI:901832.1.orf1:2001JAN12 17 LI:1091903.1:2001JAN12 53 LI:1091903.1.orf2:2001JAN12 18 LI:1089543.2:2001JAN12 54 LI:1089543.2.orf2:2001JAN12 19 LI:2049137.1:2001JAN12 55 LI:2049137.1.orf1:2001JAN12 20 LI:1171755.9:2001JAN12 56 LI:1171755.9.orf3:2001JAN12 21 LI:208529.12:2001JAN12 57 LI:208529.12.orf3:2001JAN12 22 LI:024125.6:2001JAN12 58 LI:024125.6.orf1:2001JAN12 23 LI:235557.12:2001JAN12 59 LI:235557.12.orf2:2001JAN12 24 LI:178860.1:2001JAN12 60 LI:178860.1.orf1:2001JAN12 25 LI:405798.1:2001JAN12 61 LI:405798.1.orf2:2001JAN12 26 LI:1071427.101:2001JAN12 62 LI:1071427.101.orf1:2001JAN12 27 LI:1072276.1:2001JAN12 63 LI:1072276.1.orf1:2001JAN12 28 LI:198296.1:2001JAN12 64 LI:198296.1.orf1:2001JAN12 29 LI:202943.4:2001JAN12 65 LI:202943.4.orf2:2001JAN12 30 LI:2121848.1:2001JAN12 66 LI:2121848.1.orf3:2001JAN12 31 LI:796992.1:2001JAN12 67 LI:796992.1.orf3:2001JAN12 32 LI:1183014.7:2001JAN12 68 LI:1183014.7.orf2:2001JAN12 33 LI:1171219.2:2001JAN12 69 LI:1171219.2.orf3:2001JAN12 34 LI:428428.4:2001JAN12 70 LI:428428.4.orf3:2001JAN12 35 LI:230711.5:2001JAN12 71 LI:230711.5.orf2:2001JAN12 36 LI:199716.6:2001JAN12 72 LI:199716.6.orf2:2001JAN12

[0308] TABLE 2 SEQ ID NO: Template ID GI Number Probability Score Annotation 1 LI:180252.16:2001JAN12 g12060855 9.00E−78 serologically defined breast cancer antigen NY-BR-96 (Homo sapiens) 2 LI:1072919.1:2001JAN12 g929913 2.00E−14 ribosomal protein S8 (Xenopus laevis) 3 LI:477130.1:2001JAN12 g6650751 8.00E−43 ribosomal protein I (Ceratopteris 4 LI:351355.1:2001JAN12 g14547146 3.00E−13 EGLN1 protein (Homo sapiens) 5 LI:038285.2:2001JAN12 g14250235 8.00E−17 RIKEN cDNA 4633401C23 gene (Mus musculus) 6 LI:1079031.1:2001JAN12 g5670324 1.00E−100 Gps1 (Homo sapiens) 7 LI:306216.1:2001JAN12 g12856149 1.00E−51 putative (Mus musculus) 8 LI:011799.1:2001JAN12 g7022971 1.00E−80 unnamed protein product (Homo 9 LI:109467.1:2001JAN12 g182977 1.00E−110 glyceraldehyde-3-phosphate dehydrogenase (EC 1.2.1.12) (Homo sapiens) 10 LI:1175250.1:2001JAN12 g15929781 5.00E−89 hypothetical protein FLJ12606 (Homo sapiens) 11 LI:2121744.1:2001JAN12 g10435738 3.00E−70 unnamed protein product (Homo 12 LI:1170908.1:2001JAN12 g5262560 3.00E−59 hypothetical protein (Homo sapiens) 13 LI:1173119.1:2001JAN12 g9968290 1.00E−110 zinc finger protein 304 (Homo sapiens) 14 LI:1175131.1:2001JAN12 g12483906 0 zinc finger protein HIT-40 (Rattus norvegicus) 15 LI:1174107.2:2001JAN12 g10435738 2.00E−60 unnamed protein product (Homo 16 LI:901832.1:2001JAN12 g16198398 0 Unknown (protein for MGC: 27353) (Homo sapiens) 17 LI:1091903.1:2001JAN12 g14042373 4.00E−24 unnamed protein product (Homo 18 LI:1089543.2:2001JAN12 g14348588 0 KRAB zinc finger protein (Homo sapiens) 19 LI:2049137.1:2001JAN12 g13937909 1.00E−108 Similar to KIAA0961 protein (Homo sapiens) 20 LI:1171755.9:2001JAN12 g14249844 2.00E−64 Similar to hypothetical protein FLJ23233 (Homo sapiens) 21 LI:208529.12:2001JAN12 g15430613 1.00E−177 clipin E/coronin 6 type B (Mus musculus) 22 LI:024125.6:2001JAN12 g12052959 1.00E−129 hypothetical protein (Homo sapiens 23 LI:235557.12:2001JAN12 g13506765 3.00E−84 uridine-cytidine kinase 1 (Homo sapiens) 24 LI:178860.1:2001JAN12 g14133223 4.00E−29 KIAA0876 protein (Homo sapiens) 25 LI:405798.1:2001JAN12 g193830 3.00E−26 helix-loop-helix protein (Mus musculus) 26 LI:1071427.101:2001JAN12 g5663 1.00E−77 actin (AA 1-376) (Artemia sp.) 27 LI:1072276.1:2001JAN12 g2828710 6.00E−39 matrin cyclophilin (Rattus norvegicus) 28 LI:198296.1:2001JAN12 g12853497 1.00E−147 putative (Mus musculus) 29 LI:202943.4:2001JAN12 g11177164 0 polydom protein (Mus musculus) 30 LI:2121848.1:2001JAN12 g12654199 1.00E−47 Similar to zinc finger protein 137 (clone pHZ-30) (Homo sapiens) 31 LI:796992.1:2001JAN12 g13543419 3.00E−98 Similar to zinc finger protein 304 (Homo sapiens) 32 LI:1183014.7:2001JAN12 g16198398 9.00E−39 Unknown (protein for MGC: 27353) (Homo sapiens) 33 LI:1171219.2:2001JAN12 g13121525 1.00E−104 Synthetic sequence (synthetic construct) 34 LI:428428.4:2001JAN12 g12053161 6.00E−94 hypothetical protein (Homo sapiens) 35 LI:230711.5:2001JAN12 g1002424 1.00E−101 YSPL-1 form 1 (Mus musculus) 36 LI:199716.6:2001JAN12 g14198276 0 hypothetical protein FLJ12496 (Homo sapiens)

[0309] TABLE 3 SEQ ID NO: Template ID Start Stop Frame Pfam Hit Pfam Description E-value 1 LI:180252.16:2001JAN12 36 224 forward 3 pkinase Protein kinase domain 7.00E−05 2 LI:1072919.1:2001JAN12 160 714 forward 1 Ribosomal_(—) Ribosomal protein S7e 4.30E−06 S7e 3 LI:477130.1:2001JAN12 173 547 forward 2 Ribosomal_(—) Ribosomal protein L13 1.20E−35 L13 4 LI:351355.1:2001JAN12 118 231 forward 1 zf-MYND MYND finger 8.90E−07 5 LI:038285.2:2001JAN12 85 273 forward 1 KRAB KRAB box 2.40E−34 6 LI:1079031.1:2001JAN12 1829 2041 forward 2 PCI PCI domain 2.30E−08 7 LI:306216.1:2001JAN12 455 841 forward 2 mutT MutT-like domain 6.00E−06 8 LI:011799.1:2001JAN12 1595 1735 forward 2 Kelch Kelch motif 4.80E−08 9 LI:109467.1:2001JAN12 211 651 forward 1 gpdh Glyceraldehyde 3-phosphate 2.30E−36 dehydrogenase, NAD binding domain 9 LI:109467.1:2001JAN12 735 974 forward 3 gpdh_C Glyceraldehyde 3-phosphate 2.70E−24 dehydrogenase, C-terminal domain 9 LI:109467.1:2001JAN12 974 1111 forward 2 gpdh_C Glyceraldehyde 3-phosphate 2.10E−13 dehydrogenase, C-terminal domain 10 LI:1175250.1:2001JAN12 159 311 forward 3 KRAB KRAB box 1.10E−16 10 LI:1175250.1:2001JAN12 632 700 forward 2 zf-C2H2 Zinc finger, C2H2 type 3.80E−05 11 LI:2121744.1:2001JAN12 83 274 forward 2 KRAB KRAB box 5.00E−41 12 LI:1170908.1:2001JAN12 115 183 forward 1 zf-C2H2 Zinc finger, C2H2 type 1.30E−06 13 LI:1173119.1:2001JAN12 642 710 forward 3 zf-C2H2 Zinc finger, C2H2 type 9.30E−06 14 LI:1175131.1:2001JAN12 169 381 forward 1 KRAB KRAB box 9.00E−16 14 LI:1175131.1:2001JAN12 658 726 forward 1 zf-C2H2 Zinc finger, C2H2 type 1.00E−06 14 LI:1175131.1:2001JAN12 1686 1754 forward 3 zf-C2H2 Zinc finger, C2H2 type 1.90E−06 14 LI:1175131.1:2001JAN12 1214 1282 forward 2 zf-C2H2 Zinc finger, C2H2 type 3.70E−06 15 LI:1174107.2:2001JAN12 111 302 forward 3 KRAB KRAB box 2.00E−43 16 LI:901832.1:2001JAN12 1183 1368 forward 1 KRAB KRAB box 7.10E−39 16 LI:901832.1:2001JAN12 2390 2458 forward 2 zf-C2H2 Zinc finger, C2H2 type 9.70E−08 16 LI:901832.1:2001JAN12 1978 2046 forward 1 zf-C2H2 Zinc finger, C2H2 type 4.00E−05 17 LI:1091903.1:2001JAN12 182 370 forward 2 KRAB KRAB box 6.20E−39 18 LI:1089543.2:2001JAN12 89 277 forward 2 KRAB KRAB box 2.60E−37 18 LI:1089543.2:2001JAN12 836 904 forward 2 zf-C2H2 Zinc finger, C2H2 type 8.00E−08 19 LI:2049137.1:2001JAN12 262 450 forward 1 KRAB KRAB box 1.60E−41 19 LI:2049137.1:2001JAN12 877 945 forward 1 zf-C2H2 Zinc finger, C2H2 type 1.90E−06 20 LI:1171755.9:2001JAN12 159 227 forward 3 zf-C2H2 Zinc finger, C2H2 type 1.40E−05 21 LI:208529.12:2001JAN12 78 191 forward 3 WD40 WD domain, G-beta repeat 3.70E−05 22 LI:024125.6:2001JAN12 895 1398 forward 1 FAA_(—) Fumarylacetoacetate (FAA) hydrolase 1.20E−83 hydrolase family 23 LI:235557.12:2001JAN12 17 352 forward 2 PRK Phosphoribulokinase/Uridine kinase 4.30E−31 family 24 LI:178860.1:2001JAN12 241 384 forward 1 jmjN jmjN domain 6.00E−17 25 LI:405798.1:2001JAN12 620 778 forward 2 HLH Helix-loop-helix DNA-binding domain 9.40E−16 26 LI:1071427.101:2001JAN12 558 755 forward 3 actin Actin 9.50E−47 26 LI:1071427.101:2001JAN12 101 280 forward 2 actin Actin 5.30E−32 26 LI:1071427.101:2001JAN12 412 555 forward 1 actin Actin 8.50E−25 27 LI:1072276.1:2001JAN12 172 549 forward 1 pro_(—) Cyclophilin type peptidyl-prolyl cis- 1.50E−29 isomerase trans Isomerase 27 LI:1072276.1:2001JAN12 228 320 forward 3 pro_(—) Cyclophilin type peptidyl-prolyl cis- 7.70E−08 isomerase trans isomerase 28 LI:198296.1:2001JAN12 629 766 forward 2 Kelch Kelch motif 2.00E−08 29 LI:202943.4:2001JAN12 1912 2073 forward 1 sushi Sushi domain (SCR repeat) 3.80E−18 29 LI:202943.4:2001JAN12 2249 2413 forward 2 sushi Sushi domain (SCR repeat) 9.40E−17 29 LI:202943.4:2001JAN12 2712 2873 forward 3 sushi Sushi domain (SCR repeat) 4.90E−11 30 LI:2121848.1:2001JAN12 450 518 forward 3 zf-C2H2 Zinc finger, C2H2 type 1.20E−05 30 LI:2121848.1:2001JAN12 133 201 forward 1 zf-C2H2 Zinc finger, C2H2 type 9.30E−05 31 LI:796992.1:2001JAN12 582 650 forward 3 zf-C2H2 Zinc finger, C2H2 type 6.70E−08 32 LI:1183014.7:2001JAN12 92 280 forward 2 KRAB KRAB box 3.00E−46 33 LI:1171219.2:2001JAN12 132 371 forward 3 ig Immunoglobulin domain 2.20E−09 34 LI:428428.4:2001JAN12 168 374 forward 3 zf-UBP Zn-finger in ubiquitin-hydrolases and 4.80E−14 other protein 35 LI:230711.5:2001JAN12 170 1147 forward 2 xan_(—) Xanthine/uracil permeases family 5.80E−06 ur_(—) permease 36 LI:199716.6:2001JAN12 377 1321 forward 2 Cation_(—) Cation efflux family 1.30E−53 efflux

[0310] TABLE 4 SEQ ID NO: Template ID Start Stop Frame Domain Type Topology 25 LI:405798.1:2001JAN12 1 670 forward 1 TM Non-cytosolic 25 LI:405798.1:2001JAN12 671 689 forward 1 TM Transmembrane 25 LI:405798.1:2001JAN12 690 709 forward 1 TM Cytosolic 25 LI:405798.1:2001JAN12 710 732 forward 1 TM Transmembrane 25 LI:405798.1:2001JAN12 733 845 forward 1 TM Non-cytosolic 25 LI:405798.1:2001JAN12 1 671 forward 2 TM Non-cytosolic 25 LI:405798.1:2001JAN12 672 694 forward 2 TM Transmembrane 25 LI:405798.1:2001JAN12 695 845 forward 2 TM Cytosolic 25 LI:405798.1:2001JAN12 1 583 forward 3 TM Non-cytosolic 25 LI:405798.1:2001JAN12 584 606 forward 3 TM Transmembrane 25 LI:405798.1:2001JAN12 607 671 forward 3 TM Cytosolic 25 LI:405798.1:2001JAN12 672 694 forward 3 TM Transmembrane 25 LI:405798.1:2001JAN12 695 845 forward 3 TM Non-cytosolic 26 LI:1071427.101:2001JAN12 1 282 forward 1 TM Non-cytosolic 26 LI:1071427.101:2001JAN12 283 302 forward 1 TM Transmembrane 26 LI:1071427.101:2001JAN12 303 347 forward 1 TM Cytosolic 26 LI:1071427.101:2001JAN12 1 282 forward 2 TM Non-cytosolic 26 LI:1071427.101:2001JAN12 283 302 forward 2 TM Transmembrane 26 LI:1071427.101:2001JAN12 303 346 forward 2 TM Cytosolic 26 LI:1071427.101:2001JAN12 1 283 forward 3 TM Non-cytosolic 26 LI:1071427.101:2001JAN12 284 306 forward 3 TM Transmembrane 26 LI:1071427.101:2001JAN12 307 346 forward 3 TM Cytosolic 27 LI:1072276.1:2001JAN12 1 28 forward 1 TM Non-cytosolic 27 LI:1072276.1:2001JAN12 29 51 forward 1 TM Transmembrane 27 LI:1072276.1:2001JAN12 52 316 forward 1 TM Cytosolic 27 LI:1072276.1:2001JAN12 1 184 forward 2 TM Cytosolic 27 LI:1072276.1:2001JAN12 185 202 forward 2 TM Transmembrane 27 LI:1072276.1:2001JAN12 203 250 forward 2 TM Non-cytosolic 27 LI:1072276.1:2001JAN12 251 273 forward 2 TM Transmembrane 27 LI:1072276.1:2001JAN12 274 316 forward 2 TM Cytosolic 27 LI:1072276.1:2001JAN12 1 19 forward 3 TM Cytosolic 27 LI:1072276.1:2001JAN12 20 42 forward 3 TM Transmembrane 27 LI:1072276.1:2001JAN12 43 316 forward 3 TM Non-cytosolic 28 LI:198296.1:2001JAN12 1 470 forward 1 TM Non-cytosolic 28 LI:198296.1:2001JAN12 471 493 forward 1 TM Transmembrane 28 LI:198296.1:2001JAN12 494 497 forward 1 TM Cytosolic 28 LI:198296.1:2001JAN12 498 520 forward 1 TM Transmembrane 28 LI:198296.1:2001JAN12 521 539 forward 1 TM Non-cytosolic 28 LI:198296.1:2001JAN12 540 559 forward 1 TM Transmembrane 28 LI:198296.1:2001JAN12 560 1070 forward 1 TM Cytosolic 28 LI:198296.1:2001JAN12 1071 1093 forward 1 TM Transmembrane 28 LI:198296.1:2001JAN12 1094 1107 forward 1 TM Non-cytosolic 28 LI:198296.1:2001JAN12 1108 1130 forward 1 TM Transmembrane 28 LI:198296.1:2001JAN12 1131 1142 forward 1 TM Cytosolic 28 LI:198296.1:2001JAN12 1143 1165 forward 1 TM Transmembrane 28 LI:198296.1:2001JAN12 1166 1228 forward 1 TM Non-cytosolic 28 LI:198296.1:2001JAN12 1229 1251 forward 1 TM Transmembrane 28 LI:198296.1:2001JAN12 1252 1410 forward 1 TM Cytosolic 28 LI:198296.1:2001JAN12 1 20 forward 2 TM Cytosolic 28 LI:198296.1:2001JAN12 21 43 forward 2 TM Transmembrane 28 LI:198296.1:2001JAN12 44 934 forward 2 TM Non-cytosolic 28 LI:198296.1:2001JAN12 935 957 forward 2 TM Transmembrane 28 LI:198296.1:2001JAN12 958 1153 forward 2 TM Cytosolic 28 LI:198296.1:2001JAN12 1154 1176 forward 2 TM Transmembrane 28 LI:198296.1:2001JAN12 1177 1302 forward 2 TM Non-cytosolic 28 LI:198296.1:2001JAN12 1303 1325 forward 2 TM Transmembrane 28 LI:198296.1:2001JAN12 1326 1409 forward 2 TM Cytosolic 28 LI:198296.1:2001JAN12 1 905 forward 3 TM Non-cytosolic 28 LI:198296.1:2001JAN12 906 925 forward 3 TM Transmembrane 28 LI:198296.1:2001JAN12 926 931 forward 3 TM Cytosolic 28 LI:198296.1:2001JAN12 932 954 forward 3 TM Transmembrane 28 LI:198296.1:2001JAN12 955 1152 forward 3 TM Non-cytosolic 28 LI:198296.1:2001JAN12 1153 1172 forward 3 TM Transmembrane 28 LI:198296.1:2001JAN12 1173 1192 forward 3 TM Cytosolic 28 LI:198296.1:2001JAN12 1193 1215 forward 3 TM Transmembrane 28 LI:198296.1:2001JAN12 1216 1234 forward 3 TM Non-cytosolic 28 LI:198296.1:2001JAN12 1235 1257 forward 3 TM Transmembrane 28 LI:198296.1:2001JAN12 1258 1291 forward 3 TM Cytosolic 28 LI:198296.1:2001JAN12 1292 1314 forward 3 TM Transmembrane 28 LI:198296.1:2001JAN12 1315 1346 forward 3 TM Non-cytosolic 28 LI:198296.1:2001JAN12 1347 1369 forward 3 TM Transmembrane 28 LI:198296.1:2001JAN12 1370 1409 forward 3 TM Cytosolic 29 LI:202943.4:2001JAN12 1 893 forward 3 TM Non-cytosolic 29 LI:202943.4:2001JAN12 894 916 forward 3 TM Transmembrane 29 LI:202943.4:2001JAN12 917 1086 forward 3 TM Cytosolic 30 LI:2121848.1:2001JAN12 1 292 forward 1 TM Non-cytosolic 30 LI:2121848.1:2001JAN12 293 315 forward 1 TM Transmembrane 30 LI:2121848.1:2001JAN12 316 325 forward 1 TM Cytosolic 30 LI:2121848.1:2001JAN12 1 263 forward 2 TM Non-cytosolic 30 LI:2121848.1:2001JAN12 264 286 forward 2 TM Transmembrane 30 LI:2121848.1:2001JAN12 287 292 forward 2 TM Cytosolic 30 LI:2121848.1:2001JAN12 293 315 forward 2 TM Transmembrane 30 LI:2121848.1:2001JAN12 316 324 forward 2 TM Non-cytosolic 30 LI:2121848.1:2001JAN12 1 262 forward 3 TM Non-cytosolic 30 LI:2121848.1:2001JAN12 263 285 forward 3 TM Transmembrane 30 LI:2121848.1:2001JAN12 286 291 forward 3 TM Cytosolic 30 LI:2121848.1:2001JAN12 292 314 forward 3 TM Transmembrane 30 LI:2121848.1:2001JAN12 315 324 forward 3 TM Non-cytosolic 31 LI:796992.1:2001JAN12 1 647 forward 2 TM Non-cytosolic 31 LI:796992.1:2001JAN12 648 670 forward 2 TM Transmembrane 31 LI:796992.1:2001JAN12 671 744 forward 2 TM Cytosolic 31 LI:796992.1:2001JAN12 745 767 forward 2 TM Transmembrane 31 LI:796992.1:2001JAN12 768 786 forward 2 TM Non-cytosolic 31 LI:796992.1:2001JAN12 787 809 forward 2 TM Transmembrane 31 LI:796992.1:2001JAN12 810 821 forward 2 TM Cytosolic 31 LI:796992.1:2001JAN12 822 844 forward 2 TM Transmembrane 31 LI:796992.1:2001JAN12 845 848 forward 2 TM Non-cytosolic 31 LI:796992.1:2001JAN12 849 871 forward 2 TM Transmembrane 31 LI:796992.1:2001JAN12 872 880 forward 2 TM Cytosolic 31 LI:796992.1:2001JAN12 1 403 forward 3 TM Non-cytosolic 31 LI:796992.1:2001JAN12 404 421 forward 3 TM Transmembrane 31 LI:796992.1:2001JAN12 422 425 forward 3 TM Cytosolic 31 LI:796992.1:2001JAN12 426 448 forward 3 TM Transmembrane 31 LI:796992.1:2001JAN12 449 735 forward 3 TM Non-cytosolic 31 LI:796992.1:2001JAN12 736 758 forward 3 TM Transmembrane 31 LI:796992.1:2001JAN12 759 847 forward 3 TM Cytosolic 31 LI:796992.1:2001JAN12 848 870 forward 3 TM Transmembrane 31 LI:796992.1:2001JAN12 871 879 forward 3 TM Non-cytosolic 32 LI:1183014.7:2001JAN12 1 161 forward 1 TM Cytosolic 32 LI:1183014.7:2001JAN12 162 184 forward 1 TM Transmembrane 32 LI:1183014.7:2001JAN12 185 201 forward 1 TM Non-cytosolic 33 LI:1171219.2:2001JAN12 1 279 forward 2 TM Non-cytosolic 33 LI:1171219.2:2001JAN12 280 302 forward 2 TM Transmembrane 33 LI:1171219.2:2001JAN12 303 360 forward 2 TM Cytosolic 34 LI:428428.4:2001JAN12 1 95 forward 1 TM Cytosolic 34 LI:428428.4:2001JAN12 96 118 forward 1 TM Transmembrane 34 LI:428428.4:2001JAN12 119 137 forward 1 TM Non-cytosolic 34 LI:428428.4:2001JAN12 138 160 forward 1 TM Transmembrane 34 LI:428428.4:2001JAN12 161 215 forward 1 TM Cytosolic 35 LI:230711.5:2001JAN12 1 197 forward 2 TM Non-cytosolic 35 LI:230711.5:2001JAN12 198 220 forward 2 TM Transmembrane 35 LI:230711.5:2001JAN12 221 226 forward 2 TM Cytosolic 35 LI:230711.5:2001JAN12 227 249 forward 2 TM Transmembrane 35 LI:230711.5:2001JAN12 250 274 forward 2 TM Non-cytosolic 35 LI:230711.5:2001JAN12 275 297 forward 2 TM Transmembrane 35 LI:230711.5:2001JAN12 298 362 forward 2 TM Cytosolic 35 LI:230711.5:2001JAN12 363 380 forward 2 TM Transmembrane 35 LI:230711.5:2001JAN12 381 671 forward 2 TM Non-cytosolic 36 LI:199716.6:2001JAN12 1 4 forward 1 TM Cytosolic 36 LI:199716.6:2001JAN12 5 27 forward 1 TM Transmembrane 36 LI:199716.6:2001JAN12 28 468 forward 1 TM Non-cytosolic 36 LI:199716.6:2001JAN12 1 1 forward 2 TM Cytosolic 36 LI:199716.6:2001JAN12 2 24 forward 2 TM Transmembrane 36 LI:199716.6:2001JAN12 25 45 forward 2 TM Non-cytosolic 36 LI:199716.6:2001JAN12 46 68 forward 2 TM Transmembrane 36 LI:199716.6:2001JAN12 69 128 forward 2 TM Cytosolic 36 LI:199716.6:2001JAN12 129 149 forward 2 TM Transmembrane 36 LI:199716.6:2001JAN12 150 158 forward 2 TM Non-cytosolic 36 LI:199716.6:2001JAN12 159 181 forward 2 TM Transmembrane 36 LI:199716.6:2001JAN12 182 193 forward 2 TM Cytosolic 36 LI:199716.6:2001JAN12 194 216 forward 2 TM Transmembrane 36 LI:199716.6:2001JAN12 217 230 forward 2 TM Non-cytosolic 36 LI:199716.6:2001JAN12 231 253 forward 2 TM Transmembrane 36 LI:199716.6:2001JAN12 254 300 forward 2 TM Cytosolic 36 LI:199716.6:2001JAN12 301 323 forward 2 TM Transmembrane 36 LI:199716.6:2001JAN12 324 327 forward 2 TM Non-cytosolic 36 LI:199716.6:2001JAN12 328 350 forward 2 TM Transmembrane 36 LI:199716.6:2001JAN12 351 467 forward 2 TM Cytosolic 36 LI:199716.6:2001JAN12 1 11 forward 3 TM Cytosolic 36 LI:199716.6:2001JAN12 12 34 forward 3 TM Transmembrane 36 LI:199716.6:2001JAN12 35 92 forward 3 TM Non-cytosolic 36 LI:199716.6:2001JAN12 93 112 forward 3 TM Transmembrane 36 LI:199716.6:2001JAN12 113 132 forward 3 TM Cytosolic 36 LI:199716.6:2001JAN12 133 155 forward 3 TM Transmembrane 36 LI:199716.6:2001JAN12 156 264 forward 3 TM Non-cytosolic 36 LI:199716.6:2001JAN12 265 287 forward 3 TM Transmembrane 36 LI:199716.6:2001JAN12 288 299 forward 3 TM Cytosolic 36 LI:199716.6:2001JAN12 300 322 forward 3 TM Transmembrane 36 LI:199716.6:2001JAN12 323 331 forward 3 TM Non-cytosolic 36 LI:199716.6:2001JAN12 332 351 forward 3 TM Transmembrane 36 LI:199716.6:2001JAN12 352 440 forward 3 TM Cytosolic 36 LI:199716.6:2001JAN12 441 458 forward 3 TM Transmembrane 36 LI:199716.6:2001JAN12 459 467 forward 3 TM Non-cytosolic

[0311] TABLE 5 SEQ ID NO: Template ID Component ID Start Stop 1 LI:180252.16:2001JAN12 3865849H1 145 293 1 LI:180252.16:2001JAN12 5682509H1 185 466 1 LI:180252.16:2001JAN12 4347176F6 271 817 1 LI:180252.16:2001JAN12 4347176H1 271 516 1 LI:180252.16:2001JAN12 71791503V1 529 805 1 LI:180252.16:2001JAN12 g6571938 65 489 1 LI:180252.16:2001JAN12 3765678H1 1 171 2 LI:1072919.1:2001JAN12 2749973H1 523 777 2 LI:1072919.1:2001JAN12 2659333H1 528 774 2 LI:1072919.1:2001JAN12 2046131H1 541 724 2 LI:1072919.1:2001JAN12 2456648H1 547 772 2 LI:1072919.1:2001JAN12 2046931H1 588 724 2 LI:1072919.1:2001JAN12 2547732H1 598 781 2 LI:1072919.1:2001JAN12 2625384H1 605 777 2 LI:1072919.1:2001JAN12 g5672166 610 776 2 LI:1072919.1:2001JAN12 2251571H1 612 770 2 LI:1072919.1:2001JAN12 2257870H1 612 731 2 LI:1072919.1:2001JAN12 g6463553 639 777 2 LI:1072919.1:2001JAN12 2510459T6 644 741 2 LI:1072919.1:2001JAN12 2470443H1 658 762 2 LI:1072919.1:2001JAN12 2348125H1 701 777 2 LI:1072919.1:2001JAN12 2326913H1 707 781 2 LI:1072919.1:2001JAN12 6910068J1 1 480 2 LI:1072919.1:2001JAN12 2734509H1 1 269 2 LI:1072919.1:2001JAN12 2378578H1 41 261 2 LI:1072919.1:2001JAN12 2345378H1 17 272 2 LI:1072919.1:2001JAN12 2159523H1 19 299 2 LI:1072919.1:2001JAN12 2605621H1 29 261 2 LI:1072919.1:2001JAN12 2662581H1 39 288 2 LI:1072919.1:2001JAN12 2462466H1 48 286 2 LI:1072919.1:2001JAN12 2661835H1 49 323 2 LI:1072919.1:2001JAN12 221844H1 50 224 2 LI:1072919.1:2001JAN12 2444658H1 53 290 2 LI:1072919.1:2001JAN12 2399925H1 57 291 2 LI:1072919.1:2001JAN12 2590589H1 58 312 2 LI:1072919.1:2001JAN12 2606478H1 58 306 2 LI:1072919.1:2001JAN12 5728810H1 58 642 2 LI:1072919.1:2001JAN12 2655210H1 61 374 2 LI:1072919.1:2001JAN12 2482363H1 60 385 2 LI:1072919.1:2001JAN12 2661914H1 63 318 2 LI:1072919.1:2001JAN12 2445753H1 64 331 2 LI:1072919.1:2001JAN12 2259442H1 498 733 2 LI:1072919.1:2001JAN12 2422863H1 499 752 2 LI:1072919.1:2001JAN12 2444738H1 501 741 2 LI:1072919.1:2001JAN12 2634040H1 511 770 2 LI:1072919.1:2001JAN12 2510319H1 204 462 2 LI:1072919.1:2001JAN12 2398611H1 204 427 2 LI:1072919.1:2001JAN12 2641959H1 207 468 2 LI:1072919.1:2001JAN12 2391475H2 221 481 2 LI:1072919.1:2001JAN12 2344005H1 230 476 35 LI:230711.5:2001JAN12 71592819V1 1216 1876 35 LI:230711.5:2001JAN12 71593883V1 1215 1848 35 LI:230711.5:2001JAN12 71591755V1 1225 1904 35 LI:230711.5:2001JAN12 71597148V1 1227 1907 35 LI:230711.5:2001JAN12 70687607V1 1244 1649 35 LI:230711.5:2001JAN12 72157465V1 1257 1558 35 LI:230711.5:2001JAN12 71597474V1 1264 1980 35 LI:230711.5:2001JAN12 71593826V1 1276 1956 35 LI:230711.5:2001JAN12 70680047V1 1265 1894 35 LI:230711.5:2001JAN12 70679818V1 1292 1962 35 LI:230711.5:2001JAN12 6543969H1 1303 1861 35 LI:230711.5:2001JAN12 71595653V1 1303 1887 35 LI:230711.5:2001JAN12 5100839T6 1317 1904 35 LI:230711.5:2001JAN12 71805254V1 1348 1802 35 LI:230711.5:2001JAN12 4379312H1 1348 1625 35 LI:230711.5:2001JAN12 70682506V1 1366 1945 35 LI:230711.5:2001JAN12 55119937V1 1367 1535 35 LI:230711.5:2001JAN12 71595289V1 588 1253 35 LI:230711.5:2001JAN12 71593141V1 595 1192 35 LI:230711.5:2001JAN12 71594054V1 609 1171 35 LI:230711.5:2001JAN12 71597118V1 648 1370 35 LI:230711.5:2001JAN12 71592473V1 678 1387 35 LI:230711.5:2001JAN12 70681329V1 735 898 35 LI:230711.5:2001JAN12 71592682V1 747 1331 35 LI:230711.5:2001JAN12 71596835V1 765 1446 36 LI:199716.6:2001JAN12 4581943H1 235 500 36 LI:199716.6:2001JAN12 3601317F6 330 848 36 LI:199716.6:2001JAN12 6778060R8 470 1057 36 LI:199716.6:2001JAN12 6778060J1 470 1063 36 LI:199716.6:2001JAN12 8043250H1 571 1212 36 LI:199716.6:2001JAN12 6404959H1 584 878 36 LI:199716.6:2001JAN12 6718311H1 597 1086 36 LI:199716.6:2001JAN12 71364542V1 629 1404 36 LI:199716.6:2001JAN12 4918221H1 640 888 36 LI:199716.6:2001JAN12 7730017J1 1 573 36 LI:199716.6:2001JAN12 5666595H1 48 303 36 LI:199716.6:2001JAN12 1004218H1 214 461 36 LI:199716.6:2001JAN12 3162418H1 1 217 36 LI:199716.6:2001JAN12 5178208H1 649 933 36 LI:199716.6:2001JAN12 3138872H1 662 962 36 LI:199716.6:2001JAN12 6719332H1 833 1251 36 LI:199716.6:2001JAN12 2733376H1 838 1078 36 LI:199716.6:2001JAN12 2733128F6 838 1218 36 LI:199716.6:2001JAN12 2733128H1 838 1052 36 LI:199716.6:2001JAN12 3834703H1 872 1167 36 LI:199716.6:2001JAN12 2223246H1 1043 1121

[0312] TABLE 6 SEQ ID NO: Template ID Tissue Distribution 1 LI:180252.16:2001JAN12 Exocrine Glands - 38%, Respiratory System - 23%, Nervous System - 23% 2 LI:1072919.1:2001JAN12 Endocrine System - 19%, Female Genitalia - 17%, Respiratory System - 13% 3 LI:477130.1:2001JAN12 Nervous System - 100% 4 LI:351355.1:2001JAN12 CardiovascularSystem - 52%, Unclassified/Mixed - 21%, Hemic and Immune System - 12% 5 LI:038285.2:2001JAN12 Digestive System - 30%, Liver - 20%, Pancreas - 18% 6 LI:1079031.1:2001JAN12 Stomatognathic System - 27%, Respiratory System - 16%, Female Genitalia - 12% 7 LI:306216.1:2001JAN12 Unclassified/Mixed - 30%, Liver - 20%, Cardiovascular System - 14% 8 LI:011799.1:2001JAN12 Female Genitalia - 42%, Endocrine System - 16%, Germ Cells - 11% 9 LI:109467.1:2001JAN12 Urinary Tract - 65%, Liver - 15%, Connective Tissue - 12% 10 LI:1175250.1:2001JAN12 Germ Cells - 74% 11 LI:2121744.1:2001JAN12 Nervous System - 60%, Urinary Tract - 40% 12 LI:1170908.1:2001JAN12 Unclassified/Mixed - 56%, Skin - 18%, Female Genitalia - 13% 13 LI:1173119.1:2001JAN12 Digestive System - 28%, Liver - 23%, Respiratory System - 11%, Endocrine System - 11%, Nervous System - 11% 14 LI:1175131.1:2001JAN12 Liver - 35%, Hemic and Immune System - 20%, Germ Cells - 11% 15 LI:1174107.2:2001JAN12 Sense Organs - 51%, Unclassified/Mixed - 41% 16 LI:901832.1:2001JAN12 Cardiovascular System - 31%, Female Genitalia - 21%, Nervous System - 13%, Digestive System - 13% 17 LI:1091903.1:2001JAN12 Germ Cells - 93% 18 LI:1089543.2:2001JAN12 Embryonic Structures - 56%, Unclassified/Mixed - 21%, Female Genitalia - 13% 19 LI:2049137.1:2001JAN12 Germ Cells - 51%, Unclassified/Mixed - 16% 20 LI:1171755.9:2001JAN12 Female Genitalia - 100% 21 LI:208529.12:2001JAN12 Nervous System - 100% 22 LI:024125.6:2001JAN12 Embryonic Structures - 20%, Connective Tissue - 13% 23 LI:235557.12:2001JAN12 Urinary Tract - 86% 24 LI:178860.1:2001JAN12 Respiratory System - 42%, Germ Cells - 27%, Unclassified/Mixed - 26% 25 LI:405798.1:2001JAN12 Endocrine System - 71%, Respiratory System - 18%, Nervous System - 12% 26 LI:1071427.101:2001JAN12 Liver - 68% 27 LI:1072276.1:2001JAN12 Urinary Tract - 51%, Germ Cells - 23%, Digestive System - 14% 28 LI:198296.1:2001JAN12 Embryonic Structures - 15%, Female Genitalia - 14% 29 LI:202943.4:2001JAN12 Embryonic Structures - 56%, Liver - 14%, Connective Tissue - 12% 30 LI:2121848.1:2001JAN12 Digestive System - 51%, Hemic and Immune System - 20%, Exocrine Glands - 14% 31 LI:796992.1:2001JAN12 Unclassified/Mixed - 32%, Skin - 18%, Nervous System - 12% 32 LI:1183014.7:2001JAN12 Urinary Tract - 88%, Endocrine System - 10% 33 LI:1171219.2:2001JAN12 Respiratory System - 36%, Digestive System - 22%, Musculoskeletal System - 12% 35 LI:230711.5:2001JAN12 Urinary Tract - 67%, Digestive System - 11% 36 LI:199716.6:2001JAN12 Female Genitalia - 61%, Connective Tissue - 13%

[0313] TABLE 7 SEQ ID NO: Frame Length Start Stop GI Number Probability Score Annotation 37 2 117 149 499 g12060855 7.00E−45 serologically defined breast cancer antigen NY-BR-96 37 2 117 149 499 g12847582 1.00E−40 putative 37 2 117 149 499 g7959739 4.00E−17 PRO1038 39 2 153 164 622 g6650751 1.00E−49 ribosomal protein I 39 2 153 164 622 g6091722 3.00E−40 putative ribosomal protein L13 39 2 153 164 622 g2984157 1.00E−29 ribosomal protein L13 40 1 147 1 441 g14547146 7.00E−36 EGLN1 protein 40 1 147 1 441 g11345052 7.00E−36 SM-20 40 1 147 1 441 g11320938 7.00E−36 SM-20 41 1 166 1 498 g340446 2.00E−17 zinc finger protein 7 (ZFP7) 41 1 166 1 498 g14250235 2.00E−17 RIKEN cDNA 4633401C23 gene 41 1 166 1 498 g12852573 2.00E−17 putative 45 1 182 160 705 g9956035 9.00E−48 similar to Homo sapiens glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA with GenBank Accession Number M33197.1 45 1 182 160 705 g9802302 9.00E−48 glyceraldehyde-3-phosphate dehydrogenase 45 1 182 160 705 g35053 9.00E−48 uracil DNA glycosylase 46 2 188 428 991 g15929781 6.00E−78 hypothetical protein FLJ12606 46 2 188 428 991 g10434195 8.00E−78 unnamed protein product 46 2 188 428 991 g13623354 6.00E−38 Similar to zinc finger protein 136 (clone pHZ-20) 47 2 160 2 481 g10435738 3.00E−70 unnamed protein product 47 2 160 2 481 g3342002 2.00E−57 hematopoietic cell derived zinc finger protein 47 2 160 2 481 g186774 6.00E−57 zinc finger protein 48 3 156 420 887 g12052983 3.00E−42 hypothetical protein 48 3 156 420 887 g5262560 6.00E−39 hypothetical protein 48 3 156 420 887 g10434856 2.00E−38 unnamed protein product 49 3 292 3 878 g16550444 1.00E−149 (AK055662) unnamed protein product 49 3 292 3 878 g16553223 1.00E−103 (AK057494) unnamed protein product 49 3 292 3 878 g488551 6.00E−99 zinc finger protein ZNF132 50 2 345 722 1756 g12052983 1.00E−116 hypothetical protein 50 2 345 722 1756 g14042293 1.00E−115 unnamed protein product 50 2 345 722 1756 g6467206 1.00E−109 gonadotropin inducible transcription repressor-4 51 3 132 48 443 g13623587 2.00E−45 Similar to zinc finger protein 254 51 3 132 48 443 g10435738 3.00E−35 unnamed protein product 51 3 132 48 443 g3342002 2.00E−34 hematopoietic cell derived zinc finger protein 52 1 193 1540 2118 g16198398 1.00E−105 Unknown (protein for MGC: 27353) 52 1 193 1540 2118 g8099348 2.00E−38 zinc finger protein 52 1 193 1540 2118 g5730196 3.00E−38 Kruppel-type zinc finger 53 2 101 131 433 g14042373 1.00E−24 unnamed protein product 53 2 101 131 433 g1389741 7.00E−24 KRAB/zinc finger suppressor protein 1 53 2 101 131 433 g16198398 2.00E−23 Unknown (protein for MGC: 27353) 54 2 346 92 1129 g14348588 0 KRAB zinc finger protein 54 2 346 92 1129 g10047297 0 KIAA1611 protein 54 2 346 92 1129 g10440398 1.00E−145 FLJ00032 protein 55 1 390 79 1248 g14042550 1.00E−108 unnamed protein product 55 1 390 79 1248 g13937909 1.00E−108 Similar to KIAA0961 protein 55 1 390 79 1248 g16552245 3.00E−95 (AK056753) unnamed protein product 56 3 125 3 377 g14249844 2.00E−64 Similar to hypothetical protein FLJ23233 56 3 125 3 377 g10439850 2.00E−64 unnamed protein product 56 3 125 3 377 g16552811 5.00E−60 (AK057209) unnamed protein product 57 3 310 3 932 g15430613 1.00E−177 clipin E/coronin 6 type B 57 3 310 3 932 g15430628 1.00E−176 coronin relative protein 57 3 310 3 932 g15430611 1.00E−169 clipin E/coronin 6 type A 58 1 271 682 1494 g12052959 1.00E−129 hypothetical protein 58 1 271 682 1494 g14336767 1.00E−128 similar to homoprotocatechuate catabolism bifunctional isomerase/decarboxylase 58 1 271 682 1494 g7670464 1.00E−115 unnamed protein product 59 2 120 2 361 g13924750 9.00E−60 uridine kinase 59 2 120 2 361 g13506765 9.00E−60 uridine-cytidine kinase 1 59 2 120 2 361 g10433688 9.00E−60 unnamed protein product 60 1 91 211 483 g3513300 1.00E−29 F16601_1, partial CDS 60 1 91 211 483 g14133223 1.00E−29 KIAA0876 protein 60 1 91 211 483 g13938056 4.00E−29 Similar to KIAA0677 gene product 61 2 174 287 808 g15489391 1.00E−73 (BC013789) nescient helix loop helix 1 61 2 174 287 808 g183947 1.00E−73 helix-loop-helix protein 61 2 174 287 808 g200108 5.00E−65 NSCL 62 1 139 625 1041 g950002 9.00E−10 smooth muscle gamma-actin 63 1 136 250 657 g16306743 3.00E−23 (BC001555) Unknown (protein for MGC: 5054) 63 1 136 250 657 g2828710 3.00E−23 matrin cyclophilin 63 1 136 250 657 g1770526 3.00E−23 SRcyp protein 64 1 148 1 444 g7019911 2.00E−70 unnamed protein product 64 1 148 1 444 g12853497 8.00E−70 putative 64 1 148 1 444 g15990536 9.00E−25 Similar to hypothetical protein FLJ14106 65 2 256 2006 2773 g11177164 3.00E−90 polydom protein 65 2 256 2006 2773 g12060830 6.00E−76 serologically defined breast cancer antigen NY-BR-38 65 2 256 2006 2773 g14198157 5.00E−25 polydomain protein 66 3 53 384 542 g488557 4.00E−18 zinc finger protein ZNF137 66 3 53 384 542 g3135968 1.00E−14 b34l8.1 (zinc finger protein 184 (Kruppel-like)) 66 3 53 384 542 g1769491 1.00E−14 kruppel-related zinc finger protein 67 3 292 3 878 g488551 3.00E−97 zinc finger protein ZNF132 67 3 292 3 878 g13543419 4.00E−97 Similar to zinc finger protein 304 67 3 292 3 878 g1199604 8.00E−97 zinc finger protein C2H2-25 68 2 136 26 433 g16198398 5.00E−39 Unknown (protein for MGC: 27353) 68 2 136 26 433 g7576272 1.00E−29 bA393J16.1 (zinc finger protein 33a (KOX 31)) 68 2 136 26 433 g498152 1.00E−29 ha0946 protein is Kruppel-related. 69 3 247 3 743 g13121525 1.00E−111 Synthetic sequence 69 3 247 3 743 g413074 1.00E−105 chimeric monoclonal TSH antibody, kappa-chain 69 3 247 3 743 g16741061 1.00E−104 (BC016380) Similar to Immunoglobulin kappa constant 70 3 114 306 647 g12053161 5.00E−51 hypothetical protein 70 3 114 306 647 g16041104 5.00E−46 hypothetical protein 70 3 114 306 647 g15559639 2.00E−16 Unknown (protein for MGC: 20741) 71 2 519 2 1558 g15209684 1.00E−130 unnamed protein product 71 2 519 2 1558 g1002424 1.00E−126 YSPL-1 form 1 71 2 519 2 1558 g16550532 1.00E−107 (AK055730) unnamed protein product 72 2 408 179 1402 g14198276 0 hypothetical protein FLJ12496 72 2 408 179 1402 g10434017 0 unnamed protein product 72 2 408 179 1402 g10434437 0 unnamed protein product

[0314] TABLE 8 Program Description Reference Parameter Threshold ABI A program that removes vector sequences and masks Applied Biosystems, FACTURA ambiguous bases in nucleic acid sequences. Foster City, CA. ABI/ A Fast Data Finder useful in Applied Biosystems, Mismatch < 50% PARACEL comparing and annotating amino Foster City, CA; FDF acid or nucleic acid sequences. Paracel Inc., Pasadena, CA. ABI A program that assembles nucleic acid sequences. Applied Biosystems, AutoAssembler Foster City, CA. BLAST A Basic Local Alignment Search Tool useful in Altschul, S.F. et al. (1990) ESTs: Probability sequence similarity search for amino acid and nucleic J. Mol. Biol. 215: 403-410; value = 1.0E−8 acid sequences. BLAST includes five functions: Altschul, S.F. et al. (1997) or less; blastp, blastn, blastx, tblastn, and tblastx. Nucleic Acids Res. 25: 3389-3402. Full Length sequences: Probability value = 1.0E−10 or less FASTA A Pearson and Lipman algorithm that searches for Pearson, W. R. and ESTs: fasta E similarity between a query sequence and a group of D. J. Lipman (1988) Proc. Natl. value = 1.06E−6; sequences of the same type. FASTA comprises as Acad Sci. USA 85: 2444-2448; Assembled ESTs: fasta least five functions: fasta, tfasta, fastx, tfastx, and Pearson, W. R. (1990) Methods Enzymol. 183: 63-98; Identity = 95% or ssearch. and Smith, T. F. and M. S. Waterman (1981) greater and Adv. Appl. Math. 2: 482-489. Match length = 200 bases or greater; fastx E value = 1.0E−8 or less; Full Length sequences: fastx score = 100 or greater BLIMPS A BLocks IMProved Searcher that matches a Henikoff, S. and J. G. Henikoff (1991) Probability value = sequence against those in BLOCKS, PRINTS, Nucleic Acids Res. 19: 6565-6572; Henikoff, 1.0E−3 or less DOMO, PRODOM, and PFAM databases to search J. G. and S. Henikoff (1996) Methods for gene families, sequence homology, and structural Enzymol. 266: 88-105; and Attwood, T. K. et fingerprint regions. al. (1997) J. Chem. Inf. Comput. Sci. 37: 417-424. HMMER An algorithm for searching a query sequence against Krogh, A. et al. (1994) J. Mol. Biol. PFAM hidden Markov model (HMM)-based databases of 235: 1501-1531; Sonnhammer, E. L. L. et al. hits: protein family consensus sequences, such as PFAM. (1988) Nucleic Acids Res. 26: 320-322; Probability value = Durbin, R. et al. (1998) Our World View, in 1.0E−3 or less a Nutshell, Cambridge Univ. Press, pp. 1-350. Signal peptide hits: Score = 0 or greater ProfileScan An algorithm that searches for structural and Gribskov, M. et al. (1988) CABIOS 4: 61-66; Normalized quality sequence motifs in protein sequences that match Gribskov, M. et al. (1989) Methods score ≧ GCG sequence patterns defined in Prosite. Enzymol. 183: 146-159; Bairoch, A. et al. specified “HIGH” (1997) Nucleic Acids Res. 25: 217-221. value for that particular Prosite motif. Generally, score = 1.4-2.1. Phred A base-calling algorithm that examines automated Ewing, B. et al. (1998) Genome Res. 8: 175-185; sequencer traces with high sensitivity and probability. Ewing, B. and P. Green (1998) Genome Res. 8: 186-194. Phrap A Phils Revised Assembly Program including Smith, T. F. and M. S. Waterman (1981) Adv. Score = 120 or greater; SWAT and CrossMatch, programs based on efficient Appl. Math. 2: 482-489; Smith, T. F. and Match length = implementation of the Smith-Waterman algorithm, M. S. Waterman (1981) J. Mol. Biol. 147: 195-197; 56 or greater useful in searching sequence homology and and Green, P., University of assembling DNA sequences. Washington, Seattle, WA. Consed A graphical tool for viewing and editing Phrap Gordon, D. et al. (1998) Genome Res. 8: 195-202. assemblies. SPScan A weight matrix analysis program that scans protein Nielson, H. et al. (1997) Protein Engineering Score = 3.5 or greater sequences for the presence of secretory signal  10: 1-6; Claverie, J. M. and S. Audic (1997) peptides. CABIOS 12: 431-439. TMAP A program that uses weight matrices to delineate Persson, B. and P. Argos (1994) J. Mol. Biol. transmembrane segments on protein sequences and 237: 182-192; Persson, B. and P. Argos determine orientation. (1996) Protein Sci. 5: 363-371. TMHMMER A program that uses a hidden Markov model (HMM) Sonnhammer, E.L. et al. (1998) Proc. Sixth to delineate transmembrane segments on protein Intl. Conf. on Intelligent Systems for Mol. sequences and determine orientation. Biol., Glasgow et al., eds., The Am. Assoc. for Artificial Intelligence Press, Menlo Park, CA, pp. 175-182. Motifs A program that searches amino acid sequences for Bairoch, A. et al. (1997) Nucleic Acids Res. patterns that matched those defined in Prosite.  25: 217-221; Wisconsin Package Program Manual, version 9, page M51-59, Genetics Computer Group, Madison, WI.

[0315]

1 72 1 817 DNA Homo sapiens misc_feature Incyte ID No LI180252.162001JAN12 1 aacatcccaa taaaagtggc tcgatatggc acgatattgg gatggttgaa gagtttggag 60 acaatgagct gtgggttgtc acatcattca tggcatacgg ttctgcaaaa gatctcatct 120 gtacacactt catggatggc atgaatgagc tggcgattgc ttacatcctg cagggggtgc 180 tgaaggccct cgactacatc caccacatgg gatatgtaca cagaatctcc agggttatga 240 tgccaagtct gacatctaca gtgtgggaat cacagcctgt gaactggcca acggccatgt 300 cccctttaag gatatgcctg ccacccagat gctgctagag aaactgaacg gcacagtgcc 360 ctgcctgttg gataccagca ccatccccgc tgaggagctg accatgagcc cttcgcgctc 420 agtggccaac tctggcctga gtgacagcct gaccaccagc accccccggc cctccaacgg 480 cccagtgcca gcaccctcct gaaccactct ttcttcaagc agatcaagcg acgtgcctca 540 gaggctttgc ccgaattgct tcgtcctgtc acccccatca ccaattttga gggcagccag 600 tctcaggacc acagtggaat ctttggcctg gtaacaaacc tggaagagct ggaggtggac 660 gattgggagt tctgagcctc tgcaaactgt gcgcattctc cagccaggga tgcagaggcc 720 acccagaggc ccttcctgag ggccggccac attcccgccc tcctgggcag attgggtaga 780 aaggacattc ttccaggaaa gttgactgct gactgat 817 2 781 DNA Homo sapiens misc_feature Incyte ID No LI1072919.12001JAN12 2 ggtttccgcc ctcctcctcg cgctgtttcc gcctcttgcc ttcggacgcc ggattttgac 60 gtgctctcgc gagatttggg tctcttccta agccggcgct cggcgaagtt ctccccaggg 120 gcaaagccca tgttcatggt cgagcgccaa gatcgtgaag ccccaatggg cgagaatgcc 180 ggacgaattc cgagtccggg atcttcccag gctcttctgg aggctggagc atgaactcgg 240 acctcacagg ctcagctcag gcagctgaat attacggctg ctaaggaaag tgganagttg 300 gtggtggtcg gaaagctatc ataatctttg ttccacgttc ctcaactgaa atcctttcca 360 ggaaaatcca agtccggcta gtacgcgaat tggagaaaaa gttcacatgg gaagcatgtc 420 gtctttatcg ctcacgagga gaattctgcc taagcccaac tcgaaaaagc cgtaccccaa 480 aataagccaa ggcgtccccg gagccctact ctgacagctg tgcccgatgc actcccttga 540 ggacttggtc ttccccagcg aaattgtggg catagagaat ccgcgtcaaa ctagaatggc 600 agccggctca taaagggttc attttggaca aaagcacagc agaacaatgt ggaacacaaa 660 ggttgaaact ttttctggtg tctataagaa gctcacgggc acaggatgtt aattttgaat 720 tccacagagt ttcaattgta aacaaaaatg actaaataaa aagtatatat tcacagtaaa 780 a 781 3 773 DNA Homo sapiens misc_feature Incyte ID No LI477130.12001JAN12 3 gaagtgctcc ggggaagcac cgtgacaccc ttgctcgccc gcatctctct aaccgccggc 60 gccggcgccg gcgccggctc atcgttcaca tggctgcgat gccaccggcc ttcacgggca 120 acctgaagaa agcacttgca ggtctgagaa gaatcacatt tagatgggct tcgatggacg 180 cgtacttgat gctaagggtc aggtgctggg acgattggct tcccaaatag ccgttgtgct 240 tcaaggcaag gataaaccga cctatgcgcc acatgtggaa aatggagaca tgtgcattgt 300 acttaatgca caggatatca gtgttacagg aaggaaaatg acagataaga tttactactg 360 gcatacaggg tatgttggcc atttgaagga aaggaggctc aaggaccaga tggagaaaga 420 cccaactgaa gtgattcgca aagctgtgct gcgcatgctt ccccgcaaca aactgcgtga 480 tgatagggat cgcaagctgc ggatattttc tggaattgag catccattcc atgaccgccc 540 tcttgaagcc tttgtgatgc cacctacggc aagtacggga gatgcgaccc cgtgcaaggc 600 gtgcaatgtt aagggcccag actaaagagc attcaaacag ggccaaggag gaagaagatg 660 ctaagaatgc cacagctgag gtcactgaca taggctcctc atgtgaattt gcatgatgca 720 aatttgctca gatgactgtt ttaggcctat catttatatt gacttggtag cct 773 4 442 DNA Homo sapiens misc_feature Incyte ID No LI351355.12001JAN12 4 ggccgctacc cctcctgctc ggccgccgca gtcgcctcgc cccgcccgcc cgccgccatg 60 gccaatgaca gcggcgggcc cggcgggccg agcccgagcg agcgagaccg gcagtactgc 120 gagctgtgcg ggaagatgga gaacctgctg cgctgcagcc gctgccgcag ctccttctac 180 tgctgcaagg agcaccagcg tcaggactgg aagaaagcac aagtctcgtg tgccacggca 240 gcgagggcgc cctcggccac ggagtgggcc cacacccagc attccgggcc ccgcgccgcc 300 ggttgcagtg ccgccgtgcc agggcccggg cccccgggag cccaggaagg cagcggcgcg 360 cccggggaca acgcctcccg gggacgcggc caaaggggaa aagtaaaggc caaagccccc 420 ggccgaccca gcggcggccg ct 442 5 1406 DNA Homo sapiens misc_feature Incyte ID No LI038285.22001JAN12 5 aattcactgt ctgtagcatc tgctcctcca cagagggacc ctggaatggc gatggcactc 60 ccgatgcctg gacctcagga ggcggttgtg ttcgaggatg tggctgtgta cttcacaagg 120 atagagtgga gttgcctggc ccccgaccag caggcactct acagggacgt gatgctggag 180 aactatggga acctggcctc actaggcttt cttgttgcca aaccagcact gatctcccta 240 ttggagcaag gagaggagcc gggggccttg attctgcagg tggctgaaca gagcgtggcc 300 aaagccagcc tgtgcacaga ggaccctaat acactgccca gcagaagcca gggaaggaag 360 ccctgccagc ttcagaaggt gggccaggag agaagggtgt ggcctggaag ggtagccggt 420 gggggtgctg catcctcttg gccccaccgg ggagcaccct gttcacccct aacagatgaa 480 gagaaggtga ggggggattg agttacctgc ccactggtgt gtcaaactcc atgatggggg 540 tgggaacatg cagacctggc ccctccaagg cccactgctc cccgggctgt gcgccccaca 600 gtctgtgcca ggggctgcag aaagagccat gggaagcctg gccctgtgta gggcaccaag 660 aatgggaggg gttggatcca ccctcctaga gaacaagaat cctgggcagt agccgggaca 720 tggtggggga ggctgaaggg ttgtccctga gcatccccaa catggagctc ggaagtctgg 780 gccatgggca tggaaagcac gaagtgtcag ggccagcctg gtggaaccga agagctgtgc 840 cacgatccct tccacctggt ggcagctgcc cacatgtccc gccactgggt tccatcacct 900 gagactcctg gcaggtgcct ctctgagtct tttgtcctgt gctggaaact gggatgtgca 960 tgcacacatc ttcatcaccc acagcacgga cagcgggaat aacacttcct ttggggatcc 1020 agggtttctg gtgtctccag atttttcagg cgcccaccat gttcctctca tcccagacgt 1080 cggcaaccaa ggtggaagcc aggttcatgg catgcccggc ccagctgcag tccgagtgca 1140 gatcccatgg cgagcgtggg atccagccca aagcacaagc cacgcacaag cccgccaagg 1200 ttgagtgggc aggtacctcc aacagccagc ccaggttgag tgggcaggta cctccaacag 1260 cctggagccg tgaggccttg cgcagggcgt tgccggccgt ggaggtctct ggctggcaaa 1320 gtggcaccga aagagtcctg tgtcataacc agactcactt gtagcttctg ttgctctccc 1380 tagctatttg caaagcatcc caggat 1406 6 2675 DNA Homo sapiens misc_feature Incyte ID No LI1079031.12001JAN12 6 cgagcgaggg aggggggagc aggcccggcg cgctgctgtg gtgggccctg ctgctctgct 60 ggcgaggaca ggactcagtg ccaagcgcag gaggggaggg agccccggtg ggcccggggc 120 ctgcggaggg agccgagctc ttggtgcttt tcccgaagga gcgcgggagg cgcgacgggt 180 ccggcgagtg cccggcatgg cggcttttcc agcctgcttt gtgttaagcc gaggtcctgg 240 cttctctgtg tctcccagct gggggccatg aggctccctg agatgactct tttccccttc 300 tcccaactcc gtggcgtgac tctcagccca ggtattgctg gtccgctgct caggacagat 360 tccgggggct ggtcctcctg cctcctgggg ttgaggtggc gtcccgttct tctccgtggc 420 ttggaggaaa ctacatcagg atggtggctg ggaacgtgta ggggccctca gaggcccctg 480 tgtagttggt tgtcccctgt ctgctttctg gctttcagag atgagcggca tagaatcagg 540 cgaggggttt ctgcttctga gccttagagt cttgtgagga gacccctccc tgatgtggtg 600 gcacaggagc ctgggtgggg gcgggggtga ctgggagggc acacctgggg gacagcagcg 660 gcgggagtgt ggtccgactg gcctggaaga tcttgggcag agctgacctc agagaacagt 720 gcgggtctct cgccctcctg gggcagtccc caggacgagg tgccaggtgc ctggcccatg 780 ttgcagcgcg gccgtgcgag cccatgcagg atcgacgtgg acccccagga agacccgcag 840 aatgcacctg tacgtcaact acgtggtgga gaaccccagc ctggatctgg aacagtacgc 900 ggccagctac agcggcctga ctgcgcatcg aacggctgca gttcattgct gatcactgcc 960 ccacgctgcg ggtggaggcc ctgaagatgg ccctctcctt cgtgcagaga acctttaacg 1020 tggacatgta cgaggagatc caccgcaagc tctcagaggc caccagggca ggctgcacga 1080 acgcacccga cgccatcccg tgagagcggc gtggagcccc cagccctgga cacggcctgg 1140 gtggaggcca cgcggaacga aggcgctgct tgaagctgga gaagctggac acagacctga 1200 agaactacag agggcaacct ccagccgaag agagcatccg gcgcggccac gacgacctgg 1260 gcgaccacta cctggactgt ggggacctca gcaacgccct tcaagtgcta ttcccggtgc 1320 ccgggactac tgcaccagcg ccataacacg tcatcaacat gtgcctcaag tgtcatcaag 1380 gtcatgcgtc taccttgcag aattggtctc atgtgctcag cctacgtcaa gcaaggctga 1440 cgtccacccc agtagattgc cgagcagcag aggacgagcg tgatagccag accccaggcc 1500 aatcctcagc aacgctcaat gtgtgccgcg ggcttggcag agctggccgc ctcgaggtcc 1560 aagtcgaggc tgccaaggtg cctcctgcga ggctcccttt gatcactgtt gcacttccct 1620 gtagctgctg tcccccatgc aggtggtcat ctacgtgtgg cctgtgcgcc ttggctacct 1680 ttgaccggca ggagctgcag cagcaatgtc atctccagca gctccttcaa gttgttcttg 1740 gagctggagc cacagtgtcc tgagacatca atcttcaaat tctacgagtc caagtacgcc 1800 tcatggtctc aagatgctgg acgagatgaa ggacaacctg ctcctggaca tgtatctggc 1860 cccccatgtc aggaccctgt acacccagat tcgcaaccgt gccctcatcc agtatttcag 1920 cccctacgtg tcagccgaca tgcataggat ggcggcagcc ttcaatacca cggtggccgc 1980 cctggaggac gagctgacgc agctaatcct ggaggggctg atcagttgcc cgtgtggact 2040 cacacagcaa gatcctatac gcccgggaac gtggatcagc gcagcaccac ctttgagaag 2100 tctctgttga tgggcaagga gttccagcgc cgcgcccagg cccatgatgc tgcgggcaac 2160 tgtgctccgc aaacccagat cccaagtcaa gtccccccgc cccagagaag ggagcccggg 2220 ggagactgac tcccagcgcc acagcccagt ccccggatga gccacccaca tagtgagggg 2280 gtgtacctct ggcctccaac aggacatctt gcacacccct ccccaccctc caccggagcc 2340 tcggaacctc cacggcggct cacagtgctg cctgacggcc cacgctaaag gggcctcggc 2400 cacactgggt gcacaaccca gcccgttgtg cccctcccct ggggcctgaa ggaaggcaca 2460 ggccggctgt ctatagtata gtggccacct tccctgtgaa aggaagaagg ccctgcacag 2520 ggctctgaga cccctgtggg gtttcttgtc tcccacaggg agagcaagaa ctgttgccgg 2580 cacacccaca ggcccacagt ggcacacata ttcccagaca ccctcctgtt cccgcctccg 2640 gtcaggtgca gacaaatggg cggtgtccca tttaa 2675 7 2370 DNA Homo sapiens misc_feature Incyte ID No LI306216.12001JAN12 7 ggggggtcgc cgcggtgcta gctgctcagt gggagcgggt cttcgcaact gtctccgcgt 60 ggcgcgcgcc tctagccgcc cttcccctgg cggctaacgg ccggagggag cggaggcaga 120 gcgggagtcg ggctcccatg gagaagcggc ggacaactgg gcagaggcgg agcttttcaa 180 tctcggcacc ctggtcccag tgacccgcgc tagctgtccc gtcccgcccg cgtcggagcg 240 gccgccggcc ccgggactga ccggcctcgc cgcacctccc gcaccgacta gcgctcccgg 300 gcgctcctgc gcccgactac gccctcgccc ccactccccg gcgggatggc ggcggccggg 360 cccccacggc ggcggccgga gcagcagcag cagcagcagg agcccgcctc tatgatgaag 420 ttcaagccca accagacgcg gacctacgac cgcgaggggc ttcaagaagc gggcggcgtg 480 cctgtgcttc cggagcgagc aggaggacga ggtgctgctg gtgagtagca gccggtaccc 540 agaccagtgg attgtcccag gaggaggaat gaaacccgag gaggaacctg gcggtgctgc 600 cgtgagggaa gtttatgagg aggctggagt caaaggaaaa ctaggccaga cttctgggca 660 ttaatttgag cagaaccaag gcccgaaagc acagaacata tgttcagtgt cctaacagtc 720 actgaaatat tagaagattg ggaagattct gttaatattg gaaggaagag agagtggttc 780 aaagtagaag atgctatcaa agttctccag tgtcataaac ctgtacatgc agagtatctg 840 gaaaagctaa aagctggggt tggtccccca gccaactgga aattctacag tacccttccc 900 ttccggataa taatgccttg tatgtaaccg ctgcacagac ctctgggtat gccatctagt 960 gtaagatagc agagaactgg gtaggcctct cccaccatgt gcagtctcat ggggagaggc 1020 ttctattcgt ttcctcgtca aacatctgat tgacgcttgc aaactgtctg aatttgccat 1080 gcaaggtttt caaacaattt gcatgttgtg ctcagatgct ttcaaagtct ttttgttcaa 1140 gaaaaatagt gtaaacatat tttcaataag ccaagagcca tgtggaattt tcgttctaga 1200 tgccttaact gtgccatagc ccagaatccc ctatattatt ttggttgtct atttctcaca 1260 gcatattttc agttttttgt ccatttgaca tcagtctgtg gtttattttg tcatcagatt 1320 acttgtgggt atacctaccc caaaattgtt ttctcattca cagcattagc atattcagca 1380 aatccatctg tggtgggaat taaaaatatt attcggtatt taaagaaatc cattcacccc 1440 aaaacttgtt ttacaggatt acaattttaa ttcaaacact ttccagattg gggctatttc 1500 tgtatgatcc aataacttca tttggtcaca gggtctgtaa ttgtgccagt ttatcgggga 1560 tttgtcgact catttggtct gaattatgtc acaactggta ttatgtcact agctacctga 1620 tacggctatt tcccttataa ctcaatagta ccttaagcac aagagtataa ctctgtatca 1680 gttggtgaat attttaggga aatattagca aaactgcatg tagtaaagag catcttatga 1740 aaactgtatt catggaattt gatttatgca tgctcagtgt gccagttccc attatcgata 1800 ctcgtttctt tgcagaatac cgttagaacc gttatttccc tcagtgtaga ttgcgtctta 1860 agaattattc agttatttag tggcccccac aggagtggag tcttgcaaat ctaattctaa 1920 agtgccagtc agtgatgatc gccatcacca gattgagatg aaatggcctt ctctgttcca 1980 gctgttagca ggactggaag attgttaggg ccacccttag aaatgtctca tctttttcta 2040 ggttgtcaca caggtactaa tttgtcacag taactaactt tcgaggcacc tgggacatag 2100 cctgaactaa gaattaaaat ctttttactt taataactca ctgtaaaatc cagaatcccc 2160 atctaagaca cattaggtac cttattcttg aaactccttg cacttccccc acccgggcag 2220 aaaatgaggt gggagaaagt ttgactaaaa tggagaggat gggggaaagt aaaagatgtt 2280 attttatttt ttgaaactcg cttggctcac ccaggctgga gatgcaagag gccacaatca 2340 tcaacatcac cgcaacctcc gcctcccggg 2370 8 4119 DNA Homo sapiens misc_feature Incyte ID No LI011799.12001JAN12 8 gctacatttg aaagaaccag gtaggaggaa gatcccatcg gccttgcagt ccaccagacc 60 aggtggttgg ttctctggcc tcatgggcac ctttgttact ggggactact gtcctataaa 120 cggtattaga gagtggcttg caaggattgt ttgtcaagcc ctgcgagttg gtgccgagga 180 cggagatttg atcatcaggt ttccccttcc tgaagctcga tgaagggtga tggtggcggt 240 ggtgggttgt gcatgtgtgt ggcagatgga aaaacttccc gtgtgtgttt gtctatgtta 300 ggtagtctct ggctgtgtcc acatgtctgt ctgtgcatca ctggtcagat gtctctgtgg 360 atgtgtctat ttcgggggcg gcggcagggt gatgtgtaag ttatgcttcc atgtgcaagt 420 gggtgtatat gttatatttg aaagtacctg tgaccaggtc tgcgtgcatc acacccacat 480 aagttgtttt catgaggtta aactatatga taatacctcc ccccagcaaa gctggctatt 540 gagttagcag gtcacgagct gagtctgtgt actgtagata aactgggtaa ttggactctc 600 cgacctcttc atccaaaaca aacacaaaag cccgccccca caccggaggg agtctgtgcc 660 cgtcatctgg gtgcttggtt ctagtgccct gctttccttg accccctgta gacaaggtga 720 gcgcttccgc ggaggggctt ctgtacagag gtcacagcac gctgtgtccc gggacgcacg 780 cggattcctg cacaggtgtg gtggctgcgg atggggacgg agcggagcag gctcgccggc 840 ctcctccccg gcggcggctc cgcttctcct tcctgctgtt cacttcatct cctcatctgc 900 atgtgtgaca gcggcgcgcg gactggggaa ggacagagcg ccctctcccc ggctcccgtg 960 cagcggggcg ggggctccgg gctccccagt gatgcgtcgt ctgcgcctcg ccgccgcgct 1020 ccccgggcct ggcagcgtaa gtgatgcggg ggcgggggcg ccgagactgc ggggaggggg 1080 cgcggggaaa gagaggcgtc gacgccgaga gacgctaact ccttcctccg cccggggact 1140 gcccggcacc ccgaacccct gaaagccccg gctgcggctt gcttcggcag tgtccgagca 1200 gcgggtgggg agggggcggg gaccaagcag tgcagggtgt ggtgctgccc ccggggggcg 1260 ccctccgccg ccgcgtcttc ccagtgaagt tgaccagggg ctgcggagcc catccgctgc 1320 ccgccggagg gcgcgtggcc ccagctgccc ttgattcacc gcgttccccc cgcagggcca 1380 ggcgtggacg ccgccggacc gctgagactc ggggcacggt gaagcactgg ccggggtctg 1440 gctgggtccg gcgctcggga gccagatgga ggtggcgata ggggccgtgg gagccggcgc 1500 caagtagccg gtggaccccc gcgctcgcac ctctcccggc gcccgggcgc tccccaaggc 1560 tgccatggag gtgcctaacg tcaaggactt ccagtggaag cgcctggcgc cactgcccag 1620 gcgccgggtc tactgctccc tgctggagac cgggggccag gtctatgcca tcgggggatg 1680 tgacgacaac ggcgtcccca tggactgctt cgaggtctac tccccggagg ccgaccagtg 1740 gaccgccttg ccccggctgc ccacagcccg ggcgggggtg tccgtcaccg ccctggggaa 1800 gcggatcatg ggtgattggg ggcgtgggcg accaatcagc tggcccctgg agggtcgtgg 1860 agatgtacaa catcgatgag ggcaagtgga agaagaggag catgctgcgt gaggccgcca 1920 tgggcatttc tgtcacggcc taagattgac cgagtatatg cggcaggcgg gatgggcctg 1980 gacctacgtc cacacaacca cctccaacac tatgacatgc tgaaggacat gtgggtgggc 2040 ggtagcaccc atgccccacc ccgagatatg ctgccacctc cttcctgtcg aggctccaaa 2100 gatctacgtg gctgggggga cgacagtcca agttacgcgg tgcaacgctt tcgaggtctt 2160 tgacatcgag actcgctcct ggaccaagtt tccccaaatt tccctataag cgggccttct 2220 ccagctttgt gaccctggac aaccacttgt acagcctagg aggcctgcgg caaggtcgcc 2280 tctaacgggc aggcccaagt tccctgcgga cgaatggacc gttgttcgac aatggaacag 2340 ggggggttgg ctgaagatgg aacgatcgtt ctttcctcaa gaaagcgggc gggcagcaat 2400 ttgtgtgcgc tggctctctg agtggcacgg gtcatagtcg gctgggcgga cattgggaat 2460 caacccactg tcctggagac gccggaagca tttccaccca gtggaagaac aaatgggaga 2520 tcctccctgg ccatgcccac accccggctg tgcctgctac cagcatagtc gtcaagaact 2580 gcctcctcgc ccgtgggacg gtcgtcaacc agggtctgag cgacgcacgt ggatggccct 2640 gtgtgtctct gactccatta gctgtcttct gggctcagta ccttatgccc tgtgaccata 2700 tcacttcaac tcttaacatg aggaatgatc ttgtcgcaag cagtcggggg ctacttccaa 2760 gaatgtcagc tcctgtttag caaccaggag gaggtctggc ccttggggcc tctaagttga 2820 ccgtctcgta tagctccaaa tccgtaccaa tctcagaaga actgtaagga ggcacaagat 2880 gacgtccacc agcgtgcaga gcttgactct gaagagagtc ttcagcttac tgcagcaggc 2940 aaaagaaagg cacaggaata tgttcctgac ctcgccctcc tgttgagtcc cacctgcccc 3000 ccacccccat ctccaggagg ctaggtagag cagttctgat ccgagaggat agacgtgctg 3060 ttgctgtctt tccccagctc tgaactagtt ttaaggtagc ttaggatgac acaatggacg 3120 gatgattggg gggttccaaa ccactttctt ctcccttggc ttatatctct tcaccatttg 3180 gctggtcaac tgtgggccta ccctggacct catctactca gcgagaattg gacatgaagc 3240 tagaggcagc tgccttggaa agggagtcaa ggctccattt gtcaagccca ggccatggca 3300 ggaagaatcc ctccctcctt ggggggtcct tgatggggca tgtagtgatg gggaaggagc 3360 agtctcccag gcgcgcgtgg gtctgctctc gcgcacatct ctcctatagt tccagcgttc 3420 agccgttttg ccatcccctg tccccacgca gatggcctag cccttgttgt caccgaaggc 3480 ccccatgatg tgtttctggt gtgaaacacc tacttcattt acggctgttg gcactcgaga 3540 gaagtccaca aaagatggat taattgcagc tctgtgttga atagcagcag caacaaatgg 3600 attaaaatct atagttccta tcttctctag caccctggtg tgggggatgg ggcggaaggg 3660 tgtcttgagg gggcacggga gggagcccca cttaaaccat ccctcctgca ttttcacggc 3720 tataataggg cccccagtga ctacactgtt ctataggcat gtccccacta ctgaagaagg 3780 ctctagccat tactacacag ccaccaccca gttggcccca ctccccagga aaacagcaca 3840 tgttcgttct tctcctgcca ttgagactgc cgtgttagtc ttccaattca taactcatca 3900 gcagctcagt gccttcatta tgtctagtct ccctccattc agccaaagct catttttgtc 3960 ctatccaaag tacgaaaggg tttttttagg aaacttgtaa gaatgtgcct cctcgttagc 4020 atctgtttct gactcccagt tatttttaca cataacatga tgaatacaat gcctgccctg 4080 aagggttctg gaggagtcag tgtatcactc atcaaaaaa 4119 9 1349 DNA Homo sapiens misc_feature Incyte ID No LI109467.12001JAN12 9 aaataaaata aaataaaatg agacagcaac cacacacaaa aaaatactta taaaacagat 60 tttaaaaaat attaatcaca taatgtctac tctcagacct cagtggaatt aaactgaaaa 120 tcaatagaga aagataggct ctctgttcct tctgtgtgat aaaggacaca gcagcagcca 180 tgcagcagca gccatgcagc agcagccatg tccctgagac agttggtgaa attgaaggtt 240 gtagtaaaca catttggctg tactgggcat ctggtcaact gggctgcttt taactctggc 300 aaagtggata ttgtcatcat cagtgacccc ttcactgact ccagctacat ggtctacatg 360 ttccagtatg attccaccag tggcaagctc cacagcactg tcaaggctga gaatcacaag 420 tttgtcatca gtggaaatcc tatctccatc ttccaggagc aagataccac caaaatcaaa 480 tgcagtgatg ctggcactgg ttgtgttgtg gagtcaactg gtgtcttcac tatcttgtat 540 atggctgggg cacacttaga ggagagagcc aaagagtcat catctctgct gcctttgacc 600 ccctgtttga tgggcatgaa ccatgagaag tacgaaagca acctcacaat catcagcatt 660 gcctcctgca ccaccaactg cttagcattc tctgaccaag atcatccatg atagctctgg 720 catcatggag ggactcctga ccacagtccc tgctatcact gccacccagg agacctatgg 780 atggcttttc tgggaaactg tgacgtcatg gttgtggagc tctgcagaac attattcctg 840 catctactgg aacttccatg gctgtgggca aggacatccc tgagctgaat ggggagatca 900 ctggcatggc cttcctcgtc cctaccacca atgtgtcagt tgtggacctg acctgctgtc 960 tggagtaacc tgccaaatat gatggcttca agaagatggt gaagcaggca tcggaaggcc 1020 cttcgagggc acactgggct acactgaaca ccaagttgtc ccctgtgact ttaacggtga 1080 cactccctct tccactttta attctggggc tagcattgcc ctcagcaacc attttgtgaa 1140 gttaatttcc tggtatgaca attagttttg ctacagcaac ggggtggtgg acctcatggt 1200 ccacatggcc tccaaggaat aacagccctc cggactacca gccactagtg agagcacgag 1260 agaaaaagag aggctctcag ctgctgagga gtaccctgcc tcactccgtc ccctcaccac 1320 acccaacgaa gctcccctcc atccacagt 1349 10 1261 DNA Homo sapiens misc_feature Incyte ID No LI1175250.12001JAN12 10 cgacttcgcc ggagccggct cttcctgtta gtctccgctg ctagttcttg gctctgggag 60 gcccaggtgg ctctgcagca gcctctgcca ccctgtgacc tgcatgtact gggggattcg 120 cagggaggat gtcgggacac ccgggaagcc gaggaatgga ctcggtggct tttgaggatg 180 tggctgtgaa ctttacccag gaggaatggg ctttgctaga ttcttctcag aagaatctct 240 acagagaagt gatgcaggaa acctgcagga acctggcttc tgtaggaagc caatggaaag 300 accagaatat tgaagatcac ttcgaaaaac ctgggaaaga tataagaaat catatcgtac 360 agagactgtg tgaaagtaaa gaagatggtc agtatggaga agttgtcagc caaattccaa 420 atcttgatct gaacgagaac atttctactg gattaataac catgtgaatg cagtatgttg 480 tggaaaagtc tttgtacgtc atgccctccg taataggcat atcctagctg cactcaggat 540 acaaaccata tggagagaag caatgataaa tgtgaacacg tgtgggaaat tcttcgtttc 600 tgttccaggt gttagaagac acatgataat gcacagtgga aatccagctt ataaatgtac 660 gatatgtggg aaagcttttt attttctcaa ttcagttgaa agacatcaga gaactcacac 720 aggagaaaaa ccctataaat gtaaacaatg tggtaaagca ttcactgttt ccggttcttg 780 tctaatacat gagacgaact cacactgtga gatggaaccc tacgtatgta aggaatgtgg 840 gaataccatt agattctctt gttcttttaa gacgcatgaa aggactcaca ctggagaaag 900 accctataaa tgtaccaaat gtgataaagc cttcagctgt tccacttccc ttcgttacca 960 tggaagcatt cagtactgga gagagaccct atgagtgtaa acaatgtggc aaagccttta 1020 gtcgtcttga gttccctttg taaccataga agtactcata ccggagagaa accctatgaa 1080 gtgtaaacaa tgtgatcaag ccttcagtcg cctcaagttc ctttcacctc ccacgaaaga 1140 attcatactg ggagaaaacc cctatgaatg taagaaatgc ggtaaagcct acactcgtta 1200 ccagtcacct tacttcgcca tgaaagaagt catgatatag aggctgggtg tagtgactca 1260 g 1261 11 481 DNA Homo sapiens misc_feature Incyte ID No LI2121744.12001JAN12 11 aatgtggact atcaagggag caagtggatg ccctggggct gagaggagtc ttctggtgca 60 gtcttatttt gaaaaggggc cattgacgtt tagggatgtg gccatagaat tctctctgga 120 ggagtggcaa tgcctggaca gtgctcagca gggtttgtat aggaaagtga tgttagagaa 180 ctacagaaac ctggtcttct tggcaggtat tgctctcact aagccagacc tgatcacctg 240 tctggagcaa ggaaaagagc cctggaatat aaagagacat gagatggtag ccaaaccccc 300 agttatatgt tctcattttc cccaagacct ttgggcagag caggacatta aagattcttt 360 tcaagaagcg attctgaaaa aatatggaaa atatggacat gacaatttac agttacaaaa 420 aggctgtaaa agtgtggatg agtgtaaagt gcacaaagaa catgataaca aattaaacca 480 g 481 12 1260 DNA Homo sapiens misc_feature Incyte ID No LI1170908.12001JAN12 12 gggaatgcat ggaagcactc acacttggca gaaactctat gaatgtagca atgtgggaaa 60 gccttcagat ctgccccaaa tcttcaattg catggtagga ctcacactgg agagaaaccg 120 tatcaatgta aggaatgtgg gaaagctttc ggatctgcct cacaacttcg aatccatcgt 180 aggattcaca ctggagagaa accctatgaa tgtaagaaat gtgggaaagc cttcagatat 240 gtccagaact ttcgatttca tgaaaggaca caaacacata agaatgcact ctggagaaag 300 accttataaa tataagatat atgggaaaca cttttattct gccaagttat ttcaaacaca 360 tgaaaaaatt cacactggag agaaacccta taaatgcaag caatgtggta aagccttaat 420 tgttccagtt cctttcgata tctaaaagga ctcacagtgg agaaaaactc tatgagtgta 480 agcaatgtgg gaaagtcttc agatctgtca agaacctttc aatttatgaa aggacacaca 540 ctggagagaa accctatgaa tgtaagaaat gtggaaaagc gttccataat ttctcttctt 600 ttcaaataca tgaaagttgc acagaggaga ggcgccctaa gaatgtaagc attgtgggaa 660 agcattcata tctgccaaga tcgtttgaat acatgcaaaa cacacactgg agagaaacct 720 atgaatgtaa ggaatgcaaa caagcattca attatttttc ttccttgcat atacatgaaa 780 ggactcatac gagagagaat ccgtatgaat gtaaggattg tgggaaagca ttcagcttgc 840 ttaattgctt tcatagacat gtaaagacac accagaagga aaccctatga atgtaagcaa 900 tgtggcaaaa gctttcactt cttccagttc ttttcaatat catgaaagga ctcacactgg 960 ggagaaaccg tatcaatgta agcaatgtgg gaaagccgtc agatcagcct caagacttca 1020 aatgcatgga agcactcaca cttggcagaa actctatgaa tgtaagcagt atgggaaagc 1080 cttcagatcg gctaggattc tttgaataca aataatgaat gtaaacaatt aactgtttat 1140 aataactgta tactaacaaa tgttattctt tttaaataat taagaagcta taataaaata 1200 tccattggtg tcatgtatta gatcaagctt ataatgttac attgttatta tttggatatt 1260 13 1551 DNA Homo sapiens misc_feature Incyte ID No LI1173119.12001JAN12 13 ccgagcaggg actgtacacg tgtccagcac atcttcacca gcaccaaaag gagcagatta 60 gagagaaact ttctagaggg gatggaggaa gaccgacatt tgtgaagaac cacagagttc 120 acatggcagg gaagaccttc ttgtgcagtg aatgtgggaa agcctttagc cacaaacata 180 aactttctga ccatcagaaa atccacactg gagaaagaac ttataagtgc agcaaatgtg 240 ggatattgtt tatggaaagg tccacactca atagacatca gagaactcac actggagaaa 300 ggccttatga gtgcaatgaa tgtgggaaag cctttctttg taagtctcac cttgttcgtc 360 accagacaat ccactctgga gaaaggcctt atgagtgcag tgaatgtggg aaattgttta 420 tgtggagttc cacactcatt acacatcaga gggttcacac tggaaagagg ccttatggtt 480 gcagtgaatg tgggaagttc tttaagtgca actcaaacct ctttaggcat tacagaattc 540 atacaggaaa aaggtcttat ggttgcagtg aatgtgggaa attctttatg gaaaggtcta 600 cactcagtag acatcagaga gttcacactg gagaaaggcc ttatgagtgc aatgaatgtg 660 ggaaattctt cagcttgaaa tccgtcctca ttcaacacca aagagttcac actggagaac 720 ggccttatga atgcagtgag tgtgggaagg ccttccttac aaagtcccac ctcatttgtc 780 atcagacagt tcacactgca gcaaagcagt gcagtgaatg tgggaaattc tttaggtata 840 actctacact tctcagacat cagaaagtcc acactggata aggcccttat gaatgcagtg 900 gatatgggaa agccttcagt caccaacata ttgtggctgg acagcaggca gtacacactg 960 gagaaagact gaatgccgtg aacgtgggta attatgtagg tacagctctc cagtcgctat 1020 gtatcagaga attcacactg cagaaatgtg tgttcagcaa actcgggaca ttattttggt 1080 ttgactctca tctcattaga cattggagag tttacactga agaagagtct tttcaataaa 1140 gtagaaagtg gtaaagattc aacatgcaag attgtactta ttgggcttca gaatatccac 1200 actagtgaaa gtcttctgag tacagcaaat gtgtgacatt attttgctac tactccacac 1260 tacttagaca tcatgtagtt cacactggaa aaaggccacg tatgtgcctt gaatgtagcc 1320 aaaatgatga acaacaccca gaaatctgtg atttagcact gagaactagt attatatggt 1380 ttttaaaaaa caatggtgaa gtacatgcca cataaaattt gccatcttaa ctattgtaat 1440 gtcttgttta atacttgaag tacattaaca ttgttgagca aagaatatcc tgaactcttt 1500 atcttgtaaa atgaaactct ataaccacca ttaaaaaaac aactcattcc c 1551 14 2192 DNA Homo sapiens misc_feature Incyte ID No LI1175131.12001JAN12 14 tgcgaaggcc ctggctctcc tcggttcccg gctccaggcg gcgagctgag gttgggagcc 60 tggntttccc ctccgagagg nttcaggtgc ctctgccata gcttctgtcg cctgtgctgt 120 gacccgcact ggtcgtggga gtcacctgaa aggcaagaaa tggattcagt ggcctttgag 180 gatgtggctg tgaccttcac ccaagaggag tgggctttgc tggatccttc ccagaaaaat 240 ctctgtagag atgtgatgca agaaaccttc aggaacctgg cctctatagg gaaaaaatgg 300 aaaccccaga acatatatgt agagtacgaa aatctaagga gaaacctaag aattgtggga 360 gagagactct ttgaaagtaa agaaggtcat cagcatggag aaattttgac ccaggttcca 420 gatgacatgc tgaagaaaac aactactgga gtaaaatcat gcgaaagcag tgtgtatgga 480 gaagtaggca gtgctcattc atctcttaat aggcacatca gagatgacac tggacacaag 540 gcatatgagt atcaagaata tggacagaaa ccatataaat gtaaatactg taaaaaacct 600 ttcaactgtc tctcctctgt tcagacacat gaaagggctc atagtggaag gaaactctat 660 gtttgtgagg aatgcggaaa aacatttatt tcccattcaa accttcaaag acacaggata 720 atgcaccgtg gagatggacc ttataagtgt aaattttgtg gggaaagcct tgatgtttct 780 cagtttggta tcttatccac aaacgaactc acgactggag agaaaccata tcaatgtaaa 840 cgagtgtggt aaagccttta gtcattctag tagccttcga atacatgaaa gaactcacac 900 tggggagaag ccttataaat gtaatgaatg tgggaaagca ttccatagtt ccacatgcct 960 tcatgctcat aaaagaactc acactgggga gaagccatat gaatgtaaac agtgtgggaa 1020 agccttcagc tcttcccatt cctttcaaat acatgaaaga actcacacgg gggagaaacc 1080 atatgaatgt aaggaatgtg gaaaagcatt caagtgtccc agttctgttc gcagacatga 1140 aagaacccac tctaggaaaa aaccctatga atgtaaacat tgtgggaaag tattatctta 1200 tcttaccagc tttcaaaacc acttgggaat gcacactgga gagatatctc ataaatgtaa 1260 gatatgtggg aaagcctttt attctcccag ttcacttcaa acacatgaaa aaactcacac 1320 tggagagaaa ccctataaat gcaaccaatg tggtaaagcc tttaattctt ccagttcctt 1380 ccgatatcat gaaagaactc acactggaga gaaaccttac gagtgtaagc aatgtgggaa 1440 agccttcaga tctgcctcac tccttcaaac acatggtagg actcacacgg gagagaaacc 1500 ctatgcatgt aaggaatgtg gaaaaccatt tagtaatttc tctttctttc aaatacatga 1560 aaggatgcac agagaagaga agccgtatga atgtaagggt tatgggaaaa cattcagttt 1620 gcccagttta tttcatagac atgaaaggac tcacactgga ggaaaaacct atgaatgcaa 1680 gcagtgtggc atgatccttc aactgttcga gctcctttcg atatcatgga aggactcaca 1740 ctggagagaa accctatgaa tgcaagcaat gtggaaaagc cttcagatct gcctcacagc 1800 ttcaaattca tggaaggact cacactggag agaaacctta tgaatgtaag cagtgtggga 1860 aagcctttgg atctgcctca caccttcaaa tgcatggaag gactcacact ggagagaaac 1920 cctatgaatg taagcagtgt gggaagtctt ttggatgtgc ctcgcgactt caaatgcatg 1980 gaaggactca cactggagag aaaccgtata aatgtaagca atgtgggaaa gcttttggat 2040 gtccctcaaa ccttcgaagg catggaagga ctcacactgg agagaaaccc tataaatgta 2100 accaatgtgg taaagtcttt agatgttctt cacaacttca agtgcatgga agggctcact 2160 gcatagacac cccataaccc caggctttag ga 2192 15 584 DNA Homo sapiens misc_feature Incyte ID No LI1174107.22001JAN12 15 gggcgggtct tcactgctct gtgtcctcag cgtgtgtggc ttcgtgacct gaagatactg 60 ggaaatccat agctaagatg ccaggacccc ctgaaagcct agacatgggg ccgttgacat 120 ttagggatgt ggccatagaa ttctctctgg aggagtggca atgcctggac actgctcagc 180 aggatttgta taggaaagtg atgttagaga actacagaaa cctggtcttc ttggcaggta 240 ttgctgtctc taagccagat ctggtcacct gtctggagca aggaaaagat ccctggaata 300 tgaagggaca cagtacggta gtcaaacccc caggttttct taccgccatc tgtgacagct 360 tcttgatctg tcccaagtta tatgttctca ttttgctgaa gacttttgcc cagggccagg 420 cattaaagat tcttttcaaa aagtgatact gagagaatat gtaaaatgtg gacataagga 480 tttacagtta agaaaaggat gtaaaagtat gaatgagtgt aatgtgcaca aagaaggtta 540 taatgaacta aaccagtatt tgacaactac ccagagcatt gcgg 584 16 3152 DNA Homo sapiens misc_feature Incyte ID No LI901832.12001JAN12 16 gggagggctg gagcgagggt ggactggagg tgccgcttgt cctggaggtg ggagagaggg 60 agcggctttg ccgcctggcc tgcgtcctaa tcctgtcctg gttcttctgc tcccgaaggg 120 aacgtaggtc ccgcgcctgt gataagtaag gttggatttt ctcttccctg aggtgaagga 180 tgcccggagg cctcggcagg accgcgcgga aacgggcctt ctgcccaaaa gatgctgctt 240 ctctccttat tctttcccct cagaatctcg ctgtctcctt ccaaccacct gtggtcggca 300 tccccgcgtt gtcactgcga cgcagaggcg agcgaggtgg cgggaagcac ccgcggggcg 360 gggagggacc ctgcgggcgc ggactccaca ccaagcctct gctcagcgtc accccgcttg 420 ctgtgtcctc gcaggtcgca gcttcatggc ctgatgcctt caggaagtat tttgaagtca 480 tcgtggctgt ggattggggg atttcttgtt tccactgacc tgtgaggccg cgcacgtgga 540 gggaggcacc ccgggtcctc cggcactgtc cggcctcgcc tgtgtcccta gtagcagtgg 600 gcatttccag acggtgcagc ttgtggctaa agtgacagga agatgtagga gctttcagtc 660 ttggatgagg attcgaactg aagggcttag gcccagctgt cttggagcaa aacatctgtt 720 gtgggatgtg gcggcagagg agggcaaggc cgaaggagca gacagcaccg cttcttgggg 780 agttgtgaag gcatcatgcg gagggccgag cttagcagcc aagtggagga cagcaccctc 840 catgcctgga ttcgttactc gctcgttctc gatgttgagc tgctggcata ttgcagcaca 900 actagagatg tacggatgcc cccatcttga tcttacagaa tcagaggtgc agccgcaaga 960 aagagtcaag aacagacact gagtcgcttg aggactcagg caggtgtttg ctgcattgac 1020 aacagactac accctctcgg ttttctctgc tctgccaaca ctagtggaat atgatcacat 1080 cccagagttt cacatctttt atgcccatgg ctggagatac agaggtgcga tcttggctca 1140 ctgcaacatc tgcctcctgg atattacaag atgattctcc tgtcttagac ctcctgagat 1200 agcatgggat tacagggatc agtgtcattt agggatgtga ctatgggctt cactcaagag 1260 gagtggcatc atcttgaccc tgctcagagg accctgtaga ggaatgtgat gctggagaac 1320 tacagccacc ttgtctcagt agggtattgc attcctaaac cagaagtgat cctcaaattg 1380 gagacaggca aggagccatg gatattagag gaaaaatttc gaagccagag tcatctgggt 1440 gagttagtgc cagatggaat ttaaagaatt aattaatacc agtagaaact attcaagaat 1500 gaagttcaat gagtttaaca aaggtggaaa atgtttctgt gatgaaagca tgaaataatt 1560 cattttgaag aggaaccttc tgaatataat aacaatggga acagcttctg gctgaatgaa 1620 gacctcattt ggcatcagaa gattaaaaat tgggagcaac cttttgaata caatgaatgt 1680 gggaaagctt tccctgagaa ttcactcttc cttgtacata agagagctta cacaggacag 1740 aaaacatgca aatatactga acatgggaaa acctgttata tgtcattttt tattactcat 1800 cagcaaacac atccaagaga gaaccactat gaatgtaatg aatgtggaga aagtatcttt 1860 gaggaatcca ttctctttga acatcagaat gtttacccat tcagccagaa tttaaatccc 1920 actctaattc agagaaccca ctcaattagc aatattattg aatataatga atgtggaacc 1980 tttttcagtg aaaaattagc ccttcattta caacagagaa cacatccagg ggaaaaacct 2040 tatgaatgtc atgaatgtgg aaaaaccttc acccagaagt cagcccacac aagacatcag 2100 agaacacaca cagggaaaac cctatgaatg tcacggatgt gggaagacct tctataagaa 2160 ttcagacctc attagaaatc aaagaattca cacaggggag agaccttaca gatgtcatga 2220 atggagaaat ccttcagtga aaagtcatcc cttactcaaa atcagagaac acacgtgggg 2280 agaaatcatg aatgtcatga atgtgggaaa acctcgttta agtcagttct aactgtgcat 2340 cagaaaacac acaggggaga agccctatga atgctatgca tgtggcaaca cctttctcag 2400 aaaatccgac ctcattaaac atcagagaat tcacacagga gaaaaacctt atgaatgtaa 2460 tgaatgtggg aagtcattct ccgagaagtc aacccttact aaacatctaa gaacacacag 2520 atgggaaatc ttatgcatgt attcaatgtg gaaaattttt ctgctgctac tacagtttca 2580 cagaacatct gagaagacac acaggggaga aaccttttgg atgtaatgaa tgtgggaaaa 2640 ccttccatca gaagttggcc ctaattgttc accagagaac tcatataaga cagaaaccct 2700 atggatgtaa tgaatgtgga aaatcattct gtgtgaagtc aaaactcatt gcacatcata 2760 gaacatacac aggggagaaa ccctatgaat gtaatgtttg tggaaaatta ttattaagtc 2820 aaaactaact gtacatcaca gaacacactt gaggtgaaac cctataaatg tagtaagtga 2880 gggaaattac tctgggtgaa gtcagaactt tgtagagcag agaacataaa gggtgagaga 2940 aatctgttaa tataatgata atgagaacac ctttgccctg aagtcagttc tcacagtaga 3000 gaagagaact taaagaggga aaaaacaata tgaagatatg gaatgcagga aaacattatt 3060 ctgggatttg ggccatagat tatgtttaag aactaaaagt gaaaaaacac ttattggtga 3120 atgaatatgg acacattttg ctcaatgcac ac 3152 17 631 DNA Homo sapiens misc_feature Incyte ID No LI1091903.12001JAN12 17 ggcaaccgaa ggcagtcttt agctctcatg gattgggagc tgggaaagga atgagaagac 60 agaagtcaga gacaagaaga ggctaacatg actgatacca ctataattta gtgaactgcc 120 tcttttctaa agaggactcc aaaggaagga ctggtcatct ctttcatatc tcaaaaccat 180 ggctcaggga tcagtgtctt tcaatgatgt gactgtggac ttcactcagg aggagtggca 240 gcacctggat catgctcaga agactctata tatggatgtg atgttggaaa actattgcca 300 cctcatctct gtggggtgtc acatgaccaa acctgatgtg atcctcaagt tggaacgagg 360 agaagagcca tggacatcat ttgcaggtca tacctgcttg ggtggagagg atggcctaac 420 tggatgttta tcctagcgtc aacccaccaa agatttgggg aacatgtgag tcacattctc 480 tgggacattc tactcccctt tgattttgca tttccagaca tttcagtggc taccacaaaa 540 aataaaaagt atctgtggca tcactgaaaa aaaaaaaaac aacacaaccc ccaccacgca 600 aacaacaaaa acacacaaaa cacaacaaaa c 631 18 1129 DNA Homo sapiens misc_feature Incyte ID No LI1089543.22001JAN12 18 ttcggctcga gcatttttct cctcttctcc ttttatgtga aattttgaac tctcccctta 60 gccacttggt gaaatgtgtt tttcatttta ggtacggttg acatttaggg atgtggccat 120 agaattctct ctggaggagt ggcaatgcct ggacatggct cagcagaatt tatataggga 180 cgtgatgttg gagaactaca gaaaccttgt ttctctggga ctgtgtcatt ttgatatgaa 240 tattatctcc atgttggagg aagggaaaga gccctggact gtgaagagct gtgtgaaaat 300 agcaagaaaa ccaagaacgc gggaatgtgt caaaggcgtg gtcacagata tccctcctaa 360 atgtacaatc aaggatttgc taccaaaaga gaagagcagt acagaagcag tattccacac 420 agtggtgttg gaaagacacg aaagccctga cattgaagac ttttccttca aggaacccca 480 gaaaaatgtg catgattttg agtgtcaatg gagagatgac acaggaaatt acaagggagt 540 gcttatggcc cagaaagaag gtaaaagaga tcaacgcgac agaagagaca tagaaaacaa 600 gcttatgaac aatcagcttg gagtaagctt tcattctcat ctgcctgaac tgcagctatt 660 tcaaggtgag gggaaaatgt atgaatgtaa tcaagttgag aagtctacca acaatggttc 720 ctcagtgtca ccacttcaac aaattccttc tagtgtccaa acccacaggt ctaaaaaata 780 tcatgaactt aaccattttt cattactcac acaaagacga aaagcaaaca gttgtggaaa 840 accttataaa tgtaatgaat gtggcaaggc gttcactcag aattcgaacc ttacaagtca 900 taggagaatt catagtggag agaagcctta caaatgcagt gagtgcggca aaacctttac 960 tgttcgttca aatctaacta ttcatcaggt catccatact ggagaaaaac cttacaaatg 1020 tcatgagtgt ggcaaggtct tcaggcacaa ttcatacctt gcaactcatc ggcgaattca 1080 tactggagag aaaccttaca agtgtaatga gtgtggaaaa gcctttaga 1129 19 1250 DNA Homo sapiens misc_feature Incyte ID No LI2049137.12001JAN12 19 ggaggtgaga tattttggtc cccaggagaa ctggctcagg tctncaagtt cccatccggg 60 atgactggaa agggttagga aacctctctg aggtctggtc agattccaac cctggacagc 120 agtgaacaca acctttcccc tgagccactg gaattggaca gaatgcccca ttctcctctg 180 atctccattc ctcatgtgtg gtgtcaccca gaagaggagg aaagaatgca tgatgaactt 240 ctacaagcag tatccaaggg gccggtgatg ttcagggatg tttccataga cttctctcaa 300 gaggaatggg aatgcctgga cgctgatcag atgaatttat acaaagaagt gatgttggag 360 aatttcagca acctggtttc agtgggactt tccaattcta agccagctgt gatctcctta 420 ttggaacaag gaaaagagcc ctggatggtt gatagagagc tgactagagg cctgtgttca 480 gatctggaat caatgtgtga gaccaaaata ttatctctaa agaagagaca tttcagtcaa 540 gtaataatta cccgtgaaga catgtctact tttattcagc ccacatttct tattccacct 600 caaaaaacta tgagtgaaga gaaaccatgg gaatgtaaga tatgtggaaa gacctttaat 660 caaaactcac aatttatcca acatcagaga attcattttg gtgaaaaaca ctatgaatct 720 aaggagtatg ggaagtcctt tagtcgtggc tcactcgtta ctcgacatca gaggattcac 780 actggtaaaa aaccctatga atgtaaggaa tgtggcaagg cttttagttg tagttcatat 840 ttttctcaac atcagaggat tcacactggt gagaaaccct atgaatgtaa ggaatgtgga 900 aaagccttta agtattgctc aaaccttaat gatcatcaga gaattcacac tggtgagaaa 960 ccctatgaat gtaaagtatg tggaaaagcc tttactaaaa gttcacaact ttttctacat 1020 ctgagaattc atactggtga gaaaccttat gaatgtaaag aatgtgggaa agcctttact 1080 caacactcaa ggcttattca gcatcagaga atgcatactg gtgagaaacc ttatgaatgt 1140 aagcagtgtg ggaaggcttt aatagtgcct caacacttac taaccatcac agaattcatg 1200 ctggtgagaa gctctatgaa tgtgaagaat gtggaaaggg ctttattcag 1250 20 379 DNA Homo sapiens misc_feature Incyte ID No LI1171755.92001JAN12 20 gtgaatgtgg gaagttattt agagatatgt ccaacctttt tatacaccaa atagttcaca 60 ctggagaaag gccttacggg tgtagtaact gtggaaaatc ctttagccgt aatgctcacc 120 tcattgaaca ccagagagtt cacactggag aaaagccttt tacatgcagt gaatgtggaa 180 aagctttcag gcataattcc acacttgttc agcatcacaa aatccacact ggagtaaggc 240 cttatgagtg cagtgaatgt ggaaaattgt ttagtttcaa ctccagcctc atgaaacatc 300 agagagttca cactggagaa agaccttata aggttggact tgtggctata gaattttcca 360 cattcactgc acttataag 379 21 934 DNA Homo sapiens misc_feature Incyte ID No LI208529.122001JAN12 21 ccgtccgtag tggggcggct ggaggcgggg gtgccttcat cgtcctgcct ctggccaaga 60 cagggcgagt ggataagaac tacccactgg tcactgggca cactgcccct gtgctggata 120 ttgactggtg tccacacaat gacaacgtta tcgccagtgc ctcagacgac accaccatca 180 tggtgtggca gattccagac tataccccca tgcgcaacat tacggaacct atcatcacac 240 ttgagggcca ctccaagcgt gtgggcatcc tctcctggca ccctactgcc aggaatgtcc 300 tgctcagtgc aggtggtgac aatgtgatca tcatctggaa tgtgggcacc ggggaggtgc 360 tgctgagcct ggatgatatg cacccagacg tcatccacag tgtgtgctgg aacagcaacg 420 gtagcctgct agccaccacc tgcaaggaca agaccttgcg catcgttgac cccagaaaag 480 gccaagtggt ggcggagagg tttgcggccc acgaggggat gaggcccatg cgggccgtct 540 tcacgcgcca gggccatatc ttcaccacgg gcttcacccg catgagccag cgagagctgg 600 gcctgtggga cccgaacaac ttcgaggagc cagtggcact gcaggagatg gacacaagca 660 acggggtcct attgcccttt tacgatcccg actccagcat cgtctacctg tgtggcaagg 720 gcgacagcag cattcggtac tttgagatta ccgacgagcc gcctttcgtg cactacctga 780 acacgttcag cagcaaagag ccgcagcggg gcatgggttt catgcccaaa aggggactgg 840 atgtcagcaa gtgtgagatc gcccggttct acaagctaca cgaaagaaag tgtgaaccta 900 tcatcatgac tgtgccctcc tcattacggt cgaa 934 22 2509 DNA Homo sapiens misc_feature Incyte ID No LI024125.62001JAN12 22 tcacctctga caccaaagcg aactcctgca acagaagaac tggtcttagg gctcaaatca 60 gtggccagta ttagactaac agatgagggg aagtggggac cctacagaaa gcaaacacag 120 cttcctggaa acaccaaggg cctcctccat ccaaaaacaa ctttcttctc aactgtctcc 180 aaaagcctag atgttttttg acattgtggc acctggcaca gccagcccac gggactggga 240 agacccatgt tcccagctcc ctggcgacaa cggcgacaag gccatgcacc cggtgcttac 300 tggatgccag cccctgtgct aattgctctt tatgtccagg tcaaatggaa atctcctaac 360 aaccttttgg tggaagagtc agaagacttc tgaggacatt aatattcaat gactattaat 420 gaagagaccc taaagatcat cttcttaagc cctcagacga cagaaaggga aactgaggcc 480 tgggacttgt atacttttcc aaagcctctt ctttgccagg ttttgcacct tcctctaaga 540 catcttttct tttccatctc ataattctgg atgcaaatga actcatagct catggaaact 600 ataaacccat aaaaatgcac aaaaggacat taacaaaata ttacctaaaa gtttccagaa 660 cttcatcaac cttcttcctg atccataagt gcatccacag atcccaggtt gagcaggcct 720 gcttccaaca atacccacat tgttggatgt aaattcttac acaaagactc actcggggaa 780 cttcgtccct ttctagttct agatcgcgag ctagaactag tcatgggaat catggcagca 840 tccaggccat tgtcccgctt ctgggagtgg ggaaagaaca tcgtctgcgt ggggaggaac 900 tacgcggacc acgtcaggga gatgcgcagc gcggtgttga gcgagcccgt gctgttcctg 960 aagccgtcca cggcctacgc gcccgagggc tcgcccatcc tcatgcccgc gtacactcgc 1020 aacctgcacc acgagctgga gctgggcgtg gtgatgggca agcgctgccg cgcagtcccc 1080 gaggctgcgg ccatggacta cgtgggcggc tatgccctgt gcctggatat gaccgcccgg 1140 gacgtgcagg acgagtgcaa gaagaagggg ctgccctgga ctctggcgaa gagcttcacg 1200 gcgtcctgcc cggtcagcgc gttcgtgccc aaggagaaga tccctgaccc tcacaagctg 1260 aagctctggc tcaaggtcaa cggcgaactg agacaggagg gtgagacatc ctccatgatt 1320 ttttccatcc cctacatcat cagctatgtt tctaagatca taaccttgga agaaggagat 1380 attatcttga ctgggacgcc aaagggagtt ggaccggtta aagaaaacga tgagatcgag 1440 gctggcatac acgggctggt cagtatgaca tttaaagtgg aaaagccaga atattgagtt 1500 atttcttaac aagtttcgag agagaaggga gcaagacaag agcaagcaac ggctattaaa 1560 tgtcacaatc ctttaattag aaaccattta ttggccggac gcggtggctc acgcctgtaa 1620 tcgcagcact ttgggaggcc gaggcgggcg gctcacgacg tcaggagatc cagaccatct 1680 tggctaacag ggtgaaaccc cgtctctact aaaaatacaa aaaattagcc gggcgtggtg 1740 gcgggcgcct gtagtcccag ctactctgga ggctgaggca ggagaatcaa ttgaacccgg 1800 gaggcggagc ttacagtgag ctgagattgc gccactgtac tcctgggcaa cagcgagact 1860 ccgtctcaaa aaaaaaaata aaaaaaagga acccttttat tttaaaaatg attagattgc 1920 tatgcctcaa ctcatagaag atgaaccctt caagaaaacg tgaagtagaa cgggtgggcc 1980 agaaatgaaa acaggcaagt aaagtatttc ttcggaaaac attttatcaa accaaatgtt 2040 aaaaagactt tccttttgta aaactggatt agagaagact tttcagtggg ttatctctag 2100 gatgatcagt agttcagcac ttaaaaactg cagagaaaac tgaaagttat gttccagata 2160 actttccgtt gtttaccaaa ttttcttaga tttggtcatc atcaggaagc atttgtaaaa 2220 ataaaaatct ccacaaatta ctggcccatc tcggacttgc tgaatcaatt tgataggatt 2280 aatctccagt gaagctgtgt ttacagggca ttccaagtga ttcttatcag gaaatgtgaa 2340 aaacactcct gtacataatc ggttaattta aaattttact taataagtga acaagtaatg 2400 aagatttcac ctgtttactt agggtatcta cccagaccca tcgattctga gttcgggaga 2460 tgattttgaa attactgttt tccaaataaa ggtgctccct tctaagtgg 2509 23 734 DNA Homo sapiens misc_feature Incyte ID No LI235557.122001JAN12 23 ctccaaccct gcagatgcct ttgataatga tttgatgcac aggactctga agaacatcgt 60 ggagggcaaa acggtggagg tgccgaccta tgattttgtg acacactcaa ggttaccaga 120 gaccacggtg gtctaccctg cggacgtggt tctgtttgag ggcatcttgg tgttctacag 180 ccaggagatc cgggacatgt tccacctgcg cctcttcgtg gacaccgact ccgacgtcag 240 gctgtctcga agagttctcc gggacgtgcg ccgagggagg gacctggagc agattctgac 300 gcagtacacc accttcgtga agccggcctt cgaggagttc tgcctgccgc agcagagcat 360 ctgacaggga atgagagtca gcattgagcc aatgagtggt tggatgaggg aacaaagaag 420 tatgccgatg tgatcatccc acgaggagtg gacaatatgg ttgccatcaa cctgatcgtg 480 cagcacatcc aggacattct gaatggtgac atctgcaaat ggcaccgagg agggtccaat 540 gggcggagct acaagcggac nttttctgag ccaggggacc accctgggat gctgacntct 600 ggcaaacggt nacatttgga gnccagcnnc cgtccgtcca ggntcaccca cagtagtgat 660 gcagacgtga cgtgggggaa gggggctgag ccctgtggct gggttctgac aactgtaacg 720 gttttgtcga gctt 734 24 484 DNA Homo sapiens misc_feature Incyte ID No LI178860.12001JAN12 24 cctggcaaag ctgctgccca gagtggaatc tcactagtga ataaacaagc ccaagaaaga 60 ttatcatctc atttgcaaaa aaaaaaagta cgctggtaga tcctgctacc tcatagataa 120 caccagtcaa attttttttt aaagtagcat tttcctacat tgtcaactat ctagaacata 180 cctaaaaact aagagtttac tgcttattaa atggaaacta tgaagtctaa ggccaactgt 240 gcccagaatc caaattgtaa cataatgata tttcatccaa ccaaagaaga gtttaatgat 300 ttggataaat atattgctta catggaatcc caaggtgcac acagagctgg cttggctaag 360 ataattccac ccaaagaatg gaaagccaga gagacctatg ataatatcag tgaaatctta 420 atagccactc ccctccagca ggtggcctct gggcgggcag gggtgtttac tcaataccat 480 aaaa 484 25 2537 DNA Homo sapiens misc_feature Incyte ID No LI405798.12001JAN12 25 gctggcccag tacctgccaa gcccaccact tccacctggg ccctacaccc ccacaatgtg 60 tacccctctt atctgccctg gagcctgtac agccatgcca cgctacccct gagagtctag 120 aaagctggtc actaactttg cagacggatg agccttgagc acccagagga gactggggct 180 gtcaacgctg ccccttgtcc tgccggcttg gatcccctga cagggtcctt ctaggcttca 240 gactggcacc ctgaccatgg aaccctgaag tggcagtgac ttctagagct cagtggcaga 300 ccccacgacc cttcctcccc cttcctcccc ctcccaccac cagctttcaa gctcccagag 360 ggaggggtgg ggaggggatc ctgatctcac agggcagggg gcttccatca tgatgctcaa 420 ctcagacacc atggagctgg acctgccgcc cacccactca gagactgagt cgggcttcag 480 tgactgtggg ggcggggcgg gccctgatgg tgccgggcct gggggtccgg gagggggcca 540 ggcccgaggc ccagagccgg gagagcctgg ccggaaagac ctgcagcatc tgagccgcga 600 ggagcgccgg cgccggcgcc gcgccacagc caagtaccgc acggcccacg ccacgcgaga 660 acgcatccgc gtggaagcct tcaacctggc cttcgccgag ctgcgcaagc tgctgcctac 720 gctgcccccc gacaagaagc tctccaagat tgagattctg cgcctggcca tctgctatat 780 ctcctacctg aaccacgtgc tggacgtctg aactcagcct gtctcccacc tcccgggcct 840 ctctggggcc cctttccacc gctcactgct tagaaaggcc gcatcctccc cgagccctta 900 taccttggca tggagtccca aaggccctgg gcacaggcag agagcccacc ggctggtcat 960 gagggcctct tcctttctct gacccaggca tcctcgaggg ctattctcct gggttccttc 1020 cggggtttat tgctgaggcc cagctgtgca gaattgtttg ctagtgtggt tggtatggaa 1080 tccttgctgg ctttactaag ccagccacac ttggagtctg cccccaagct ctctcactga 1140 atgctgcctc ttctacccct atgtccaaat tttcagccac cacagacctc agctgtgtat 1200 cctatctgtt ctagcttctc ctgcccctgg tggggatggg ctgtcagaat tgcaagggag 1260 gaaggctggg gttagagtgg ggagtgggct tcttcctcca agatctcagt ctctcagtgc 1320 ttggcagagg ggtgaggccc tggggaggca ggggttggtg ccctgactcc tgtgagggga 1380 atctcagtag ctgggaatta tggaaaaact cttcctgttt ctgtccatct tgttcctgtg 1440 gcttagcaca tacagacctc agatcttact tggtagtgag tgccttgccc tctttgagct 1500 atttggctac ttccctgtcc ctctgactcc tactgtccca attttctccc tccctgtgtg 1560 tcactagaga aaaaaaaaaa caaaaaccta gattccggat taggggatga catcccaaac 1620 agcccggagt atttgcagaa ggctcaggca acgagtgggc cacatctcac ttctgcttcc 1680 tcatctcagc ccactctgaa aatgtgcagc accctcactg gttcctcccc ccaacgcaag 1740 gaggatgccc aattgttgcc ctctaaaaat gcacagttct cctggcccta ggacttactt 1800 attacatttt tttctctttc cttgagctgc ctttggcaag ggaagagacc cccaactctg 1860 cgcccctact ccatgctgct gatccccacc tgcgcactat agcgcagggt cagcagtgga 1920 atgaagggcc ttagaacctg catagaagaa atgaactcac tgcatttctg tgctccctcc 1980 tccctcgcac caaactccta gctctacaag tatatttatt tatttattta tttattcatc 2040 tatttattta cttattnatt tatttataaa tattgctatt tattgccgag ttgtgcactt 2100 tggggtagag tgaggggctc ccagcagctc tagctgggtc tctcttgctt cctccctgct 2160 tacgcctttc cttttcttgc tcccttcttc aactcctggt gtgtgtgagc atgccctttg 2220 cttgccacac catatccttt ccccagatcc acctgtcctg acactctagt cctccaggat 2280 agtgctcctc ccccagctcc agggctcctg gatgtccttc ctcaactccc tccaccccta 2340 gacaatccta cctggtccca tctgcctctt ttctctcccc agcctgccct gtgacccttg 2400 cctcttcctg atactcccaa gagcaggccc caggggtctg tgtcacatat ctctgtgtga 2460 ttccttctgg ttgcatcccc aatttcatac aaaaagaaaa ataaaagtga cctcgttcta 2520 gcaccaaaaa aaaaaaa 2537 26 1041 DNA Homo sapiens misc_feature Incyte ID No LI1071427.1012001JAN12 26 gggcataccc ctcgtagatg ggcacagtgt gggtgacccc gtcaccggag tccatcacga 60 tgccagtggt acggccagag gcgtacaggg atagcacagc ctggacctga ctgactacct 120 catgaagatc ctcaccgagc gcggctacag cttcaccacc acggccgagc gggaaatcgt 180 gcgtgacatt aaggagaagc tgtgctacgt cgccctggac ttcgagcaag agatggccac 240 ggctgcttcc agctcctccc tggagaagag ctacgagctg cctggccggg acctgactga 300 ctacctcatg aagatcctca ccgagcgcgg ctacagcttc accaccacgg ccgagcggga 360 aatcgtgcgt gacattaagg agaagctgtg ctacgtcgcc ctggacttcg agcaagagat 420 ggccacggct gcttccagcc ttccttcctg ggcatggagt cctgtggcat ccacgaaact 480 accttcaact ccatcatgaa gtgtgacgtg gacatccgca aagacctgta cgccaacaca 540 gtgctgtctg gcggcaccac catgtaccct ggcatgccga caggatgcag aaggagatca 600 ctgccctggc acccagcaca atgaagatca agatcattgc tcctcctgag cgcaagtact 660 ccgtgtggat cggcggctcc atcctggcct cgctgtccac cttccagcag atgtggatca 720 gcaagcagga gtatgacgag tccggcccct ccatcgtcca ccgcaaatgc ttctagcgcg 780 gactatgact tagttgcgtt acaccctttc ttgacaaaac ctaacttgcg cagaaaacaa 840 gatgagatgg catggcttta tttgtttttt tggtttggtt tgggtttttt tttttttttg 900 ggggtggact caggatttaa aacacgggaa cgggtgaagg gtgacagcag tcggtgggag 960 cgagcatccc ccaaagttca caaggtggcc gaggacttgg atggcccatg gtgggtttta 1020 aatagtcatt ccaaatttga g 1041 27 950 DNA Homo sapiens misc_feature Incyte ID No LI1072276.12001JAN12 27 ggcagcgact gcgcgcctga actctagcgg agccgggttg attttctaaa cgcttcaaaa 60 tcctaagact cagcactgtt gcggggagca cagggcatca cgttgtcctt gttttttttt 120 ggtcttttct tcatttgaag attaagtatt ggagccatgg gaataaaggt tcaacgtcct 180 cgatgttttt ttgacattgc cattaacaat caacctgctg gaagagttgt ctttgaactt 240 attttctgac tgtgtgcccc aaaacatgcg agaactttcg ttgtctttgt acaggtgaaa 300 aggggaccgg gaaatcaact cagaaaccat tacattcata agagttgtct ctttcacaga 360 gttgtcaagg attttatggt tcaaggtggt gacttcagtg aacggaaatg gacgaggcag 420 gggaatctat ctatggagga ttttttgaag acgagagttt cgctgttaaa cacaacaaca 480 gaatttctct tgtcaatggc caacagaggg aaggatacaa atggttcaca gttcttcata 540 acaacgaaac caactcctca ctttagcatg ggcactcatg ttgctttttg gacaagtaac 600 tctctggtca acgaagcttg taagagcaga ttgaaaacca ggaaaacagg atgcagctag 660 gcaaaccgtt tgcggaggta cggatactca gttgctggac gagctgattc ccaaactcta 720 aagttaagaa agaagaaaag aaaaggcata aatcatcatc atcttcctcc tcctcatcta 780 gtgactcaga tagctcaagt gattctcagt cctcttctga ttcctctgat tccgaaagtg 840 ctactgtaga tccatcaaag ataagtccga agcaacatcg gaaaaattcc cgaaaacaca 900 agacagaaaa gctaaagcga aagtcagcga gatgagtgca tctagtgaga 950 28 4230 DNA Homo sapiens misc_feature Incyte ID No LI198296.12001JAN12 28 aaaacactct tcacaaaatg caaaaatttt gcgttacaga cttttgagga tgtatcccag 60 cacgaagaat ttcttgagct tgacaaagat gaacttattg attatatttg tagtgatgaa 120 cttgttattg gtaaagagga gatggttttt gaagccgtca tgcgttgggt ctatcgtgcc 180 gttgatctga gaagaccact gttacacgag ctcctgacac atgtgagact ccctcttgtt 240 gcatcccaac tactttgttc aaacagtgtg aaaggtggga cattgatcca gaattctcct 300 gagtgttatc agttgttgca tgaagcaaga cggtaccaca tacttgggaa tgaaatgatg 360 tccccaagga ctaggccacg caggtccact ggctattctg aggtgatagt tgtcgttgga 420 ggatgtgagc gagttggaag gatttaatct tccatacact gagtgctacg atcctgtaac 480 aggagaatgg aagtctttgg ctaagcttcc agaatttacc aaatcagagt atgcagtctg 540 tgctctaagg aatgacattc ttgtttcagg tggaagaatc aacagccgtg atgtctggat 600 ttataactca cagttaacat attcggctca ggagtttgcc tctctcaata aaggcagatg 660 gcgtcacaaa atggctgtcc tccttggtaa agtatatgtt gtcggtggct atgatgggca 720 aaacagactt agcagcgtag aatgttatga ttccttttca aatcgatgga ctgaagttgc 780 tccccttaag gaagccgtga gttctcctgg cagtggataa gctggggtag gcaaacggtt 840 tgtgattggt ggaggacctg atgataatac ttgttctgat aaggttcaat cttatgatcc 900 agaaaccaat tcttggctac ttcgtgcagc tatcccaatt gccaaaaggt gtataacagc 960 tgtatcccct aaacaaccct gatcctatgt tgcccggtgg acctgaccca aggcaatata 1020 cctgttacga tcccagttga aggattactg ggatgcacgt acagaataca ttcagccgtc 1080 agggaaaact gtggtatgtc tgtgtgtaat gggtaaaata tatatccctg ggcggaagac 1140 gggaaaatgg agaagccaca gacactattc tctgttatga tcctgcaaca agtatcatca 1200 caggggctat gctgcagatg cgccaggcca gttgtcccta tcatggttgt gtgtactatt 1260 catagataca ttgagaaatg ctttaaactc tggaagacag gatacctcac cgaagaagcc 1320 acactgatcc aagatgggag ggttttaaag attctagcag tgcgaacttc acatatttcc 1380 tttgtgccat atgcaaaaat agggaaagaa taataatttg gtgcctttct cctcaaaata 1440 tcaatctttc aaactataat aaagcctttc ctataattga aaaaaaaaac ttttttgtta 1500 aaggtaatgg tggttgttac ttggcctttg aagagtgtac ctttgtaagt atttgtaaga 1560 agtctatgtg aattaggaaa tgtctgtctg catacctttt aggagcgtgt gaatggtgtc 1620 ttcacttatt atgtatgttt atctgtatgt atattcctta ttttgtcata tatgtagaga 1680 aaattgcatg acttgaggca tcatttaggt tgaagaagtt aatgcttaga atgcattcta 1740 ggagaaaaaa tcagttttaa aaacctttgt tgttaacaaa gtatatccag attggttaat 1800 tttattgaag ggtttttttc tgtaattgat aaaaatgtaa tgacaacaat tcaggcatca 1860 taaaatactg aactattgtg actttattct tagaattgct gtcttacatt aaacatgttt 1920 ttagggggaa gttaggtagg agatagaaaa ataagtgccc ctacaagggg gattaaaatt 1980 acaagggtta attcctaaga gaaaaatgga atggcctttg aaggaaaaat gacccactat 2040 ggctctcaaa gtttttatgc atcatctctt caatcctcta agaaagcctc ttttcttaac 2100 ttgataaagc agtggaaacc cattntgcaa tattgttttg tgaaaaacag ggacagacag 2160 ccaggtacag agactcacac ctgtactccc aactactcag caggctgggg caggaggatt 2220 gcttgagccc aggagtctga ggctacagtg agctatgaac gcacacggca ccctagcctg 2280 ggcaacaggt tgcgacactg tctcaagaga aaagaaaaag aaaaataggg ataggttttc 2340 cttcctagcc cagtagagtt tgacctcatt agtatggtgc tttgggtgag gacctcttcc 2400 ttgattatcc cactttctag tgaacagcta aaattcctga gagtctctac tgttaaggta 2460 cctttaatag gataaagcag ggaccaccta tctcagtggg tccatttttc ttttaaaatt 2520 agttatctga aaaaacttag cagtagttcc catctttaag gtaagtcttt catttggtcc 2580 ccattgtgta aaatactaat caacattttc aagcttctgt acaacagact gcttttgtct 2640 agatttctca actccacttt ataaagctta tcagttttca gagaggaatg tgaatttttt 2700 tttctaatgc aaataaatgg atatggcagg aactaccagc ataagtgatt attgtgattc 2760 tgggtggacg gatataattt acaacattta gggatgttct aggtagcctg ctgtagtttg 2820 acttccagtc actgttgtct ttcacattat aatttgtata tttcttgtga tagaagggat 2880 gatgcaaata tgtaattaaa gtgtcaccag atttctgtta aaaccaaggt tgaaataaaa 2940 agcctaacat tggtaagcta cattgttttc tcattttaga atgattcaga gatttcagat 3000 agacattttt taaactttaa tgcttagcta gaatctacat tctgaggaaa actctaaaaa 3060 acttaaaaat ttttagggaa tttttatgtt gttgcaaaat cagtagatgt ttaaaatgga 3120 tagataccat tttgtgataa caacaattca gaagacgaat tttctatcct cttagttgaa 3180 agaatgtagg tacagtttgg atacttgtac tttaatttta gagtaaacat ctgcattata 3240 ctcttataga taatagaatt atttagttaa gaaattcttt acagtaaatg agataatgtg 3300 tgaaaaagta ttttgtaaat gctgaggatt ctacaaatga tagttgttat tttcatgtgt 3360 atttgtaaga tcatgtccat ttcatgaata taggacttca cataaaaaaa gactttctca 3420 agacaacttt atattctagt atttttctgt tgtaaaaagt attaactatt tacttttatt 3480 ttgttataca tttattttaa tatccatgtg tttattatag taaatttgaa atgaaatcct 3540 gaaaaacaga atttttttaa acacagacct cacaccaata ttaatttttt ctctacataa 3600 tttaaaacta cataaattaa gtacttaaaa tttatattga aggccaccaa gaacttaggt 3660 tgaatcttag aaaatttaaa taactatttt taaagttacc caacttaata ttttactttt 3720 ttaatattta tcttccttta ctaattcttg actaaataat agcattagac ttgataacaa 3780 taaaaaaacg aattttagag tagaattact atatcaaaag gggtatatta aacaaattgg 3840 tgtcagattg tattcattct ctcatcacat aaagattttt cttttgatag gtgatgctca 3900 tatgaacctt tggtttagaa tctatntatg gacatgtgta tgtatgnaga tagtatggtt 3960 gtatacacac atatatacca aacaccatga attttagcag gtctgtgatg atcagcaaaa 4020 aagcacataa agtaaacaat tagttgacca tgctaaattc aattctggaa tttttttttt 4080 atttgggcat ttctagaact ttttacattt gaaagtacat gatgagtatt agtaaccgat 4140 gacttatgta taatccagaa tctttatgac aatttagttt tacaaggtcc gaagagatga 4200 gtttgctaaa ccccagctgt gatacctcag 4230 29 3262 DNA Homo sapiens misc_feature Incyte ID No LI202943.42001JAN12 29 cgcgtccgca aaccacatgg ctttacatag ggaattctag gtgtaggatt ccaaaatttc 60 aggcaacaac gagtctagtg ggagaagtag ctgggagagg gaatgataga gctgggagag 120 agggaaacag aagagaatct cctgctgccc ctgaaatcat acctgctccc ctccaccccc 180 atctctaaaa aatctgtgaa tgttttcaat aggactaaat taatgtgtaa taactccatc 240 ttaatggaac aagtagggct tatctaaagt gttattaaac tttcaggtga gtcactggct 300 acctcctgcc cagaggaact cagtaaagga aacgtgttag catggcctga tttcttgtca 360 ggaattgtgg ggaaagtgaa gatcgattct aagagcatat tttgttctgg ttgcccacgc 420 ttaggagggt cagtgcctca tctgagaact gcatctgaag atttaaagcc aggttccaaa 480 gtcaatctgt tctgtgatcc aggcttccag ctggtcggga accctgtgca gtactgtctg 540 aatcaaggac agtggacaca accacttcct cactgtgaac gcattagctg tggggtgcca 600 cctcctttgg agaatggctt ccattcagcc gatgacttct atgctggcag cacagtaaac 660 taccagtgca acaatggcta ctatctattg ggtgactcag ggatgttctg tacagataat 720 gggagctagg aacggcgttt caccatcctg ccgtgatgtc gatgagtgtg cagttggatc 780 agattgtagt gagcatgctt cttgcctgaa acgtagatgg atcctacata tgttcatgtg 840 tcccaccgta cacaggagat gggaaaaact gtgcagaacc tataaaatgc taaggctcca 900 gcgcagaatc cggaaaatgg ccactcctca ggtgagattt atacacgtag gtgcccgaag 960 tcacattatt acgtgtcagg aaggataccc agttgatggg agtaaccaaa atcacatgtt 1020 tggagtactg gagaatggaa tcatctaata ccaatattgt aaagctgttt catgtggtaa 1080 accggactat tccagaaaat ggttgcattg acggagttag ccacttttac ctatttgggc 1140 agcaaagtga catataggtg taataaagga tatactctgg ccggtgataa agaatcatcc 1200 tgtcttgcta acagttcttg gagtcattcc cctcctgtgt gtgaaccagt gaagtgttct 1260 agtccggaca atataactaa tggacaacta tatatagagt gggcttacct acctttctac 1320 tgcatcataa ttcatgcgat acaggataca gcttacaggg cccttcccat tattgaatgc 1380 acggcttctg gcatctggga cagagcggca ccctgcctgt cacctcgtct tctgtggaga 1440 accacctgcc atcaaagatg ctgtcattac ggggaataac ttcactttca ggaacaccgt 1500 cacttacact tgcaaagaag gctatactct tgctggtctt gacaccattg aatgcctggc 1560 cgacggcaag tggagtagaa gtgaccagca gtgcctggct gtctcctgtg atgagccacc 1620 cattgtggac cacgcctctc cagagactgc ccatcggctc ttcggagaca ttgcattcta 1680 ctactgctct gatggttaca gcctagcaga caattcccag cttctctgca atgcccaggg 1740 caagtggggt acccccagaa ggtcaagaca tgccccgttg tatagctcat ttctgtgaaa 1800 aaacctccat cggtttccta tagcatcttg gaatctgtga gcaaagcaaa atttgcagct 1860 ggctcagttg tgagctttaa atgcatggaa ggctttgtac tgaacacctc agcaaagatt 1920 gaatgtatga gaggtgggca gtggaaccct tcccccatgt ccatccagtg catccctgtg 1980 cggtgtggag agccaccaag catcatgaat ggctatgcaa gtggatcaaa ctacagtttt 2040 ggagccatgg tggcttacag ctgcaacaag gggttctaca tcaaagggga aaagaagagc 2100 acctgcgaag ccacagggca gtggagtagt cctataccga cgtgccaccc ggtatcttgt 2160 ggtgaaccac ctaaggttga gaatggcttt ctggagcata caactggcag gatctttgag 2220 agtgaagttg aggtatcagt gtaacccggg ctataagtca gtcggaagtc ctgtatttgt 2280 ctgccaagcc aatcgccact ggcacagtga atcccctctg atgtgtgttc ctctcgactg 2340 tggaaaacct cccccgatcc agaatggctt catgaaagga gaaaactttg aagtagggtc 2400 caaggttcag tttttctgta atgagggtta tgagcttgtt ggtgacagtt cttggacatg 2460 tcagaaatct ggcaaatgga ataagaagtc aaatccaaag tgcatgcctg ccaagtgccc 2520 agagccgccc ctcttggaaa accagctagt attaaaggag ttgaccaccg aggtaggagt 2580 tgtgacattt tcctgtaaag aagggcatgt cctgcaaggc ccctctgtcc tgaaatgctt 2640 gccatcccag caatggaatg actctttccc tgtttgtaag attgttcttt gtaccccacc 2700 tcccctaatt tcctttggtg tccccattcc ttcttctgct cttcattttg gaagtactgt 2760 caaggtattc ttgatgtagg tgggtttttc ctaagcagga aattctacca ccctctgcca 2820 acctgatggc acctggaggc tctccactga cagaatgtgt tccagtagaa tgtccccaac 2880 ctgaggaaat ccccaatgga atcattgatg tgcaaggcct tgcctatctc agcacagctc 2940 tctatacctg caagccaggc tttgaattgg tgggaaatac taccaccctt tgtggagaaa 3000 atggtcactg gcttggagga aaaccaagat gtaaagccat tgagtgccgt gaaacccaag 3060 gagattttga atggcaaatt ctcttacacg gacctacact atggacagac cgttacctac 3120 tcttgcaacc agaggctttc ggctcgaagg tcccagtgcc ttgacctgtt tagagacagg 3180 tgattgggat gtagattgcc ccatcttgca atagcatcca ctgtgattcc ccacaaccat 3240 tgaaatggtt ttgtaaaggt gc 3262 30 975 DNA Homo sapiens misc_feature Incyte ID No LI2121848.12001JAN12 30 gaatcttggg cgtgattcac acctggccca acaaactaga agtcacactg gagagaaacc 60 ttacaagtgt actgagtgtg gcaaagcttt agtgggcagt caacacttat tcaccatcag 120 gcaatccatg gtatagggta actttataaa tgtaatgatt gtcacaaagt cttcagtaac 180 actacaaccg tttcaaatca ttggagaatc cataatgaga gattttgaac agtgtaataa 240 atgtggcaaa tttttcagac attgttcata ccttgcaggt catcggtgaa ctcatgctgg 300 agagaaacct tacaaatgtc atgattgtgg caaggtcttc agtctagctt catcgtatgc 360 aaaacaggag acgtcataca ggagactaac ttcacaagta tgatgattgc agcaaagcct 420 ttacttcacg ttcacaccta attagacatc agagaatcca tactggacag aaatcttaca 480 aatgtcatca gtgtggcaag gtcttcagtc tgagatcacc ccttaaggaa catcagaaaa 540 ttcatttttg agatgattgt tccaaatgca atgagtatag caaaccatca agcattaatt 600 ggcattagag tcaattcagc attgacttga gtttgaattg acttaacatt gagttcaagc 660 attaattgac attaaagtgt ttatgttata gaagattggg cctaggcggg gtggctctac 720 gcctgtaatc cctagctact ttgggtaggc catagtacct aattagtatc tacttgaggt 780 caggtagttt gtagtaccta gtactggcct tactagtact atgtagtcta cttttcccac 840 cctgtatttt gtttctttat ataaaaactg ttacgggttt ttatgggtat ctgttgtata 900 tctataatca ctatttgttt gtataatcta ttcaacaata ttatagactt cctaatccta 960 tcatatatgg gttgt 975 31 2641 DNA Homo sapiens misc_feature Incyte ID No LI796992.12001JAN12 31 gtgtgctgga aaggaaattc ttcagccgaa gctccaacct cattcagcat aagagggttc 60 acactggtga aaagcaatat gagtgcagcg actgtgggaa gttcttcagc cagcgttcca 120 acctcattca tcataagagg gttcatacgg gcagaagtgc ccatgagtgc agtgaatgtg 180 ggaaatcttt caactgcaac tccagcctaa ttaaacattg gagagttcac actggagaaa 240 gaccttacaa gtgtaacgaa tgtgggaaat tcttcagcca cattgccagc ctcattcaac 300 atcagatagt tcacactggc gagcggcctc acgggtgtgg tgagtgtggg aaagccttca 360 gccgaagctc tgacctcatg aaacatcagc gagttcacac tggtgagcgg ccttatgaat 420 gcaatgaatg tgggaagtta tttagccaga gctccagcct caatagccat cggagacttc 480 acactggtga acggccttac cagtgcagtg aatgtgggaa attctttaac caaagctcca 540 gcctcaataa ccaccggaga cttcacaccg gcgagcggcc ttatgagtgc agcgaatgtg 600 ggaaaacctt caggcagagg tccaatctga ggcagcacct gaaagttcac aaaccagaca 660 ggccttacga atgcagcgaa tgtgggaaag ccttcaacca aaggcctacc ctcattcggc 720 atcagaagat tcacatcaga gaaaggagca tggagaatgt gctccttccc tgttcacagc 780 acacaccaga gataagctct gagaacagac cttatcaggg cgctgtcaac tacaagttga 840 aacttgttca tccaagtacc caccctgggg aggttcccta ggaatgctag ctgtgttgga 900 agctttctgg agacaagtta cattctctta ctgtagagtt tatcagcgtt ttttcactgc 960 tggggttgtg atagaagcca tgtcagcacc acacactgca gctctccaaa gagtgtgtcc 1020 accactccac tgtgctcagg gaaggcagac ctctcctctc tctttccaat ccctaaaggg 1080 aattaggagt agtctgaagc cttgggaaga tgtcattccc gccctgtatg gctggtttag 1140 ccatggacat gaccagcttt tggctgtgaa gacctgagca gggttttgcc aacagcttgt 1200 tctagagaag gtttcccttt ttctgggaca ttgttggtct catgttatgc ctgtgaagga 1260 tttgtccagc cttcatgtta ctctacacaa caacttatct cctgtgtatt gccctggttc 1320 atgtgatgat aatggcctta tgataaagcc gcctttagtc ttccatgttc tgatcactgt 1380 gtggggtggt tcaagagcag agttaagatc taccaaactg aaggggtctc cagattatct 1440 tggaggggac aggaggatgg cagagaaaca actgtcaatc cagatttgac ctcatttgca 1500 ttgccaccaa ggcctcctag gaaaaattgt aggaatttat gggtataata ttgtggtctg 1560 aatggcgtga atttttatcc cgaggagggg gcagttgtga caacctccag tgcatgtggg 1620 aacagcatga attgggtccc ttattcccag ggggtgcccc atattcccca atactgtaaa 1680 gcagatgctg tttagcacct gccaaggagc catatgccct gaagttcagc attaggcagg 1740 tatctcttaa ctgtaagaca taccaggccc agctgggacc ataatttgta cagaaacact 1800 ggatgtgatt aatagggagt aggcgagatt atagcaaacc agcagaaatg gaactctgct 1860 aaatgtgcat ccgtgaatgc tcccttgaat gtggctgtgc aggattcagg gtttgcagaa 1920 attctcagga cctcagacct ctgtcctatg actaatgtta ctggcagagc aaataatcct 1980 aaaggttttg gttttgtgga ttaccatcct ccgtgctgtg catctgaagg ccagtgctgt 2040 gctgggcagg aaaataggga ctgagaaaaa gcagatccta tactataggg actgtagtat 2100 ctatgacgta gccagccatt ctttgctccc aaggcaagaa gaaagagatg acagagtcaa 2160 tatagggttg ccaaatcgga ttttctaaaa tgagtaggaa gttggatttt tatgtgcaac 2220 agtttctttt aatgctttgt tgatatgtga ttgtcatgca ataattattc atatttggta 2280 agttttgtac atatattatg tacactcagg gaaccaatac cataatcatg ataatgaacg 2340 tatccatcac ctgcaaagct acctcatgcc cctttacatt ccctccttgc cttccctagg 2400 aaaccgttga tttacatttt ttactttaga tttgtttgcc ttttctagaa ttaacacaat 2460 tggaatcata aagtatttat actctctttt ggtctggttt ctttcatgca gcataattat 2520 cttgagaatc atccatgctg tgtgtatata tagttcattc cttttactac tgagtagtgc 2580 tatactgggt gagtgcacca tagtttttta tggttcattt aaaaatgtta aaaaaatctg 2640 a 2641 32 604 DNA Homo sapiens misc_feature Incyte ID No LI1183014.72001JAN12 32 aaagatggta agaattagtc cctaaacatc ttttttcacg tcaactgatt cttatcactt 60 cagactgagc aaaattgtga ttttccaggg atcagtgtcg tttagggatg tgactgtggg 120 cttcactcaa gaggagtggc agcatctgga ccctgctcag aggaccctgt acagggatgt 180 gatgctggag aactacagcc accttgtctc agtagggtat tgcattccta aaccagaagt 240 gattctcaag ttggagaaag gcgaggagcc atggatatta gaggaaaaat ttccaagcca 300 gagtcatctg ggtgagttag tatgtgccag atggaattta aaggaaggta gatcacaaag 360 ggtaagtttg gataataaga ccattgaaat gttctttagg aatcatgttt tagaggctcc 420 agacctttgg aagtaacatg ttgacgtgac ccaaatatgc agtgactctg aatcacccag 480 catctcccag tatcactttc atacacacat cttgttgttt tttttaaaat tgtgatataa 540 actatatagt ttagccagag attaataaaa ttttatatat atatgtaaca ctcatgtacc 600 catc 604 33 1081 DNA Homo sapiens misc_feature Incyte ID No LI1171219.22001JAN12 33 aaaaaacctc agttcacctt ctcacaatga ggctccctgc tcagctcctg gggctgctaa 60 tgctctgggt ctctggatcc agtggggata ttgtgatgac tcagtctcca ctctccctgt 120 ccgtcacccc tggagagccg gcctccatct cctgcaggtc tagtcagagc ctcctgcata 180 gtaatggaaa caactatttg gattggttcc tgcagaagcc agggcagcct ccacagctcc 240 tgatctattt gggttctagt cgggcctccg gggtccctga caggttcagt ggcggtggat 300 caggcacaga ttttacactg aaaatcagca gagtggaggc tgaggatgtt ggggtttatt 360 actgcatgca agtagtacaa ataccttcca ctttcggcgg agggaccaag gtggagatca 420 aacgaactgt ggctgcacca tctgtcttca tcttcccgcc atctgatgag cagttgaaat 480 ctggaactgc ctctgttgtg tgcctgctga ataacttcta tcccagagag gccaaagtac 540 agtggaaggt ggataacgcc ctccaatcgg gtaactccca ggagagtgtc acagagcagg 600 acagcaagga cagcacctac agcctcagca gcaccctgac gctgagcaaa gcagactacg 660 agaaacacaa agtctacgcc tgcgaagtca cccatcaggg cctgagctcg cccgtcacaa 720 agagcttcaa caggggagag tgttagaggg agaagtgccc ccacctgctc ctcagttcca 780 gcctgacccc ctcccatcct ttggcctctg accctttttc cacaggggac ctacccctat 840 tgcggtcctc cagctcatct ttcagctcac ccccctcctc ctccttggct ttaattatgg 900 ctaatgttgg aggagaatga ataaatacag tgaatctttg gcagaagaaa aaaaaaaaag 960 agggggcccc aattatgggc ctctcgaccg ggatttatcc ggaccggtac ttgagggggg 1020 gtgcagattc cgattcaagt tatgtacgca cctcgagggg gccggaccca ttccctttgg 1080 t 1081 34 647 DNA Homo sapiens misc_feature Incyte ID No LI428428.42001JAN12 34 ggccgccccg gctcggcctg ttttcagatg cttcaagtgt tgtgaacaga gacttgttgg 60 attatgcatt tctcagctag actaaataaa tgctagcaat ggatacgtgc aaacatgttg 120 ggcagctgca gcttgctcaa gaccattcca gcctcaaccc tcagaaatgg cactgtgtgg 180 actgcaacac gaccgagtcc atttgggctt gccttagctg ctcccatgtt gcctgtggaa 240 gatatattga agagcatgca ctcaagcact ttcaagaaag cagtcatcct gttgcatgga 300 ggtgaatgag atgtacgttt ttgttacctt gtgatgatta tgttctgaat gataacgcaa 360 ctggagacct gaagttacta cgacgtacat taagtgccat caaaagtcaa aattatcact 420 gcacaactcg tagtgggagg tttttacggt ccatgggtac aggtgatgat tcttatttct 480 tacatgacgg tgcccaatct ctgcttcaaa gtgaagatca actgtatact gctctttggc 540 acaggagaag gatactaatg ggtaaaatct ttcgaacatg gtttgaacaa tcacccattg 600 gaagaaaaaa agcaagaaga accatttcag gaaaaaatag tagtaac 647 35 2014 DNA Homo sapiens misc_feature Incyte ID No LI230711.52001JAN12 35 cgggcagaca agacaaagcg aaaggcaagg cagcatgagc cgatcacccc tcaatcccag 60 ccaactccga tcagtgggct cccaggatgc cctggccccc ttgcctccac ctgctcccca 120 gaatccctcc acccactctt gggacccttt gtgtggatct ctgccttggg gcctcagctg 180 tcttctggct ctgcagcatg tcttggtcat ggcttctctg ctctgtgtct cccacctgct 240 cctgctttgc agtctctccc caggaggact ctcttactcc ccttctcagc tcctggcctc 300 cagcttcttt tcatgtggta tgtctaccat cctgcaaact tggatgggca gcaggctgcc 360 tcttgtccag gctccatcct tagagttcct tatccctgct ctggtgctga ccagccagaa 420 gctaccccgg gccatccaga cacctggaaa ctcctccctc atgctgcacc tttgtagggg 480 acctagctgc catggcctgg ggcactggaa cacttctctc caggaggtgt ccggggcagt 540 ggtagtatct gggctgctgc agggcatgat ggggctgctg gggagtcccg gccacgtgtt 600 cccccactgt gggcccctgg tgctggctcc cagcctggtt gtggcagggc tctctgccca 660 cagggaggta gcccagttct gcttcacaca ctgggggttg gccttgctgg ttatcctgct 720 catggtggtc tgttctcagc acctgggctc ctgccagttt catgtgtgcc cctggaggcg 780 agcttcaacg tcatcaactc acactcctct ccctgtcttc cggctccttt cggtgctgat 840 cccagtggcc tgtgtgtgga ttgtttctgc ctttgtggga ttcagtgtta tcccccagga 900 actgtctgcc cccaccaagg caccatggat ttggctgcct cacccaggct ggatctcagc 960 aagtggctca cttagtgggg ctactctgcg tggggcttgg actctccccc aggttggctc 1020 agctcctcac caccatccca ctgcctgttg ttgcttctac ctggctgaca tagactctgg 1080 gcgaaatatc ttcattgtgg gcttctccat cttcatggcc ttgctgctgc caagatggtt 1140 tcgggaagcc ccagtcctgt tcagcacagg ctggagcccc ttggatgtat tactgcactc 1200 actgctgaca cagcccatct tcctggctgg actctcaggc ttcctactag agaacacgat 1260 tcctggcaca cagcttgagc gaggcctagg tcaagggcta ccatctcctt tcactgccca 1320 agaggctcga atgcctcaga agcccaggga gaaggctgct caagtgtaca gacttccttt 1380 ccccatccaa aacctctgtc cctgcatccc ccagcctctc cactgcctct gcccactgcc 1440 tgaagaccct ggggatgagg aaggaggctc ctctgagcca gaagagatgg cagacttgct 1500 gcctggctca ggggagccat gccctgaatc tagcagagaa gggtttaggt cccagaaatg 1560 accagaacgc ctacttctgc cctggttaat ttagccctaa ctctcatctg ctggagagtc 1620 agctcccaaa ctgttctttc ttgtaggcag aggatatgtg tgtgtgtatt acatgggact 1680 gtctagaggt tccatttccc aatagggtgg gttgcctttc cttgtcttaa ttaggcctaa 1740 ctgttccaga gcagaggcca tgatttagtg gaccatgaat gattgagatt ttgcctgtgt 1800 actatcaatg ccacttgaac ccaagcattc actttaatac ttactgagca tctcccatgt 1860 gcaaggtcct ggaactacag ggataagaca gggtccatgc cgtctcaagg catttacggt 1920 ttaaaaagac ctttgtaatt actaacgaaa atgcaaagca gaaagcagtc tgtaataaag 1980 attaaaataa tgccgtggga gcaaagagga aaag 2014 36 1404 DNA Homo sapiens misc_feature Incyte ID No LI199716.62001JAN12 36 gtgctatatt cttcattttg tgtaagcatt tccccccttt ttttgtatgt ttaacaaatt 60 tctatttatg gattttgatg gtcacatcat ttacttattt tgggaaattc ttcagtgctt 120 gcatttagtg ccgacagtta ctgtgttggt tttggtagct taaacttcga aaatttaaac 180 aatattgttt tttctctttg tagctgccaa tatcttatca tctccctcta agagaggaca 240 aaaaggtacc cttattggat attctcctga aggaacacct ctttataact tcatgggtga 300 tgcttttcag catagctctc aatcgatccc taggtttatt aaggaatcac taaaacaaat 360 tcttgaggag agtgactcta ggcagatctt ttacttcttg tgcttgaatc tgctttttac 420 ctttgtggaa ttattctatg gcgtgctgac caatagtctg ggcctgatct cggatggatt 480 ccacatgctt tttgactgct ctgctttagt catgggactt tttgctgccc tgatgagtag 540 gtggaaagcc actcggattt tctcctatgg gtacggccga atagaaattc tgtctggatt 600 tattaatgga ctttttctaa tagtaatagc gttttttgtg tttatggagt cagtggctag 660 attgattgat cctccagaat tagacactca catgttaaca ccagtctcag ttggagggct 720 gatagtaaac cttattggta tctgtgcctt tagccatgcc catagccatg cccatggagc 780 ttctcaagga agctgtcact catctgatca cagccattca catcatatgc atggacacag 840 tgaccatggg catggtcaca gccacggatc tgcgggtgga ggcatgaatg ctaacatgag 900 gggtgtattt ctacatgttt tggcagatac tcttggcagc attggtgtga tcgtatccac 960 agttcttata gagcagtttg gatggttcat cgctgaccca ctctgttctc tttttattgc 1020 tatattaata tttctcagtg ttgttccact gattaaagat gcctgccagg ttctactcct 1080 gagattgcca ccagaatatg aaaaagaact acatattgct ttagaaaaga tacagaaaat 1140 tgaaggatta atatcatacc gagaccctca tttttggcgt cattctgcta gtattgtggc 1200 aggaacaatt catatacagg tgacatctga tgtgctagaa caaagaatag tacggcaggt 1260 tacaggaata cttaaagatg ctggagtaaa caatttaaca attcaagtgg aaaaggaggc 1320 atactttcaa catatgtctg gcctaagtac tggatttcat gatgttctgg ctatgaccaa 1380 aacaaatgga atccataaaa tact 1404 37 117 PRT Homo sapiens misc_feature Incyte ID No LI180252.16.orf22001JAN12 37 Ala Gly Asp Cys Leu His Pro Ala Gly Gly Ala Glu Gly Pro Arg 1 5 10 15 Leu His Pro Pro His Gly Ile Cys Thr Gln Asn Leu Gln Gly Tyr 20 25 30 Asp Ala Lys Ser Asp Ile Tyr Ser Val Gly Ile Thr Ala Cys Glu 35 40 45 Leu Ala Asn Gly His Val Pro Phe Lys Asp Met Pro Ala Thr Gln 50 55 60 Met Leu Leu Glu Lys Leu Asn Gly Thr Val Pro Cys Leu Leu Asp 65 70 75 Thr Ser Thr Ile Pro Ala Glu Glu Leu Thr Met Ser Pro Ser Arg 80 85 90 Ser Val Ala Asn Ser Gly Leu Ser Asp Ser Leu Thr Thr Ser Thr 95 100 105 Pro Arg Pro Ser Asn Gly Pro Val Pro Ala Pro Ser 110 115 38 77 PRT Homo sapiens misc_feature Incyte ID No LI1072919.1.orf12001JAN12 38 Gly Phe Arg Pro Pro Pro Arg Ala Val Ser Ala Ser Cys Leu Arg 1 5 10 15 Thr Pro Asp Phe Asp Val Leu Ser Arg Asp Leu Gly Leu Phe Leu 20 25 30 Ser Arg Arg Ser Ala Lys Phe Ser Pro Gly Ala Lys Pro Met Phe 35 40 45 Met Val Glu Arg Gln Asp Arg Glu Ala Pro Met Gly Glu Asn Ala 50 55 60 Gly Arg Ile Pro Ser Pro Gly Ser Ser Gln Ala Leu Leu Glu Ala 65 70 75 Gly Ala 39 153 PRT Homo sapiens misc_feature Incyte ID No LI477130.1.orf22001JAN12 39 Met Gly Phe Asp Gly Arg Val Leu Asp Ala Lys Gly Gln Val Leu 1 5 10 15 Gly Arg Leu Ala Ser Gln Ile Ala Val Val Leu Gln Gly Lys Asp 20 25 30 Lys Pro Thr Tyr Ala Pro His Val Glu Asn Gly Asp Met Cys Ile 35 40 45 Val Leu Asn Ala Gln Asp Ile Ser Val Thr Gly Arg Lys Met Thr 50 55 60 Asp Lys Ile Tyr Tyr Trp His Thr Gly Tyr Val Gly His Leu Lys 65 70 75 Glu Arg Arg Leu Lys Asp Gln Met Glu Lys Asp Pro Thr Glu Val 80 85 90 Ile Arg Lys Ala Val Leu Arg Met Leu Pro Arg Asn Lys Leu Arg 95 100 105 Asp Asp Arg Asp Arg Lys Leu Arg Ile Phe Ser Gly Ile Glu His 110 115 120 Pro Phe His Asp Arg Pro Leu Glu Ala Phe Val Met Pro Pro Thr 125 130 135 Ala Ser Thr Gly Asp Ala Thr Pro Cys Lys Ala Cys Asn Val Lys 140 145 150 Gly Pro Asp 40 147 PRT Homo sapiens misc_feature Incyte ID No LI351355.1.orf12001JAN12 40 Gly Arg Tyr Pro Ser Cys Ser Ala Ala Ala Val Ala Ser Pro Arg 1 5 10 15 Pro Pro Ala Ala Met Ala Asn Asp Ser Gly Gly Pro Gly Gly Pro 20 25 30 Ser Pro Ser Glu Arg Asp Arg Gln Tyr Cys Glu Leu Cys Gly Lys 35 40 45 Met Glu Asn Leu Leu Arg Cys Ser Arg Cys Arg Ser Ser Phe Tyr 50 55 60 Cys Cys Lys Glu His Gln Arg Gln Asp Trp Lys Lys Ala Gln Val 65 70 75 Ser Cys Ala Thr Ala Ala Arg Ala Pro Ser Ala Thr Glu Trp Ala 80 85 90 His Thr Gln His Ser Gly Pro Arg Ala Ala Gly Cys Ser Ala Ala 95 100 105 Val Pro Gly Pro Gly Pro Pro Gly Ala Gln Glu Gly Ser Gly Ala 110 115 120 Pro Gly Asp Asn Ala Ser Arg Gly Arg Gly Gln Arg Gly Lys Val 125 130 135 Lys Ala Lys Ala Pro Gly Arg Pro Ser Gly Gly Arg 140 145 41 166 PRT Homo sapiens misc_feature Incyte ID No LI038285.2.orf12001JAN12 41 Asn Ser Leu Ser Val Ala Ser Ala Pro Pro Gln Arg Asp Pro Gly 1 5 10 15 Met Ala Met Ala Leu Pro Met Pro Gly Pro Gln Glu Ala Val Val 20 25 30 Phe Glu Asp Val Ala Val Tyr Phe Thr Arg Ile Glu Trp Ser Cys 35 40 45 Leu Ala Pro Asp Gln Gln Ala Leu Tyr Arg Asp Val Met Leu Glu 50 55 60 Asn Tyr Gly Asn Leu Ala Ser Leu Gly Phe Leu Val Ala Lys Pro 65 70 75 Ala Leu Ile Ser Leu Leu Glu Gln Gly Glu Glu Pro Gly Ala Leu 80 85 90 Ile Leu Gln Val Ala Glu Gln Ser Val Ala Lys Ala Ser Leu Cys 95 100 105 Thr Glu Asp Pro Asn Thr Leu Pro Ser Arg Ser Gln Gly Arg Lys 110 115 120 Pro Cys Gln Leu Gln Lys Val Gly Gln Glu Arg Arg Val Trp Pro 125 130 135 Gly Arg Val Ala Gly Gly Gly Ala Ala Ser Ser Trp Pro His Arg 140 145 150 Gly Ala Pro Cys Ser Pro Leu Thr Asp Glu Glu Lys Val Arg Gly 155 160 165 Asp 42 188 PRT Homo sapiens misc_feature Incyte ID No LI1079031.1.orf12001JAN12 42 Arg Ala Arg Glu Gly Gly Ala Gly Pro Ala Arg Cys Cys Gly Gly 1 5 10 15 Pro Cys Cys Ser Ala Gly Glu Asp Arg Thr Gln Cys Gln Ala Gln 20 25 30 Glu Gly Arg Glu Pro Arg Trp Ala Arg Gly Leu Arg Arg Glu Pro 35 40 45 Ser Ser Trp Cys Phe Ser Arg Arg Ser Ala Gly Gly Ala Thr Gly 50 55 60 Pro Ala Ser Ala Arg His Gly Gly Phe Ser Ser Leu Leu Cys Val 65 70 75 Lys Pro Arg Ser Trp Leu Leu Cys Val Ser Gln Leu Gly Ala Met 80 85 90 Arg Leu Pro Glu Met Thr Leu Phe Pro Phe Ser Gln Leu Arg Gly 95 100 105 Val Thr Leu Ser Pro Gly Ile Ala Gly Pro Leu Leu Arg Thr Asp 110 115 120 Ser Gly Gly Trp Ser Ser Cys Leu Leu Gly Leu Arg Trp Arg Pro 125 130 135 Val Leu Leu Arg Gly Leu Glu Glu Thr Thr Ser Gly Trp Trp Leu 140 145 150 Gly Thr Cys Arg Gly Pro Gln Arg Pro Leu Cys Ser Trp Leu Ser 155 160 165 Pro Val Cys Phe Leu Ala Phe Arg Asp Glu Arg His Arg Ile Arg 170 175 180 Arg Gly Val Ser Ala Ser Glu Pro 185 43 106 PRT Homo sapiens misc_feature Incyte ID No LI306216.1.orf12001JAN12 43 Cys Lys His Ile Phe Asn Lys Pro Arg Ala Met Trp Asn Phe Arg 1 5 10 15 Ser Arg Cys Leu Asn Cys Ala Ile Ala Gln Asn Pro Leu Tyr Tyr 20 25 30 Phe Gly Cys Leu Phe Leu Thr Ala Tyr Phe Gln Phe Phe Val His 35 40 45 Leu Thr Ser Val Cys Gly Leu Phe Cys His Gln Ile Thr Cys Gly 50 55 60 Tyr Thr Tyr Pro Lys Ile Val Phe Ser Phe Thr Ala Leu Ala Tyr 65 70 75 Ser Ala Asn Pro Ser Val Val Gly Ile Lys Asn Ile Ile Arg Tyr 80 85 90 Leu Lys Lys Ser Ile His Pro Lys Thr Cys Phe Thr Gly Leu Gln 95 100 105 Phe 44 194 PRT Homo sapiens misc_feature Incyte ID No LI011799.1.orf22001JAN12 44 Ile Asn Trp Val Ile Gly Leu Ser Asp Leu Phe Ile Gln Asn Lys 1 5 10 15 His Lys Ser Pro Pro Pro His Arg Arg Glu Ser Val Pro Val Ile 20 25 30 Trp Val Leu Gly Ser Ser Ala Leu Leu Ser Leu Thr Pro Cys Arg 35 40 45 Gln Gly Glu Arg Phe Arg Gly Gly Ala Ser Val Gln Arg Ser Gln 50 55 60 His Ala Val Ser Arg Asp Ala Arg Gly Phe Leu His Arg Cys Gly 65 70 75 Gly Cys Gly Trp Gly Arg Ser Gly Ala Gly Ser Pro Ala Ser Ser 80 85 90 Pro Ala Ala Ala Pro Leu Leu Leu Pro Ala Val His Phe Ile Ser 95 100 105 Ser Ser Ala Cys Val Thr Ala Ala Arg Gly Leu Gly Lys Asp Arg 110 115 120 Ala Pro Ser Pro Arg Leu Pro Cys Ser Gly Ala Gly Ala Pro Gly 125 130 135 Ser Pro Val Met Arg Arg Leu Arg Leu Ala Ala Ala Leu Pro Gly 140 145 150 Pro Gly Ser Val Ser Asp Ala Gly Ala Gly Ala Pro Arg Leu Arg 155 160 165 Gly Gly Gly Ala Gly Lys Glu Arg Arg Arg Arg Arg Glu Thr Leu 170 175 180 Thr Pro Ser Ser Ala Arg Gly Leu Pro Gly Thr Pro Asn Pro 185 190 45 182 PRT Homo sapiens misc_feature Incyte ID No LI109467.1.orf12001JAN12 45 Arg Thr Gln Gln Gln Pro Cys Ser Ser Ser His Ala Ala Ala Ala 1 5 10 15 Met Ser Leu Arg Gln Leu Val Lys Leu Lys Val Val Val Asn Thr 20 25 30 Phe Gly Cys Thr Gly His Leu Val Asn Trp Ala Ala Phe Asn Ser 35 40 45 Gly Lys Val Asp Ile Val Ile Ile Ser Asp Pro Phe Thr Asp Ser 50 55 60 Ser Tyr Met Val Tyr Met Phe Gln Tyr Asp Ser Thr Ser Gly Lys 65 70 75 Leu His Ser Thr Val Lys Ala Glu Asn His Lys Phe Val Ile Ser 80 85 90 Gly Asn Pro Ile Ser Ile Phe Gln Glu Gln Asp Thr Thr Lys Ile 95 100 105 Lys Cys Ser Asp Ala Gly Thr Gly Cys Val Val Glu Ser Thr Gly 110 115 120 Val Phe Thr Ile Leu Tyr Met Ala Gly Ala His Leu Glu Glu Arg 125 130 135 Ala Lys Glu Ser Ser Ser Leu Leu Pro Leu Thr Pro Cys Leu Met 140 145 150 Gly Met Asn His Glu Lys Tyr Glu Ser Asn Leu Thr Ile Ile Ser 155 160 165 Ile Ala Ser Cys Thr Thr Asn Cys Leu Ala Phe Ser Asp Gln Asp 170 175 180 His Pro 46 188 PRT Homo sapiens misc_feature Incyte ID No LI1175250.1.orf22001JAN12 46 Ser Glu Arg Glu His Phe Tyr Trp Ile Asn Asn His Val Asn Ala 1 5 10 15 Val Cys Cys Gly Lys Val Phe Val Arg His Ala Leu Arg Asn Arg 20 25 30 His Ile Leu Ala Ala Leu Arg Ile Gln Thr Ile Trp Arg Glu Ala 35 40 45 Met Ile Asn Val Asn Thr Cys Gly Lys Phe Phe Val Ser Val Pro 50 55 60 Gly Val Arg Arg His Met Ile Met His Ser Gly Asn Pro Ala Tyr 65 70 75 Lys Cys Thr Ile Cys Gly Lys Ala Phe Tyr Phe Leu Asn Ser Val 80 85 90 Glu Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys 95 100 105 Lys Gln Cys Gly Lys Ala Phe Thr Val Ser Gly Ser Cys Leu Ile 110 115 120 His Glu Thr Asn Ser His Cys Glu Met Glu Pro Tyr Val Cys Lys 125 130 135 Glu Cys Gly Asn Thr Ile Arg Phe Ser Cys Ser Phe Lys Thr His 140 145 150 Glu Arg Thr His Thr Gly Glu Arg Pro Tyr Lys Cys Thr Lys Cys 155 160 165 Asp Lys Ala Phe Ser Cys Ser Thr Ser Leu Arg Tyr His Gly Ser 170 175 180 Ile Gln Tyr Trp Arg Glu Thr Leu 185 47 160 PRT Homo sapiens misc_feature Incyte ID No LI2121744.1.orf22001JAN12 47 Met Trp Thr Ile Lys Gly Ala Ser Gly Cys Pro Gly Ala Glu Arg 1 5 10 15 Ser Leu Leu Val Gln Ser Tyr Phe Glu Lys Gly Pro Leu Thr Phe 20 25 30 Arg Asp Val Ala Ile Glu Phe Ser Leu Glu Glu Trp Gln Cys Leu 35 40 45 Asp Ser Ala Gln Gln Gly Leu Tyr Arg Lys Val Met Leu Glu Asn 50 55 60 Tyr Arg Asn Leu Val Phe Leu Ala Gly Ile Ala Leu Thr Lys Pro 65 70 75 Asp Leu Ile Thr Cys Leu Glu Gln Gly Lys Glu Pro Trp Asn Ile 80 85 90 Lys Arg His Glu Met Val Ala Lys Pro Pro Val Ile Cys Ser His 95 100 105 Phe Pro Gln Asp Leu Trp Ala Glu Gln Asp Ile Lys Asp Ser Phe 110 115 120 Gln Glu Ala Ile Leu Lys Lys Tyr Gly Lys Tyr Gly His Asp Asn 125 130 135 Leu Gln Leu Gln Lys Gly Cys Lys Ser Val Asp Glu Cys Lys Val 140 145 150 His Lys Glu His Asp Asn Lys Leu Asn Gln 155 160 48 156 PRT Homo sapiens misc_feature Incyte ID No LI1170908.1.orf32001JAN12 48 Leu Phe Gln Phe Leu Ser Ile Ser Lys Arg Thr His Ser Gly Glu 1 5 10 15 Lys Leu Tyr Glu Cys Lys Gln Cys Gly Lys Val Phe Arg Ser Val 20 25 30 Lys Asn Leu Ser Ile Tyr Glu Arg Thr His Thr Gly Glu Lys Pro 35 40 45 Tyr Glu Cys Lys Lys Cys Gly Lys Ala Phe His Asn Phe Ser Ser 50 55 60 Phe Gln Ile His Glu Ser Cys Thr Glu Glu Arg Arg Pro Lys Asn 65 70 75 Val Ser Ile Val Gly Lys His Ser Tyr Leu Pro Arg Ser Phe Glu 80 85 90 Tyr Met Gln Asn Thr His Trp Arg Glu Thr Tyr Glu Cys Lys Glu 95 100 105 Cys Lys Gln Ala Phe Asn Tyr Phe Ser Ser Leu His Ile His Glu 110 115 120 Arg Thr His Thr Arg Glu Asn Pro Tyr Glu Cys Lys Asp Cys Gly 125 130 135 Lys Ala Phe Ser Leu Leu Asn Cys Phe His Arg His Val Lys Thr 140 145 150 His Gln Lys Glu Thr Leu 155 49 292 PRT Homo sapiens misc_feature Incyte ID No LI1173119.1.orf32001JAN12 49 Glu Gln Gly Leu Tyr Thr Cys Pro Ala His Leu His Gln His Gln 1 5 10 15 Lys Glu Gln Ile Arg Glu Lys Leu Ser Arg Gly Asp Gly Gly Arg 20 25 30 Pro Thr Phe Val Lys Asn His Arg Val His Met Ala Gly Lys Thr 35 40 45 Phe Leu Cys Ser Glu Cys Gly Lys Ala Phe Ser His Lys His Lys 50 55 60 Leu Ser Asp His Gln Lys Ile His Thr Gly Glu Arg Thr Tyr Lys 65 70 75 Cys Ser Lys Cys Gly Ile Leu Phe Met Glu Arg Ser Thr Leu Asn 80 85 90 Arg His Gln Arg Thr His Thr Gly Glu Arg Pro Tyr Glu Cys Asn 95 100 105 Glu Cys Gly Lys Ala Phe Leu Cys Lys Ser His Leu Val Arg His 110 115 120 Gln Thr Ile His Ser Gly Glu Arg Pro Tyr Glu Cys Ser Glu Cys 125 130 135 Gly Lys Leu Phe Met Trp Ser Ser Thr Leu Ile Thr His Gln Arg 140 145 150 Val His Thr Gly Lys Arg Pro Tyr Gly Cys Ser Glu Cys Gly Lys 155 160 165 Phe Phe Lys Cys Asn Ser Asn Leu Phe Arg His Tyr Arg Ile His 170 175 180 Thr Gly Lys Arg Ser Tyr Gly Cys Ser Glu Cys Gly Lys Phe Phe 185 190 195 Met Glu Arg Ser Thr Leu Ser Arg His Gln Arg Val His Thr Gly 200 205 210 Glu Arg Pro Tyr Glu Cys Asn Glu Cys Gly Lys Phe Phe Ser Leu 215 220 225 Lys Ser Val Leu Ile Gln His Gln Arg Val His Thr Gly Glu Arg 230 235 240 Pro Tyr Glu Cys Ser Glu Cys Gly Lys Ala Phe Leu Thr Lys Ser 245 250 255 His Leu Ile Cys His Gln Thr Val His Thr Ala Ala Lys Gln Cys 260 265 270 Ser Glu Cys Gly Lys Phe Phe Arg Tyr Asn Ser Thr Leu Leu Arg 275 280 285 His Gln Lys Val His Thr Gly 290 50 345 PRT Homo sapiens misc_feature Incyte ID No LI1175131.1.orf22001JAN12 50 Cys Thr Val Glu Met Asp Leu Ile Ser Val Asn Phe Val Gly Lys 1 5 10 15 Ala Leu Met Phe Leu Ser Leu Val Ser Tyr Pro Gln Thr Asn Ser 20 25 30 Arg Leu Glu Arg Asn His Ile Asn Val Asn Glu Cys Gly Lys Ala 35 40 45 Phe Ser His Ser Ser Ser Leu Arg Ile His Glu Arg Thr His Thr 50 55 60 Gly Glu Lys Pro Tyr Lys Cys Asn Glu Cys Gly Lys Ala Phe His 65 70 75 Ser Ser Thr Cys Leu His Ala His Lys Arg Thr His Thr Gly Glu 80 85 90 Lys Pro Tyr Glu Cys Lys Gln Cys Gly Lys Ala Phe Ser Ser Ser 95 100 105 His Ser Phe Gln Ile His Glu Arg Thr His Thr Gly Glu Lys Pro 110 115 120 Tyr Glu Cys Lys Glu Cys Gly Lys Ala Phe Lys Cys Pro Ser Ser 125 130 135 Val Arg Arg His Glu Arg Thr His Ser Arg Lys Lys Pro Tyr Glu 140 145 150 Cys Lys His Cys Gly Lys Val Leu Ser Tyr Leu Thr Ser Phe Gln 155 160 165 Asn His Leu Gly Met His Thr Gly Glu Ile Ser His Lys Cys Lys 170 175 180 Ile Cys Gly Lys Ala Phe Tyr Ser Pro Ser Ser Leu Gln Thr His 185 190 195 Glu Lys Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Asn Gln Cys 200 205 210 Gly Lys Ala Phe Asn Ser Ser Ser Ser Phe Arg Tyr His Glu Arg 215 220 225 Thr His Thr Gly Glu Lys Pro Tyr Glu Cys Lys Gln Cys Gly Lys 230 235 240 Ala Phe Arg Ser Ala Ser Leu Leu Gln Thr His Gly Arg Thr His 245 250 255 Thr Gly Glu Lys Pro Tyr Ala Cys Lys Glu Cys Gly Lys Pro Phe 260 265 270 Ser Asn Phe Ser Phe Phe Gln Ile His Glu Arg Met His Arg Glu 275 280 285 Glu Lys Pro Tyr Glu Cys Lys Gly Tyr Gly Lys Thr Phe Ser Leu 290 295 300 Pro Ser Leu Phe His Arg His Glu Arg Thr His Thr Gly Gly Lys 305 310 315 Thr Tyr Glu Cys Lys Gln Cys Gly Met Ile Leu Gln Leu Phe Glu 320 325 330 Leu Leu Ser Ile Ser Trp Lys Asp Ser His Trp Arg Glu Thr Leu 335 340 345 51 132 PRT Homo sapiens misc_feature Incyte ID No LI1174107.2.orf32001JAN12 51 Pro Glu Asp Thr Gly Lys Ser Ile Ala Lys Met Pro Gly Pro Pro 1 5 10 15 Glu Ser Leu Asp Met Gly Pro Leu Thr Phe Arg Asp Val Ala Ile 20 25 30 Glu Phe Ser Leu Glu Glu Trp Gln Cys Leu Asp Thr Ala Gln Gln 35 40 45 Asp Leu Tyr Arg Lys Val Met Leu Glu Asn Tyr Arg Asn Leu Val 50 55 60 Phe Leu Ala Gly Ile Ala Val Ser Lys Pro Asp Leu Val Thr Cys 65 70 75 Leu Glu Gln Gly Lys Asp Pro Trp Asn Met Lys Gly His Ser Thr 80 85 90 Val Val Lys Pro Pro Gly Phe Leu Thr Ala Ile Cys Asp Ser Phe 95 100 105 Leu Ile Cys Pro Lys Leu Tyr Val Leu Ile Leu Leu Lys Thr Phe 110 115 120 Ala Gln Gly Gln Ala Leu Lys Ile Leu Phe Lys Lys 125 130 52 193 PRT Homo sapiens misc_feature Incyte ID No LI901832.1.orf12001JAN12 52 Lys His Glu Ile Ile His Phe Glu Glu Glu Pro Ser Glu Tyr Asn 1 5 10 15 Asn Asn Gly Asn Ser Phe Trp Leu Asn Glu Asp Leu Ile Trp His 20 25 30 Gln Lys Ile Lys Asn Trp Glu Gln Pro Phe Glu Tyr Asn Glu Cys 35 40 45 Gly Lys Ala Phe Pro Glu Asn Ser Leu Phe Leu Val His Lys Arg 50 55 60 Ala Tyr Thr Gly Gln Lys Thr Cys Lys Tyr Thr Glu His Gly Lys 65 70 75 Thr Cys Tyr Met Ser Phe Phe Ile Thr His Gln Gln Thr His Pro 80 85 90 Arg Glu Asn His Tyr Glu Cys Asn Glu Cys Gly Glu Ser Ile Phe 95 100 105 Glu Glu Ser Ile Leu Phe Glu His Gln Asn Val Tyr Pro Phe Ser 110 115 120 Gln Asn Leu Asn Pro Thr Leu Ile Gln Arg Thr His Ser Ile Ser 125 130 135 Asn Ile Ile Glu Tyr Asn Glu Cys Gly Thr Phe Phe Ser Glu Lys 140 145 150 Leu Ala Leu His Leu Gln Gln Arg Thr His Pro Gly Glu Lys Pro 155 160 165 Tyr Glu Cys His Glu Cys Gly Lys Thr Phe Thr Gln Lys Ser Ala 170 175 180 His Thr Arg His Gln Arg Thr His Thr Gly Lys Thr Leu 185 190 53 101 PRT Homo sapiens misc_feature Incyte ID No LI1091903.1.orf22001JAN12 53 Arg Gly Leu Gln Arg Lys Asp Trp Ser Ser Leu Ser Tyr Leu Lys 1 5 10 15 Thr Met Ala Gln Gly Ser Val Ser Phe Asn Asp Val Thr Val Asp 20 25 30 Phe Thr Gln Glu Glu Trp Gln His Leu Asp His Ala Gln Lys Thr 35 40 45 Leu Tyr Met Asp Val Met Leu Glu Asn Tyr Cys His Leu Ile Ser 50 55 60 Val Gly Cys His Met Thr Lys Pro Asp Val Ile Leu Lys Leu Glu 65 70 75 Arg Gly Glu Glu Pro Trp Thr Ser Phe Ala Gly His Thr Cys Leu 80 85 90 Gly Gly Glu Asp Gly Leu Thr Gly Cys Leu Ser 95 100 54 346 PRT Homo sapiens misc_feature Incyte ID No LI1089543.2.orf22001JAN12 54 Val Arg Leu Thr Phe Arg Asp Val Ala Ile Glu Phe Ser Leu Glu 1 5 10 15 Glu Trp Gln Cys Leu Asp Met Ala Gln Gln Asn Leu Tyr Arg Asp 20 25 30 Val Met Leu Glu Asn Tyr Arg Asn Leu Val Ser Leu Gly Leu Cys 35 40 45 His Phe Asp Met Asn Ile Ile Ser Met Leu Glu Glu Gly Lys Glu 50 55 60 Pro Trp Thr Val Lys Ser Cys Val Lys Ile Ala Arg Lys Pro Arg 65 70 75 Thr Arg Glu Cys Val Lys Gly Val Val Thr Asp Ile Pro Pro Lys 80 85 90 Cys Thr Ile Lys Asp Leu Leu Pro Lys Glu Lys Ser Ser Thr Glu 95 100 105 Ala Val Phe His Thr Val Val Leu Glu Arg His Glu Ser Pro Asp 110 115 120 Ile Glu Asp Phe Ser Phe Lys Glu Pro Gln Lys Asn Val His Asp 125 130 135 Phe Glu Cys Gln Trp Arg Asp Asp Thr Gly Asn Tyr Lys Gly Val 140 145 150 Leu Met Ala Gln Lys Glu Gly Lys Arg Asp Gln Arg Asp Arg Arg 155 160 165 Asp Ile Glu Asn Lys Leu Met Asn Asn Gln Leu Gly Val Ser Phe 170 175 180 His Ser His Leu Pro Glu Leu Gln Leu Phe Gln Gly Glu Gly Lys 185 190 195 Met Tyr Glu Cys Asn Gln Val Glu Lys Ser Thr Asn Asn Gly Ser 200 205 210 Ser Val Ser Pro Leu Gln Gln Ile Pro Ser Ser Val Gln Thr His 215 220 225 Arg Ser Lys Lys Tyr His Glu Leu Asn His Phe Ser Leu Leu Thr 230 235 240 Gln Arg Arg Lys Ala Asn Ser Cys Gly Lys Pro Tyr Lys Cys Asn 245 250 255 Glu Cys Gly Lys Ala Phe Thr Gln Asn Ser Asn Leu Thr Ser His 260 265 270 Arg Arg Ile His Ser Gly Glu Lys Pro Tyr Lys Cys Ser Glu Cys 275 280 285 Gly Lys Thr Phe Thr Val Arg Ser Asn Leu Thr Ile His Gln Val 290 295 300 Ile His Thr Gly Glu Lys Pro Tyr Lys Cys His Glu Cys Gly Lys 305 310 315 Val Phe Arg His Asn Ser Tyr Leu Ala Thr His Arg Arg Ile His 320 325 330 Thr Gly Glu Lys Pro Tyr Lys Cys Asn Glu Cys Gly Lys Ala Phe 335 340 345 Arg 55 390 PRT Homo sapiens misc_feature Incyte ID No LI2049137.1.orf12001JAN12 55 Glu Thr Ser Leu Arg Ser Gly Gln Ile Pro Thr Leu Asp Ser Ser 1 5 10 15 Glu His Asn Leu Ser Pro Glu Pro Leu Glu Leu Asp Arg Met Pro 20 25 30 His Ser Pro Leu Ile Ser Ile Pro His Val Trp Cys His Pro Glu 35 40 45 Glu Glu Glu Arg Met His Asp Glu Leu Leu Gln Ala Val Ser Lys 50 55 60 Gly Pro Val Met Phe Arg Asp Val Ser Ile Asp Phe Ser Gln Glu 65 70 75 Glu Trp Glu Cys Leu Asp Ala Asp Gln Met Asn Leu Tyr Lys Glu 80 85 90 Val Met Leu Glu Asn Phe Ser Asn Leu Val Ser Val Gly Leu Ser 95 100 105 Asn Ser Lys Pro Ala Val Ile Ser Leu Leu Glu Gln Gly Lys Glu 110 115 120 Pro Trp Met Val Asp Arg Glu Leu Thr Arg Gly Leu Cys Ser Asp 125 130 135 Leu Glu Ser Met Cys Glu Thr Lys Ile Leu Ser Leu Lys Lys Arg 140 145 150 His Phe Ser Gln Val Ile Ile Thr Arg Glu Asp Met Ser Thr Phe 155 160 165 Ile Gln Pro Thr Phe Leu Ile Pro Pro Gln Lys Thr Met Ser Glu 170 175 180 Glu Lys Pro Trp Glu Cys Lys Ile Cys Gly Lys Thr Phe Asn Gln 185 190 195 Asn Ser Gln Phe Ile Gln His Gln Arg Ile His Phe Gly Glu Lys 200 205 210 His Tyr Glu Ser Lys Glu Tyr Gly Lys Ser Phe Ser Arg Gly Ser 215 220 225 Leu Val Thr Arg His Gln Arg Ile His Thr Gly Lys Lys Pro Tyr 230 235 240 Glu Cys Lys Glu Cys Gly Lys Ala Phe Ser Cys Ser Ser Tyr Phe 245 250 255 Ser Gln His Gln Arg Ile His Thr Gly Glu Lys Pro Tyr Glu Cys 260 265 270 Lys Glu Cys Gly Lys Ala Phe Lys Tyr Cys Ser Asn Leu Asn Asp 275 280 285 His Gln Arg Ile His Thr Gly Glu Lys Pro Tyr Glu Cys Lys Val 290 295 300 Cys Gly Lys Ala Phe Thr Lys Ser Ser Gln Leu Phe Leu His Leu 305 310 315 Arg Ile His Thr Gly Glu Lys Pro Tyr Glu Cys Lys Glu Cys Gly 320 325 330 Lys Ala Phe Thr Gln His Ser Arg Leu Ile Gln His Gln Arg Met 335 340 345 His Thr Gly Glu Lys Pro Tyr Glu Cys Lys Gln Cys Gly Lys Ala 350 355 360 Leu Ile Val Pro Gln His Leu Leu Thr Ile Thr Glu Phe Met Leu 365 370 375 Val Arg Ser Ser Met Asn Val Lys Asn Val Glu Arg Ala Leu Phe 380 385 390 56 125 PRT Homo sapiens misc_feature Incyte ID No LI1171755.9.orf32001JAN12 56 Glu Cys Gly Lys Leu Phe Arg Asp Met Ser Asn Leu Phe Ile His 1 5 10 15 Gln Ile Val His Thr Gly Glu Arg Pro Tyr Gly Cys Ser Asn Cys 20 25 30 Gly Lys Ser Phe Ser Arg Asn Ala His Leu Ile Glu His Gln Arg 35 40 45 Val His Thr Gly Glu Lys Pro Phe Thr Cys Ser Glu Cys Gly Lys 50 55 60 Ala Phe Arg His Asn Ser Thr Leu Val Gln His His Lys Ile His 65 70 75 Thr Gly Val Arg Pro Tyr Glu Cys Ser Glu Cys Gly Lys Leu Phe 80 85 90 Ser Phe Asn Ser Ser Leu Met Lys His Gln Arg Val His Thr Gly 95 100 105 Glu Arg Pro Tyr Lys Val Gly Leu Val Ala Ile Glu Phe Ser Thr 110 115 120 Phe Thr Ala Leu Ile 125 57 310 PRT Homo sapiens misc_feature Incyte ID No LI208529.12.orf32001JAN12 57 Val Arg Ser Gly Ala Ala Gly Gly Gly Gly Ala Phe Ile Val Leu 1 5 10 15 Pro Leu Ala Lys Thr Gly Arg Val Asp Lys Asn Tyr Pro Leu Val 20 25 30 Thr Gly His Thr Ala Pro Val Leu Asp Ile Asp Trp Cys Pro His 35 40 45 Asn Asp Asn Val Ile Ala Ser Ala Ser Asp Asp Thr Thr Ile Met 50 55 60 Val Trp Gln Ile Pro Asp Tyr Thr Pro Met Arg Asn Ile Thr Glu 65 70 75 Pro Ile Ile Thr Leu Glu Gly His Ser Lys Arg Val Gly Ile Leu 80 85 90 Ser Trp His Pro Thr Ala Arg Asn Val Leu Leu Ser Ala Gly Gly 95 100 105 Asp Asn Val Ile Ile Ile Trp Asn Val Gly Thr Gly Glu Val Leu 110 115 120 Leu Ser Leu Asp Asp Met His Pro Asp Val Ile His Ser Val Cys 125 130 135 Trp Asn Ser Asn Gly Ser Leu Leu Ala Thr Thr Cys Lys Asp Lys 140 145 150 Thr Leu Arg Ile Val Asp Pro Arg Lys Gly Gln Val Val Ala Glu 155 160 165 Arg Phe Ala Ala His Glu Gly Met Arg Pro Met Arg Ala Val Phe 170 175 180 Thr Arg Gln Gly His Ile Phe Thr Thr Gly Phe Thr Arg Met Ser 185 190 195 Gln Arg Glu Leu Gly Leu Trp Asp Pro Asn Asn Phe Glu Glu Pro 200 205 210 Val Ala Leu Gln Glu Met Asp Thr Ser Asn Gly Val Leu Leu Pro 215 220 225 Phe Tyr Asp Pro Asp Ser Ser Ile Val Tyr Leu Cys Gly Lys Gly 230 235 240 Asp Ser Ser Ile Arg Tyr Phe Glu Ile Thr Asp Glu Pro Pro Phe 245 250 255 Val His Tyr Leu Asn Thr Phe Ser Ser Lys Glu Pro Gln Arg Gly 260 265 270 Met Gly Phe Met Pro Lys Arg Gly Leu Asp Val Ser Lys Cys Glu 275 280 285 Ile Ala Arg Phe Tyr Lys Leu His Glu Arg Lys Cys Glu Pro Ile 290 295 300 Ile Met Thr Val Pro Ser Ser Leu Arg Ser 305 310 58 271 PRT Homo sapiens misc_feature Incyte ID No LI024125.6.orf12001JAN12 58 Ser Ile Ser Ala Ser Thr Asp Pro Arg Leu Ser Arg Pro Ala Ser 1 5 10 15 Asn Asn Thr His Ile Val Gly Cys Lys Phe Leu His Lys Asp Ser 20 25 30 Leu Gly Glu Leu Arg Pro Phe Leu Val Leu Asp Arg Glu Leu Glu 35 40 45 Leu Val Met Gly Ile Met Ala Ala Ser Arg Pro Leu Ser Arg Phe 50 55 60 Trp Glu Trp Gly Lys Asn Ile Val Cys Val Gly Arg Asn Tyr Ala 65 70 75 Asp His Val Arg Glu Met Arg Ser Ala Val Leu Ser Glu Pro Val 80 85 90 Leu Phe Leu Lys Pro Ser Thr Ala Tyr Ala Pro Glu Gly Ser Pro 95 100 105 Ile Leu Met Pro Ala Tyr Thr Arg Asn Leu His His Glu Leu Glu 110 115 120 Leu Gly Val Val Met Gly Lys Arg Cys Arg Ala Val Pro Glu Ala 125 130 135 Ala Ala Met Asp Tyr Val Gly Gly Tyr Ala Leu Cys Leu Asp Met 140 145 150 Thr Ala Arg Asp Val Gln Asp Glu Cys Lys Lys Lys Gly Leu Pro 155 160 165 Trp Thr Leu Ala Lys Ser Phe Thr Ala Ser Cys Pro Val Ser Ala 170 175 180 Phe Val Pro Lys Glu Lys Ile Pro Asp Pro His Lys Leu Lys Leu 185 190 195 Trp Leu Lys Val Asn Gly Glu Leu Arg Gln Glu Gly Glu Thr Ser 200 205 210 Ser Met Ile Phe Ser Ile Pro Tyr Ile Ile Ser Tyr Val Ser Lys 215 220 225 Ile Ile Thr Leu Glu Glu Gly Asp Ile Ile Leu Thr Gly Thr Pro 230 235 240 Lys Gly Val Gly Pro Val Lys Glu Asn Asp Glu Ile Glu Ala Gly 245 250 255 Ile His Gly Leu Val Ser Met Thr Phe Lys Val Glu Lys Pro Glu 260 265 270 Tyr 59 120 PRT Homo sapiens misc_feature Incyte ID No LI235557.12.orf22001JAN12 59 Ser Asn Pro Ala Asp Ala Phe Asp Asn Asp Leu Met His Arg Thr 1 5 10 15 Leu Lys Asn Ile Val Glu Gly Lys Thr Val Glu Val Pro Thr Tyr 20 25 30 Asp Phe Val Thr His Ser Arg Leu Pro Glu Thr Thr Val Val Tyr 35 40 45 Pro Ala Asp Val Val Leu Phe Glu Gly Ile Leu Val Phe Tyr Ser 50 55 60 Gln Glu Ile Arg Asp Met Phe His Leu Arg Leu Phe Val Asp Thr 65 70 75 Asp Ser Asp Val Arg Leu Ser Arg Arg Val Leu Arg Asp Val Arg 80 85 90 Arg Gly Arg Asp Leu Glu Gln Ile Leu Thr Gln Tyr Thr Thr Phe 95 100 105 Val Lys Pro Ala Phe Glu Glu Phe Cys Leu Pro Gln Gln Ser Ile 110 115 120 60 91 PRT Homo sapiens misc_feature Incyte ID No LI178860.1.orf12001JAN12 60 Met Glu Thr Met Lys Ser Lys Ala Asn Cys Ala Gln Asn Pro Asn 1 5 10 15 Cys Asn Ile Met Ile Phe His Pro Thr Lys Glu Glu Phe Asn Asp 20 25 30 Leu Asp Lys Tyr Ile Ala Tyr Met Glu Ser Gln Gly Ala His Arg 35 40 45 Ala Gly Leu Ala Lys Ile Ile Pro Pro Lys Glu Trp Lys Ala Arg 50 55 60 Glu Thr Tyr Asp Asn Ile Ser Glu Ile Leu Ile Ala Thr Pro Leu 65 70 75 Gln Gln Val Ala Ser Gly Arg Ala Gly Val Phe Thr Gln Tyr His 80 85 90 Lys 61 174 PRT Homo sapiens misc_feature Incyte ID No LI405798.1.orf22001JAN12 61 Ser Ser Val Ala Asp Pro Thr Thr Leu Pro Pro Pro Ser Ser Pro 1 5 10 15 Ser His His Gln Leu Ser Ser Ser Gln Arg Glu Gly Trp Gly Gly 20 25 30 Asp Pro Asp Leu Thr Gly Gln Gly Ala Ser Ile Met Met Leu Asn 35 40 45 Ser Asp Thr Met Glu Leu Asp Leu Pro Pro Thr His Ser Glu Thr 50 55 60 Glu Ser Gly Phe Ser Asp Cys Gly Gly Gly Ala Gly Pro Asp Gly 65 70 75 Ala Gly Pro Gly Gly Pro Gly Gly Gly Gln Ala Arg Gly Pro Glu 80 85 90 Pro Gly Glu Pro Gly Arg Lys Asp Leu Gln His Leu Ser Arg Glu 95 100 105 Glu Arg Arg Arg Arg Arg Arg Ala Thr Ala Lys Tyr Arg Thr Ala 110 115 120 His Ala Thr Arg Glu Arg Ile Arg Val Glu Ala Phe Asn Leu Ala 125 130 135 Phe Ala Glu Leu Arg Lys Leu Leu Pro Thr Leu Pro Pro Asp Lys 140 145 150 Lys Leu Ser Lys Ile Glu Ile Leu Arg Leu Ala Ile Cys Tyr Ile 155 160 165 Ser Tyr Leu Asn His Val Leu Asp Val 170 62 139 PRT Homo sapiens misc_feature Incyte ID No LI1071427.101.orf12001JAN12 62 Arg Ser Arg Ser Leu Leu Leu Leu Ser Ala Ser Thr Pro Cys Gly 1 5 10 15 Ser Ala Ala Pro Ser Trp Pro Arg Cys Pro Pro Ser Ser Arg Cys 20 25 30 Gly Ser Ala Ser Arg Ser Met Thr Ser Pro Ala Pro Pro Ser Ser 35 40 45 Thr Ala Asn Ala Ser Ser Ala Asp Tyr Asp Leu Val Ala Leu His 50 55 60 Pro Phe Leu Thr Lys Pro Asn Leu Arg Arg Lys Gln Asp Glu Met 65 70 75 Ala Trp Leu Tyr Leu Phe Phe Trp Phe Gly Leu Gly Phe Phe Phe 80 85 90 Phe Leu Gly Val Asp Ser Gly Phe Lys Thr Arg Glu Arg Val Lys 95 100 105 Gly Asp Ser Ser Arg Trp Glu Arg Ala Ser Pro Lys Val His Lys 110 115 120 Val Ala Glu Asp Leu Asp Gly Pro Trp Trp Val Leu Asn Ser His 125 130 135 Ser Lys Phe Glu 63 136 PRT Homo sapiens misc_feature Incyte ID No LI1072276.1.orf12001JAN12 63 Leu Cys Ala Pro Lys His Ala Arg Thr Phe Val Val Phe Val Gln 1 5 10 15 Val Lys Arg Gly Pro Gly Asn Gln Leu Arg Asn His Tyr Ile His 20 25 30 Lys Ser Cys Leu Phe His Arg Val Val Lys Asp Phe Met Val Gln 35 40 45 Gly Gly Asp Phe Ser Glu Arg Lys Trp Thr Arg Gln Gly Asn Leu 50 55 60 Ser Met Glu Asp Phe Leu Lys Thr Arg Val Ser Leu Leu Asn Thr 65 70 75 Thr Thr Glu Phe Leu Leu Ser Met Ala Asn Arg Gly Lys Asp Thr 80 85 90 Asn Gly Ser Gln Phe Phe Ile Thr Thr Lys Pro Thr Pro His Phe 95 100 105 Ser Met Gly Thr His Val Ala Phe Trp Thr Ser Asn Ser Leu Val 110 115 120 Asn Glu Ala Cys Lys Ser Arg Leu Lys Thr Arg Lys Thr Gly Cys 125 130 135 Ser 64 148 PRT Homo sapiens misc_feature Incyte ID No LI198296.1.orf12001JAN12 64 Lys Thr Leu Phe Thr Lys Cys Lys Asn Phe Ala Leu Gln Thr Phe 1 5 10 15 Glu Asp Val Ser Gln His Glu Glu Phe Leu Glu Leu Asp Lys Asp 20 25 30 Glu Leu Ile Asp Tyr Ile Cys Ser Asp Glu Leu Val Ile Gly Lys 35 40 45 Glu Glu Met Val Phe Glu Ala Val Met Arg Trp Val Tyr Arg Ala 50 55 60 Val Asp Leu Arg Arg Pro Leu Leu His Glu Leu Leu Thr His Val 65 70 75 Arg Leu Pro Leu Val Ala Ser Gln Leu Leu Cys Ser Asn Ser Val 80 85 90 Lys Gly Gly Thr Leu Ile Gln Asn Ser Pro Glu Cys Tyr Gln Leu 95 100 105 Leu His Glu Ala Arg Arg Tyr His Ile Leu Gly Asn Glu Met Met 110 115 120 Ser Pro Arg Thr Arg Pro Arg Arg Ser Thr Gly Tyr Ser Glu Val 125 130 135 Ile Val Val Val Gly Gly Cys Glu Arg Val Gly Arg Ile 140 145 65 256 PRT Homo sapiens misc_feature Incyte ID No LI202943.4.orf22001JAN12 65 Met Ala Met Gln Val Asp Gln Thr Thr Val Leu Glu Pro Trp Trp 1 5 10 15 Leu Thr Ala Ala Thr Arg Gly Ser Thr Ser Lys Gly Lys Arg Arg 20 25 30 Ala Pro Ala Lys Pro Gln Gly Ser Gly Val Val Leu Tyr Arg Arg 35 40 45 Ala Thr Arg Tyr Leu Val Val Asn His Leu Arg Leu Arg Met Ala 50 55 60 Phe Trp Ser Ile Gln Leu Ala Gly Ser Leu Arg Val Lys Leu Arg 65 70 75 Tyr Gln Cys Asn Pro Gly Tyr Lys Ser Val Gly Ser Pro Val Phe 80 85 90 Val Cys Gln Ala Asn Arg His Trp His Ser Glu Ser Pro Leu Met 95 100 105 Cys Val Pro Leu Asp Cys Gly Lys Pro Pro Pro Ile Gln Asn Gly 110 115 120 Phe Met Lys Gly Glu Asn Phe Glu Val Gly Ser Lys Val Gln Phe 125 130 135 Phe Cys Asn Glu Gly Tyr Glu Leu Val Gly Asp Ser Ser Trp Thr 140 145 150 Cys Gln Lys Ser Gly Lys Trp Asn Lys Lys Ser Asn Pro Lys Cys 155 160 165 Met Pro Ala Lys Cys Pro Glu Pro Pro Leu Leu Glu Asn Gln Leu 170 175 180 Val Leu Lys Glu Leu Thr Thr Glu Val Gly Val Val Thr Phe Ser 185 190 195 Cys Lys Glu Gly His Val Leu Gln Gly Pro Ser Val Leu Lys Cys 200 205 210 Leu Pro Ser Gln Gln Trp Asn Asp Ser Phe Pro Val Cys Lys Ile 215 220 225 Val Leu Cys Thr Pro Pro Pro Leu Ile Ser Phe Gly Val Pro Ile 230 235 240 Pro Ser Ser Ala Leu His Phe Gly Ser Thr Val Lys Val Phe Leu 245 250 255 Met 66 53 PRT Homo sapiens misc_feature Incyte ID No LI2121848.1.orf32001JAN12 66 Leu His Lys Tyr Asp Asp Cys Ser Lys Ala Phe Thr Ser Arg Ser 1 5 10 15 His Leu Ile Arg His Gln Arg Ile His Thr Gly Gln Lys Ser Tyr 20 25 30 Lys Cys His Gln Cys Gly Lys Val Phe Ser Leu Arg Ser Pro Leu 35 40 45 Lys Glu His Gln Lys Ile His Phe 50 67 292 PRT Homo sapiens misc_feature Incyte ID No LI796992.1.orf32001JAN12 67 Val Leu Glu Arg Lys Phe Phe Ser Arg Ser Ser Asn Leu Ile Gln 1 5 10 15 His Lys Arg Val His Thr Gly Glu Lys Gln Tyr Glu Cys Ser Asp 20 25 30 Cys Gly Lys Phe Phe Ser Gln Arg Ser Asn Leu Ile His His Lys 35 40 45 Arg Val His Thr Gly Arg Ser Ala His Glu Cys Ser Glu Cys Gly 50 55 60 Lys Ser Phe Asn Cys Asn Ser Ser Leu Ile Lys His Trp Arg Val 65 70 75 His Thr Gly Glu Arg Pro Tyr Lys Cys Asn Glu Cys Gly Lys Phe 80 85 90 Phe Ser His Ile Ala Ser Leu Ile Gln His Gln Ile Val His Thr 95 100 105 Gly Glu Arg Pro His Gly Cys Gly Glu Cys Gly Lys Ala Phe Ser 110 115 120 Arg Ser Ser Asp Leu Met Lys His Gln Arg Val His Thr Gly Glu 125 130 135 Arg Pro Tyr Glu Cys Asn Glu Cys Gly Lys Leu Phe Ser Gln Ser 140 145 150 Ser Ser Leu Asn Ser His Arg Arg Leu His Thr Gly Glu Arg Pro 155 160 165 Tyr Gln Cys Ser Glu Cys Gly Lys Phe Phe Asn Gln Ser Ser Ser 170 175 180 Leu Asn Asn His Arg Arg Leu His Thr Gly Glu Arg Pro Tyr Glu 185 190 195 Cys Ser Glu Cys Gly Lys Thr Phe Arg Gln Arg Ser Asn Leu Arg 200 205 210 Gln His Leu Lys Val His Lys Pro Asp Arg Pro Tyr Glu Cys Ser 215 220 225 Glu Cys Gly Lys Ala Phe Asn Gln Arg Pro Thr Leu Ile Arg His 230 235 240 Gln Lys Ile His Ile Arg Glu Arg Ser Met Glu Asn Val Leu Leu 245 250 255 Pro Cys Ser Gln His Thr Pro Glu Ile Ser Ser Glu Asn Arg Pro 260 265 270 Tyr Gln Gly Ala Val Asn Tyr Lys Leu Lys Leu Val His Pro Ser 275 280 285 Thr His Pro Gly Glu Val Pro 290 68 136 PRT Homo sapiens misc_feature Incyte ID No LI1183014.7.orf22001JAN12 68 Thr Ser Phe Phe Thr Ser Thr Asp Ser Tyr His Phe Arg Leu Ser 1 5 10 15 Lys Ile Val Ile Phe Gln Gly Ser Val Ser Phe Arg Asp Val Thr 20 25 30 Val Gly Phe Thr Gln Glu Glu Trp Gln His Leu Asp Pro Ala Gln 35 40 45 Arg Thr Leu Tyr Arg Asp Val Met Leu Glu Asn Tyr Ser His Leu 50 55 60 Val Ser Val Gly Tyr Cys Ile Pro Lys Pro Glu Val Ile Leu Lys 65 70 75 Leu Glu Lys Gly Glu Glu Pro Trp Ile Leu Glu Glu Lys Phe Pro 80 85 90 Ser Gln Ser His Leu Gly Glu Leu Val Cys Ala Arg Trp Asn Leu 95 100 105 Lys Glu Gly Arg Ser Gln Arg Val Ser Leu Asp Asn Lys Thr Ile 110 115 120 Glu Met Phe Phe Arg Asn His Val Leu Glu Ala Pro Asp Leu Trp 125 130 135 Lys 69 247 PRT Homo sapiens misc_feature Incyte ID No LI1171219.2.orf32001JAN12 69 Lys Thr Ser Val His Leu Leu Thr Met Arg Leu Pro Ala Gln Leu 1 5 10 15 Leu Gly Leu Leu Met Leu Trp Val Ser Gly Ser Ser Gly Asp Ile 20 25 30 Val Met Thr Gln Ser Pro Leu Ser Leu Ser Val Thr Pro Gly Glu 35 40 45 Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 50 55 60 Asn Gly Asn Asn Tyr Leu Asp Trp Phe Leu Gln Lys Pro Gly Gln 65 70 75 Pro Pro Gln Leu Leu Ile Tyr Leu Gly Ser Ser Arg Ala Ser Gly 80 85 90 Val Pro Asp Arg Phe Ser Gly Gly Gly Ser Gly Thr Asp Phe Thr 95 100 105 Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr 110 115 120 Cys Met Gln Val Val Gln Ile Pro Ser Thr Phe Gly Gly Gly Thr 125 130 135 Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile 140 145 150 Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val 155 160 165 Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln 170 175 180 Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser 185 190 195 Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser 200 205 210 Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 215 220 225 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys 230 235 240 Ser Phe Asn Arg Gly Glu Cys 245 70 114 PRT Homo sapiens misc_feature Incyte ID No LI428428.4.orf32001JAN12 70 Met Arg Cys Thr Phe Leu Leu Pro Cys Asp Asp Tyr Val Leu Asn 1 5 10 15 Asp Asn Ala Thr Gly Asp Leu Lys Leu Leu Arg Arg Thr Leu Ser 20 25 30 Ala Ile Lys Ser Gln Asn Tyr His Cys Thr Thr Arg Ser Gly Arg 35 40 45 Phe Leu Arg Ser Met Gly Thr Gly Asp Asp Ser Tyr Phe Leu His 50 55 60 Asp Gly Ala Gln Ser Leu Leu Gln Ser Glu Asp Gln Leu Tyr Thr 65 70 75 Ala Leu Trp His Arg Arg Arg Ile Leu Met Gly Lys Ile Phe Arg 80 85 90 Thr Trp Phe Glu Gln Ser Pro Ile Gly Arg Lys Lys Ala Arg Arg 95 100 105 Thr Ile Ser Gly Lys Asn Ser Ser Asn 110 71 519 PRT Homo sapiens misc_feature Incyte ID No LI230711.5.orf22001JAN12 71 Gly Gln Thr Arg Gln Ser Glu Arg Gln Gly Ser Met Ser Arg Ser 1 5 10 15 Pro Leu Asn Pro Ser Gln Leu Arg Ser Val Gly Ser Gln Asp Ala 20 25 30 Leu Ala Pro Leu Pro Pro Pro Ala Pro Gln Asn Pro Ser Thr His 35 40 45 Ser Trp Asp Pro Leu Cys Gly Ser Leu Pro Trp Gly Leu Ser Cys 50 55 60 Leu Leu Ala Leu Gln His Val Leu Val Met Ala Ser Leu Leu Cys 65 70 75 Val Ser His Leu Leu Leu Leu Cys Ser Leu Ser Pro Gly Gly Leu 80 85 90 Ser Tyr Ser Pro Ser Gln Leu Leu Ala Ser Ser Phe Phe Ser Cys 95 100 105 Gly Met Ser Thr Ile Leu Gln Thr Trp Met Gly Ser Arg Leu Pro 110 115 120 Leu Val Gln Ala Pro Ser Leu Glu Phe Leu Ile Pro Ala Leu Val 125 130 135 Leu Thr Ser Gln Lys Leu Pro Arg Ala Ile Gln Thr Pro Gly Asn 140 145 150 Ser Ser Leu Met Leu His Leu Cys Arg Gly Pro Ser Cys His Gly 155 160 165 Leu Gly His Trp Asn Thr Ser Leu Gln Glu Val Ser Gly Ala Val 170 175 180 Val Val Ser Gly Leu Leu Gln Gly Met Met Gly Leu Leu Gly Ser 185 190 195 Pro Gly His Val Phe Pro His Cys Gly Pro Leu Val Leu Ala Pro 200 205 210 Ser Leu Val Val Ala Gly Leu Ser Ala His Arg Glu Val Ala Gln 215 220 225 Phe Cys Phe Thr His Trp Gly Leu Ala Leu Leu Val Ile Leu Leu 230 235 240 Met Val Val Cys Ser Gln His Leu Gly Ser Cys Gln Phe His Val 245 250 255 Cys Pro Trp Arg Arg Ala Ser Thr Ser Ser Thr His Thr Pro Leu 260 265 270 Pro Val Phe Arg Leu Leu Ser Val Leu Ile Pro Val Ala Cys Val 275 280 285 Trp Ile Val Ser Ala Phe Val Gly Phe Ser Val Ile Pro Gln Glu 290 295 300 Leu Ser Ala Pro Thr Lys Ala Pro Trp Ile Trp Leu Pro His Pro 305 310 315 Gly Trp Ile Ser Ala Ser Gly Ser Leu Ser Gly Ala Thr Leu Arg 320 325 330 Gly Ala Trp Thr Leu Pro Gln Val Gly Ser Ala Pro His His His 335 340 345 Pro Thr Ala Cys Cys Cys Phe Tyr Leu Ala Asp Ile Asp Ser Gly 350 355 360 Arg Asn Ile Phe Ile Val Gly Phe Ser Ile Phe Met Ala Leu Leu 365 370 375 Leu Pro Arg Trp Phe Arg Glu Ala Pro Val Leu Phe Ser Thr Gly 380 385 390 Trp Ser Pro Leu Asp Val Leu Leu His Ser Leu Leu Thr Gln Pro 395 400 405 Ile Phe Leu Ala Gly Leu Ser Gly Phe Leu Leu Glu Asn Thr Ile 410 415 420 Pro Gly Thr Gln Leu Glu Arg Gly Leu Gly Gln Gly Leu Pro Ser 425 430 435 Pro Phe Thr Ala Gln Glu Ala Arg Met Pro Gln Lys Pro Arg Glu 440 445 450 Lys Ala Ala Gln Val Tyr Arg Leu Pro Phe Pro Ile Gln Asn Leu 455 460 465 Cys Pro Cys Ile Pro Gln Pro Leu His Cys Leu Cys Pro Leu Pro 470 475 480 Glu Asp Pro Gly Asp Glu Glu Gly Gly Ser Ser Glu Pro Glu Glu 485 490 495 Met Ala Asp Leu Leu Pro Gly Ser Gly Glu Pro Cys Pro Glu Ser 500 505 510 Ser Arg Glu Gly Phe Arg Ser Gln Lys 515 72 408 PRT Homo sapiens misc_feature Incyte ID No LI199716.6.orf22001JAN12 72 Thr Ile Leu Phe Phe Leu Phe Val Ala Ala Asn Ile Leu Ser Ser 1 5 10 15 Pro Ser Lys Arg Gly Gln Lys Gly Thr Leu Ile Gly Tyr Ser Pro 20 25 30 Glu Gly Thr Pro Leu Tyr Asn Phe Met Gly Asp Ala Phe Gln His 35 40 45 Ser Ser Gln Ser Ile Pro Arg Phe Ile Lys Glu Ser Leu Lys Gln 50 55 60 Ile Leu Glu Glu Ser Asp Ser Arg Gln Ile Phe Tyr Phe Leu Cys 65 70 75 Leu Asn Leu Leu Phe Thr Phe Val Glu Leu Phe Tyr Gly Val Leu 80 85 90 Thr Asn Ser Leu Gly Leu Ile Ser Asp Gly Phe His Met Leu Phe 95 100 105 Asp Cys Ser Ala Leu Val Met Gly Leu Phe Ala Ala Leu Met Ser 110 115 120 Arg Trp Lys Ala Thr Arg Ile Phe Ser Tyr Gly Tyr Gly Arg Ile 125 130 135 Glu Ile Leu Ser Gly Phe Ile Asn Gly Leu Phe Leu Ile Val Ile 140 145 150 Ala Phe Phe Val Phe Met Glu Ser Val Ala Arg Leu Ile Asp Pro 155 160 165 Pro Glu Leu Asp Thr His Met Leu Thr Pro Val Ser Val Gly Gly 170 175 180 Leu Ile Val Asn Leu Ile Gly Ile Cys Ala Phe Ser His Ala His 185 190 195 Ser His Ala His Gly Ala Ser Gln Gly Ser Cys His Ser Ser Asp 200 205 210 His Ser His Ser His His Met His Gly His Ser Asp His Gly His 215 220 225 Gly His Ser His Gly Ser Ala Gly Gly Gly Met Asn Ala Asn Met 230 235 240 Arg Gly Val Phe Leu His Val Leu Ala Asp Thr Leu Gly Ser Ile 245 250 255 Gly Val Ile Val Ser Thr Val Leu Ile Glu Gln Phe Gly Trp Phe 260 265 270 Ile Ala Asp Pro Leu Cys Ser Leu Phe Ile Ala Ile Leu Ile Phe 275 280 285 Leu Ser Val Val Pro Leu Ile Lys Asp Ala Cys Gln Val Leu Leu 290 295 300 Leu Arg Leu Pro Pro Glu Tyr Glu Lys Glu Leu His Ile Ala Leu 305 310 315 Glu Lys Ile Gln Lys Ile Glu Gly Leu Ile Ser Tyr Arg Asp Pro 320 325 330 His Phe Trp Arg His Ser Ala Ser Ile Val Ala Gly Thr Ile His 335 340 345 Ile Gln Val Thr Ser Asp Val Leu Glu Gln Arg Ile Val Arg Gln 350 355 360 Val Thr Gly Ile Leu Lys Asp Ala Gly Val Asn Asn Leu Thr Ile 365 370 375 Gln Val Glu Lys Glu Ala Tyr Phe Gln His Met Ser Gly Leu Ser 380 385 390 Thr Gly Phe His Asp Val Leu Ala Met Thr Lys Thr Asn Gly Ile 395 400 405 His Lys Ile 

What is claimed is:
 1. An isolated polynucleotide comprising a polynucleotide sequence selected from the group consisting of: a) a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36, b) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36, c) a polynucleotide sequence complementary to a), d) a polynucleotide sequence complementary to b), and e) an RNA equivalent of a) through d).
 2. An isolated polynucleotide of claim 1, comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36.
 3. An isolated polynucleotide comprising at least 60 contiguous nucleotides of a polynucleotide of claim
 1. 4. A composition for the detection of expression of disease detection and treatment molecule polynucleotides comprising at least one of the polynucleotides of claim 1 and a detectable label.
 5. A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 1, the method comprising: a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.
 6. A method for detecting a target polynucleotide in a sample, said target polynucleotide comprising a sequence of a polynucleotide of claim 1, the method comprising: a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.
 7. A method of claim 5, wherein the probe comprises at least 30 contiguous nucleotides.
 8. A method of claim 5, wherein the probe comprises at least 60 contiguous nucleotides.
 9. A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim
 1. 10. A cell transformed with a recombinant polynucleotide of claim
 9. 11. A transgenic organism comprising a recombinant polynucleotide of claim
 9. 12. A method for producing a disease detection and treatment molecule polypeptide, the method comprising: a) culturing a cell under conditions suitable for expression of the disease detection and treatment molecule polypeptide, wherein said cell is transformed with a recombinant polynucleotide of claim 9, and b) recovering the disease detection and treatment molecule polypeptide so expressed.
 13. A purified disease detection and treatment molecule polypeptide (MDDT) encoded by at least one of the polynucleotides of claim
 2. 14. An isolated antibody which specifically binds to a disease detection and treatment molecule polypeptide of claim
 13. 15. A method of identifying a test compound which specifically binds to the disease detection and treatment molecule polypeptide of claim 13, the method comprising the steps of: a) providing a test compound; b) combining the disease detection and treatment molecule polypeptide with the test compound for a sufficient time and under suitable conditions for binding; and c) detecting binding of the disease detection and treatment molecule polypeptide to the test compound, thereby identifying the test compound which specifically binds the disease detection and treatment molecule polypeptide.
 16. A microarray wherein at least one element of the microarray is a polynucleotide of claim
 3. 17. A method for generating a transcript image of a sample which contains polynucleotides, the method comprising the steps of: a) labeling the polynucleotides of the sample, b) contacting the elements of the microarray of claim 16 with the labeled polynucleotides of the sample under conditions suitable for the formation of a hybridization complex, and c) quantifying the expression of the polynucleotides in the sample.
 18. A method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a polynucleotide sequence of claim 1, the method comprising: a) exposing a sample comprising the target polynucleotide to a compound, under conditions suitable for the expression of the target polynucleotide, b) detecting altered expression of the target polynucleotide, and c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.
 19. A method for assessing toxicity of a test compound, said method comprising: a) treating a biological sample containing nucleic acids with the test compound; b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide of claim 1 under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide of claim 1 or fragment thereof; c) quantifying the amount of hybridization complex; and d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.
 20. An array comprising different nucleotide molecules affixed in distinct physical locations on a solid substrate, wherein at least one of said nucleotide Molecules comprises a first oligonucleotide or polynucleotide sequence specifically hybridizable with at least 30 contiguous nucleotides of a target polynucleotide, said target polynucleotide having a sequence of claim
 1. 21. An array of claim 20, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to at least 30 contiguous nucleotides of said target polynucleotide.
 22. An array of claim 20, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to at least 60 contiguous nucleotides of said target polynucleotide
 23. An array of claim 20, which is a microarray.
 24. An array of claim 20, further comprising said target polynucleotide hybridized to said first oligonucleotide or polynucleotide.
 25. An array of claim 20, wherein a linker joins at least one of said nucleotide molecules to said solid substrate.
 26. An array of claim 20, wherein each distinct physical location on the substrate contains multiple nucleotide molecules having the same sequence, and each distinct physical location on the substrate contains nucleotide molecules having a sequence which differs from the sequence of nucleotide molecules at another physical location on the substrate.
 27. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of: a) an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72, b) a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72.
 28. An isolated polypeptide of claim 27, comprising a polypeptide sequence selected from the group consisting of SEQ ID NO: 37-72. 